%PDF-1.4
%
1 0 obj
<<
/Metadata 2 0 R
/PageLabels 3 0 R
/Pages 4 0 R
/Type /Catalog
>>
endobj
5 0 obj
<<
/CreationDate (D:20090204161825Z)
/Creator (QuarkXPress\(tm\) 6.5)
/ModDate (D:20150902014155-07'00')
/Producer (QuarkXPress\(tm\) 6.5)
/XPressPrivate <2525446F63756D656E7450726F63657373436F6C6F72733A204379616E204D6167656E74612059656C6C6F7720426C61636B0A2525456E64436F6D6D656E7473>
/rgid (PB:285924953_AS:321748870860802@1453722316352)
>>
endobj
2 0 obj
<<
/Length 1534
/Subtype /XML
/Type /Metadata
>>
stream
2009-02-04T16:18:25Z
QuarkXPress(tm) 6.5
2015-09-02T01:41:55-07:00
2015-09-02T01:41:55-07:00
QuarkXPress(tm) 6.5
%%DocumentProcessColors: Cyan Magenta Yellow Black
%%EndComments
uuid:3d760dfe-1dd2-11b2-0a00-8609273dd000
uuid:3d760e03-1dd2-11b2-0a00-10f600000000
application/pdf
endstream
endobj
3 0 obj
<<
/Nums [0 6 0 R]
>>
endobj
4 0 obj
<<
/Count 6
/Kids [7 0 R 8 0 R 9 0 R 10 0 R 11 0 R 12 0 R]
/Type /Pages
>>
endobj
6 0 obj
<<
/S /D
/St 38
>>
endobj
7 0 obj
<<
/Annots [13 0 R]
/Contents 14 0 R
/MediaBox [0 0 595.276 841.89001]
/Parent 4 0 R
/Resources <<
/ExtGState <<
/GS0 15 0 R
/GS1 16 0 R
/GS2 17 0 R
/GS3 18 0 R
/GS4 19 0 R
>>
/Font <<
/T1_0 20 0 R
/T1_1 21 0 R
/T1_2 22 0 R
/T1_3 23 0 R
/T1_4 24 0 R
/T1_5 25 0 R
/T1_6 26 0 R
/T1_7 27 0 R
/T1_8 28 0 R
>>
/ProcSet [/PDF /Text]
>>
/Type /Page
>>
endobj
8 0 obj
<<
/Annots [29 0 R]
/Contents 30 0 R
/MediaBox [0 0 595.276 841.89001]
/Parent 4 0 R
/Resources <<
/ExtGState <<
/GS0 15 0 R
/GS1 31 0 R
/GS2 32 0 R
/GS3 33 0 R
/GS4 34 0 R
>>
/Font <<
/T1_0 23 0 R
/T1_1 22 0 R
/T1_2 20 0 R
/T1_3 21 0 R
/T1_4 24 0 R
/T1_5 25 0 R
/T1_6 27 0 R
/T1_7 28 0 R
>>
/ProcSet [/PDF /Text]
>>
/Type /Page
>>
endobj
9 0 obj
<<
/Annots [35 0 R]
/Contents 36 0 R
/MediaBox [0 0 595.276 841.89001]
/Parent 4 0 R
/Resources <<
/ExtGState <<
/GS0 15 0 R
/GS1 37 0 R
/GS2 38 0 R
/GS3 39 0 R
/GS4 40 0 R
>>
/Font <<
/T1_0 22 0 R
/T1_1 23 0 R
/T1_2 20 0 R
/T1_3 24 0 R
/T1_4 27 0 R
/T1_5 25 0 R
/T1_6 28 0 R
>>
/ProcSet [/PDF /Text]
>>
/Type /Page
>>
endobj
10 0 obj
<<
/Annots [41 0 R]
/Contents 42 0 R
/MediaBox [0 0 595.276 841.89001]
/Parent 4 0 R
/Resources <<
/ExtGState <<
/GS0 15 0 R
/GS1 43 0 R
/GS2 44 0 R
/GS3 45 0 R
/GS4 46 0 R
>>
/Font <<
/T1_0 23 0 R
/T1_1 22 0 R
/T1_2 20 0 R
/T1_3 24 0 R
/T1_4 47 0 R
/T1_5 25 0 R
/T1_6 21 0 R
/T1_7 48 0 R
/T1_8 28 0 R
>>
/ProcSet [/PDF /Text]
>>
/Type /Page
>>
endobj
11 0 obj
<<
/Annots [49 0 R 50 0 R 51 0 R 52 0 R 53 0 R 54 0 R 55 0 R 56 0 R 57 0 R 58 0 R
59 0 R 60 0 R 61 0 R 62 0 R 63 0 R 64 0 R 65 0 R 66 0 R 67 0 R 68 0 R
69 0 R 70 0 R 71 0 R 72 0 R 73 0 R 74 0 R 75 0 R]
/Contents [76 0 R 77 0 R 78 0 R 79 0 R 80 0 R 81 0 R 82 0 R 83 0 R 84 0 R 85 0 R
86 0 R 87 0 R 88 0 R 89 0 R 90 0 R 91 0 R 92 0 R 93 0 R 94 0 R 95 0 R
96 0 R]
/MediaBox [0 0 595.276 841.89001]
/Parent 4 0 R
/Resources <<
/ExtGState <<
/GS0 15 0 R
/GS1 97 0 R
/GS2 98 0 R
/GS3 99 0 R
/GS4 100 0 R
>>
/Font <<
/T1_0 22 0 R
/T1_1 23 0 R
/T1_2 20 0 R
/T1_3 24 0 R
/T1_4 25 0 R
/T1_5 27 0 R
/T1_6 47 0 R
/T1_7 101 0 R
/T1_8 28 0 R
>>
/ProcSet [/PDF /Text]
>>
/Type /Page
>>
endobj
12 0 obj
<<
/Annots [102 0 R 103 0 R 104 0 R 105 0 R 106 0 R 107 0 R 108 0 R 109 0 R 110 0 R 111 0 R
112 0 R 113 0 R 114 0 R 115 0 R 116 0 R 117 0 R 118 0 R 119 0 R 120 0 R 121 0 R
122 0 R 123 0 R 124 0 R 125 0 R 126 0 R 127 0 R 128 0 R 129 0 R 130 0 R 131 0 R]
/Contents [132 0 R 133 0 R 134 0 R 135 0 R 136 0 R 137 0 R 138 0 R 139 0 R 140 0 R 141 0 R
142 0 R 143 0 R 144 0 R 145 0 R 146 0 R 147 0 R 148 0 R 149 0 R 150 0 R 151 0 R
152 0 R 153 0 R 154 0 R 155 0 R]
/MediaBox [0 0 595.276 841.89001]
/Parent 4 0 R
/Resources <<
/ExtGState <<
/GS0 15 0 R
/GS1 156 0 R
/GS2 157 0 R
/GS3 158 0 R
/GS4 159 0 R
>>
/Font <<
/T1_0 23 0 R
/T1_1 22 0 R
/T1_2 20 0 R
/T1_3 24 0 R
/T1_4 47 0 R
/T1_5 101 0 R
/T1_6 27 0 R
/T1_7 21 0 R
/T1_8 28 0 R
/F10 160 0 R
>>
/ProcSet [/PDF /Text]
>>
/Type /Page
>>
endobj
13 0 obj
<<
/A 161 0 R
/Border [0 0 0]
/Rect [262.31 9.0 302.105 16.0]
/Subtype /Link
/Type /Annot
>>
endobj
14 0 obj
<<
/Length 15415
>>
stream
q
0 0.89 595 841 re
W n
1 g
/GS0 gs
0 841.89 0 0 re
f
Q
0.27 0.06 0 0 k
/GS1 gs
586.772 785.1971 581.952 65.197 re
f
0.95 0.7 0.06 0 K
2 w
/GS2 gs
587.163 785.8901 m
1200.621 785.8901 l
S
0 1 0.60001 0.27 k
/GS1 gs
-8.504 785.718 28.347 64.676 re
f
0.27 0.06 0 0 k
/GS2 gs
21.827 785.1971 581.953 65.197 re
f
BT
0 0 0 1 k
/GS3 gs
/T1_0 1 Tf
-0.021 Tc 0.02901 Tw 12.5 0 0 12.5 42.5197 793.7891 Tm
[(R)26 (e)24 (vie)21 (w ar)-18 (ticle)10 (s)]TJ
ET
/GS2 gs
-8.112 785.8901 m
605.345 785.8901 l
S
BT
/GS3 gs
/T1_1 1 Tf
-0.0002 Tc 0 Tw 7 0 0 7 441.9043 793.7717 Tm
(\251)Tj
0 Tc 0.026 Tw 1.12159 0.00001 Td
[(T)12 (he In)5 (t)20 (ensiv)18 (e C)11 (ar)25 (e S)8 (ocie)8 (t)20 (y 2)18 (009)]TJ
ET
BT
/T1_2 1 Tf
0 Tw 8.5 0 0 8.5 401.6363 29.4783 Tm
(V)Tj
0.026 Tw 0.51587 0.00001 Td
(olume 10, Number 1)Tj
8.5376 -0.0706 Td
(,)Tj
0 Tw 0.52672 0.07059 Td
(Januar)Tj
-0.0002 Tc 2.6018 0.00001 Td
(y)Tj
0 Tc 0.74743 0 Td
(2009)Tj
ET
BT
/T1_3 1 Tf
9.3 0 0 9.3 534.3687 28.8783 Tm
(JICS)Tj
ET
BT
/T1_0 1 Tf
9 0 0 9 42.5197 29.0855 Tm
(38)Tj
ET
BT
0.95 0.7 0.06 0 k
/T1_0 1 Tf
-0.021 Tc 0.02299 Tw 11 0 0 11 42.5197 485.5606 Tm
[(W)10 (hat is s)10 (elenium)58 (?)]TJ
ET
BT
0 0 0 1 k
/T1_4 1 Tf
-0.011 Tc 0.332 Tw 9.5 0 0 9.5 42.5197 470.6354 Tm
[(Selenium is a trace mineral with impor)10 (t)-1 (a)-1 (n)-1 (t)-1 ( )-1 (s)-1 (t)-1 (r)-1 (uctural and)]TJ
0.177 Tw 0 -1.2727 TD
[(enzymatic r)14.2 (oles, found in minute quantities within the body)135 (.)]TJ
0.12601 Tw 0 -1.27269 TD
(The main dietar)Tj
-0.0105 Tc 6.70987 0 Td
(y)Tj
-0.011 Tc 0.84528 0 Td
[(sour)40 (ces of selenium ar)19 (e fr)20 (om br)19 (ead, cer)20 (eals,)]TJ
0.30099 Tw -7.55515 -1.2727 Td
[(\336)-1 (sh, and meat; brazil nuts contain the highest quantity of)]TJ
0.464 Tw 0 -1.27268 TD
(selenium per gram.)Tj
ET
BT
/T1_4 1 Tf
0 Tc 0 Tw 5.415 0 0 5.415 125.5114 425.9337 Tm
(1)Tj
ET
BT
/T1_4 1 Tf
-0.011 Tc 0.464 Tw 9.5 0 0 9.5 135.0279 422.2731 Tm
(The Recommended Daily Allowance)Tj
0.185 Tw -9.73771 -1.27269 Td
(\(RDA\) of selenium is 60)Tj
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 9.5 0 0 9.5 145.1482 410.1826 Tm
(m)Tj
ET
BT
/T1_4 1 Tf
-0.0105 Tc 9.5 0 0 9.5 150.5268 410.1826 Tm
(g)Tj
-0.011 Tc 0.185 Tw 0.90363 0 Td
(for women and 75)Tj
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 9.5 0 0 9.5 237.2757 410.1826 Tm
(m)Tj
ET
BT
/T1_4 1 Tf
-0.0105 Tc 9.5 0 0 9.5 242.6544 410.1826 Tm
(g)Tj
-0.011 Tc 0.185 Tw 0.90363 0 Td
(for men.)Tj
ET
BT
/T1_4 1 Tf
0 Tc 0 Tw 5.415 0 0 5.415 285.616 413.8431 Tm
(2)Tj
ET
BT
/T1_4 1 Tf
-0.00999 Tc 0.037 Tw 9.5 0 0 9.5 42.5197 398.0919 Tm
[(T)1 (h)1 (e)1 ( W)71 (o)1 (r)1 (l)1 (d)1 ( H)1 (e)1 (a)1 (l)1 (t)1 (h)1 ( O)1 (r)30 (ganisation )-1 (suggests )-1 (40)]TJ
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 9.5 0 0 9.5 214.4311 398.0919 Tm
(m)Tj
ET
BT
/T1_4 1 Tf
-0.011 Tc 0.03799 Tw 9.5 0 0 9.5 219.8098 398.0919 Tm
(g/day of selenium)Tj
0.04401 Tw -18.66212 -1.27269 Td
(is necessar)Tj
-0.0105 Tc 4.33944 0 Td
(y)Tj
-0.011 Tc 0.76302 0 Td
[(to pr)17.2 (event disease, but in the UK, cur)]TJ
0 Tc 15.4066 0 Td
(r)Tj
-0.011 Tc 0.33973 0 Td
(ent intake is)Tj
0.052 Tw -20.84879 -1.2727 Td
(estimated at 34)Tj
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 9.5 0 0 9.5 104.1816 373.9109 Tm
(m)Tj
ET
BT
/T1_4 1 Tf
-0.011 Tc 9.5 0 0 9.5 109.5603 373.9109 Tm
(g/day;)Tj
ET
BT
/T1_4 1 Tf
0 Tc 5.415 0 0 5.415 132.522 377.5714 Tm
(3)Tj
ET
BT
/T1_4 1 Tf
-0.011 Tc 0.052 Tw 9.5 0 0 9.5 138.1259 373.9109 Tm
(this value has fallen following changes)Tj
0.076 Tw -10.06381 -1.2727 Td
[(in the wheat supply for br)9.4 (ead manufactur)20 (e fr)19 (om selenium-rich)]TJ
0.35899 Tw 0 -1.27269 TD
[(Nor)10 (th America to the r)19 (elatively selenium-depleted Eur)20 (ope.)]TJ
0.131 Tw 0 -1.2727 TD
[(This r)20 (educed intake has been r)19 (e\337ected in lower plasma levels)]TJ
0.157 Tw 0 -1.27268 TD
(in the general population.)Tj
ET
BT
/T1_4 1 Tf
0 Tw 5.415 0 0 5.415 146.4311 329.2091 Tm
(4,5)Tj
ET
BT
/T1_4 1 Tf
0.157 Tw 9.5 0 0 9.5 157.1321 325.5485 Tm
(The mean plasma selenium level)Tj
0.19501 Tw -12.06446 -1.2727 Td
[(believed to be necessar)-5 (y for optimal selenopr)20 (otein activity is)]TJ
0.08 Tw 0 -1.27269 TD
(about 100)Tj
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 9.5 0 0 9.5 84.3533 301.3674 Tm
(m)Tj
ET
BT
/T1_4 1 Tf
-0.011 Tc 9.5 0 0 9.5 89.732 301.3674 Tm
(g/L;)Tj
ET
BT
/T1_4 1 Tf
0 Tc 5.415 0 0 5.415 104.2861 305.028 Tm
(6)Tj
ET
BT
/T1_4 1 Tf
-0.011 Tc 0.08 Tw 9.5 0 0 9.5 110.1626 301.3674 Tm
(the cur)Tj
0 Tc 2.95088 0.00001 Td
(r)Tj
-0.011 Tc 0.33973 0.00001 Td
(ent EU average is 79)Tj
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 9.5 0 0 9.5 225.2235 301.3674 Tm
(m)Tj
ET
BT
/T1_4 1 Tf
-0.011 Tc 9.5 0 0 9.5 230.6022 301.3674 Tm
(g/L.)Tj
ET
BT
/T1_4 1 Tf
0 Tc 5.415 0 0 5.415 245.1562 305.028 Tm
(7)Tj
ET
BT
/T1_4 1 Tf
-0.011 Tc 0.08 Tw 9.5 0 0 9.5 251.0328 301.3674 Tm
(At risk of)Tj
0.328 Tw -21.94875 -1.27269 Td
[(selenium de\336)-6.3 (ciency ar)]TJ
-0.0105 Tc 9.69225 0.00002 Td
(e)Tj
-0.011 Tc 1.01025 0 Td
(people with poor quality diets, eg)Tj
0.244 Tw -10.7025 -1.27271 Td
[(alcoholics, or those with r)20 (educed dietar)-5 (y intake, eg chr)19 (onic)]TJ
0.021 Tw 0 -1.27268 TD
[(illness, and patients r)9.3 (eceiving total par)11.4 (enteral nutrition \(TPN\). )]TJ
ET
BT
0.95 0.7 0.06 0 k
/T1_0 1 Tf
-0.021 Tc 0.02299 Tw 11 0 0 11 42.5197 242.5011 Tm
[(W)10 (hat ar)15 (e the c)11 (ons)10 (equenc)12 (e)10 (s o)15 (f s)9 (elenium)]TJ
0 Tw 0 -1.28096 TD
[(de)4 (f)5 (icienc)11 (y)10 (?)]TJ
ET
BT
0 0 0 1 k
/T1_4 1 Tf
-0.011 Tc 0.367 Tw 9.5 0 0 9.5 42.5197 213.4853 Tm
[(T)129 (wo selenium-de\336cient disease states have been described:)]TJ
0.02299 Tw 0 -1.27269 TD
[(Keshan disease \(a car)7.9 (diomyopathy\) and Kashin-Bek disease \(an)]TJ
0.181 Tw T*
[(osteoar)10 (thr)19 (opathy\). Patients on long-term TPN or with sever)20 (e)]TJ
0.22301 Tw 0 -1.2727 TD
[(malnutrition can develop featur)3.3 (es similar to Keshan disease.)]TJ
0.116 Tw 0 -1.27268 TD
[(Low plasma selenium levels without over)10 (t de\336)-1 (ciency give rise)]TJ
0.75999 Tw 0 -1.27269 TD
[(to an impair)20 (ed immune r)19 (esponse and may incr)20 (ease)]TJ
0.38901 Tw T*
[(susceptibility to disor)8 (ders including car)20 (diovascular disease,)]TJ
0.489 Tw 0 -1.2727 TD
[(mood disor)14.9 (ders, cancer)]TJ
-0.0105 Tc 10.35911 0.00002 Td
(,)Tj
-0.011 Tc 0.986 0 Td
[(male infer)4.9 (tility and spontaneous)]TJ
0.185 Tw -11.34511 -1.27269 Td
[(abor)10 (tions. It is postulated that har)-1 (mless viruses may become)]TJ
0.114 Tw T*
[(viru)-1 (l)-1 (e)-1 (n)-1 (t)-1 ( )-1 (b)-1 (y)-1 ( )-1 (p)-1 (a)-1 (s)-1 (s)-1 (i)-1 (n)-1 (g)-1 ( )-1 (t)-1 (h)-1 (r)18 (ough a selenium-)1 (de\336)-1 (cient host; Keshan)]TJ
0.073 Tw 0 -1.27269 TD
(disease may be secondar)Tj
-0.0105 Tc 10.08955 0.00001 Td
(y)Tj
-0.011 Tc 0.79176 0 Td
[(to coxsackie vir)-7.4 (us infection, and the)]TJ
0.252 Tw -10.8813 -1.2727 Td
[(emer)30 (gence of HIV in Zair)19 (e and new strains of in\337uenza in)]TJ
0.429 Tw 0 -1.27267 TD
[(China may be r)12.8 (elated to these countries being r)]TJ
0 Tw 22.52585 0.00002 Td
(elatively)Tj
0.34801 Tw -22.52584 -1.27271 Td
(selenium de\336cient. Plasma selenium levels appear to be a)Tj
0.349 Tw 27.82429 45.40576 Td
[(str)20 (ong pr)19 (edictor of outcome in HIV disease and selenium)]TJ
0.32201 Tw 0 -1.28798 TD
[(supplementation appears to inhibit the pr)20 (ogr)19 (ession of HIV)]TJ
0.021 Tw 0 -1.28797 TD
[(disease to AIDS and pr)20 (events HIV r)19 (eplication.)]TJ
ET
BT
/T1_4 1 Tf
0 Tc 0 Tw 5.415 0 0 5.415 483.4133 466.8517 Tm
(8)Tj
ET
BT
/T1_4 1 Tf
-0.011 Tc 0.16701 Tw 9.5 0 0 9.5 318.189 450.9552 Tm
(In critically ill patients, plasma selenium levels fall during)Tj
0.07201 Tw -1.19354 -1.28796 Td
[(periods of oxidative str)20 (ess as occurs with sever)19 (e sepsis and the)]TJ
0.11501 Tw 0 -1.28798 TD
[(s)-1 (y)-1 (s)-1 (t)-1 (e)-1 (m)-1 (i)-1 (c)-1 ( )-1 (i)-1 (n)-1 (\337)-1 (ammator)-5 (y r)19 (esponse syndr)20 (ome \(SIRS\) and ther)20 (e is)]TJ
0 Tw 0 -1.28797 TD
(incr)Tj
0.505 Tw 1.58621 0 Td
(easing evidence that selenium may be an impor)Tj
-0.00999 Tc 0 Tw 22.70003 0 Td
(tant)Tj
-0.011 Tc 0.479 Tw -24.28624 -1.28798 Td
[(adjuvant therapy possibly of)-4.7 (fering a mor)3.6 (tality bene\336)]TJ
-0.0105 Tc 24.02926 0 Td
(t)Tj
-0.011 Tc 0 Tw 1.03206 0 Td
(to)Tj
-0.00999 Tc 0.021 Tw -25.06133 -1.28799 Td
(patients with sever)Tj
-0.0105 Tc 7.61734 0 Td
(e)Tj
-0.011 Tc 0 Tw 0.70265 0 Td
(sepsis.)Tj
ET
BT
0.95 0.7 0.06 0 k
/T1_0 1 Tf
-0.021 Tc 0.02299 Tw 11 0 0 11 306.8504 367.0367 Tm
[(W)10 (hat is the e)25 (videnc)11 (e that critic)5 (ally ill p)8 (atien)5 (t)7 (s)]TJ
0 -1.29416 TD
[(ar)15 (e s)10 (elenium de)4 (f)5 (icien)5 (t)14 (?)]TJ
ET
BT
0 0 0 1 k
/T1_4 1 Tf
-0.011 Tc 0.14301 Tw 9.5 0 0 9.5 306.8504 337.7305 Tm
[(Plasma selenium levels ar)20 (e r)19 (educed in the critically ill due to)]TJ
0.39 Tw 0 -1.28796 TD
[(the chr)16.6 (onic de\336)-3.5 (ciency in the general population, r)]TJ
0 Tw 22.97546 0.00003 Td
(educed)Tj
0.369 Tw -22.97545 -1.288 Td
[(nutritional intake, haemodilution and biological \337)-22.5 (uid loss.)]TJ
0 Tw 0 -1.28798 TD
(However)Tj
-0.0105 Tc 3.55876 0.00001 Td
(,)Tj
-0.011 Tc 0.44501 Tw 0.94152 0 Td
[(it is dif)6.3 (\336)-1 (cult to interpr)20 (et micr)20 (onutrient plasma)]TJ
0.272 Tw -4.50028 -1.28797 Td
[(concentrations thr)20 (oughout the acute phase r)19 (esponse due to)]TJ
0.474 Tw T*
[(r)19 (educed binding pr)20 (oteins, in par)10 (ticular albumin, thr)19 (ough)]TJ
0.418 Tw 0 -1.28796 TD
[(utilisation and r)20 (edistribution. It was \336rst established that)]TJ
0.14101 Tw 0 -1.28798 TD
[(selenium de\336ciency occurr)19 (ed in critically ill patients in 1990,)]TJ
0.02299 Tw T*
[(wher)20 (e a 40% r)19 (eduction in plasma selenium on admission to the)]TJ
0.11 Tw 0 -1.28797 TD
[(intensive car)20 (e unit \(ICU\) was demonstrated, not explained by)]TJ
0.021 Tw 0 -1.28798 TD
[(an incr)20 (ease in urinar)-5 (y selenium excr)19 (etion.)]TJ
ET
BT
/T1_4 1 Tf
0 Tc 0 Tw 5.415 0 0 5.415 469.1903 219.0336 Tm
(9)Tj
ET
BT
/T1_4 1 Tf
-0.011 Tc 0.08099 Tw 9.5 0 0 9.5 318.189 203.1371 Tm
[(For)40 (ceville and colleagues)]TJ
ET
BT
/T1_4 1 Tf
0 Tw 5.415 0 0 5.415 416.0493 206.7978 Tm
(10)Tj
ET
BT
/T1_4 1 Tf
0.08099 Tw 9.5 0 0 9.5 424.6834 203.1371 Tm
(studied selenium kinetics in 134)Tj
0.461 Tw -12.40347 -1.28796 Td
(consecutive admissions to the ICU with sepsis, SIRS or)Tj
0.133 Tw T*
[(ischaemia-r)20 (eper)9 (fusion injur)-5 (y)134 (. Mean plasma selenium levels on)]TJ
0.06799 Tw T*
[(admission wer)20 (e low at 0.68)]TJ
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 9.5 0 0 9.5 416.4899 166.4298 Tm
(m)Tj
ET
BT
/T1_4 1 Tf
-0.011 Tc 0.06799 Tw 9.5 0 0 9.5 421.8686 166.4298 Tm
(mol/L \(54)Tj
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 9.5 0 0 9.5 463.2306 166.4298 Tm
(m)Tj
ET
BT
/T1_4 1 Tf
-0.011 Tc 0.06799 Tw 9.5 0 0 9.5 468.6093 166.4298 Tm
[(g/L\) with a dif)10 (fer)19 (ence)]TJ
0.065 Tw -17.02725 -1.28797 Td
(in levels between patients with and without SIRS \(0.62)Tj
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 9.5 0 0 9.5 524.5408 154.1941 Tm
(m)Tj
ET
BT
/T1_4 1 Tf
-0.011 Tc 9.5 0 0 9.5 529.9194 154.1941 Tm
(mol/L)Tj
-23.48094 -1.28798 Td
(\(49)Tj
ET
BT
/T1_5 1 Tf
0 Tc 9.5 0 0 9.5 322.4725 141.9583 Tm
(m)Tj
ET
BT
/T1_4 1 Tf
-0.011 Tc 0.31799 Tw 9.5 0 0 9.5 327.8512 141.9583 Tm
(g/L\) and 0.83)Tj
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 9.5 0 0 9.5 387.929 141.9583 Tm
(m)Tj
ET
BT
/T1_4 1 Tf
-0.011 Tc 0.31799 Tw 9.5 0 0 9.5 393.3077 141.9583 Tm
(mol/L \(66)Tj
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 9.5 0 0 9.5 437.0524 141.9583 Tm
(m)Tj
ET
BT
/T1_4 1 Tf
-0.011 Tc 0.31799 Tw 9.5 0 0 9.5 442.431 141.9583 Tm
[(g/L\) r)20 (e)-1 (s)-1 (p)-1 (e)-1 (c)-1 (t)-1 (i)-1 (v)-1 (e)-1 (l)-1 (y)143 (, p<0.001\).)]TJ
0.41701 Tw -14.27164 -1.28796 Td
[(Non-sur)-10 (vivors\325 plasma selenium levels fell despite modest)]TJ
0.18401 Tw T*
(supplementation \(40)Tj
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 9.5 0 0 9.5 391.4242 117.4869 Tm
(m)Tj
ET
BT
/T1_4 1 Tf
-0.011 Tc 0.18401 Tw 9.5 0 0 9.5 396.8029 117.4869 Tm
(g/day\) and patients with a level below)Tj
0 Tw -9.46868 -1.28798 Td
(0.7)Tj
ET
BT
/T1_5 1 Tf
0 Tc 9.5 0 0 9.5 321.2363 105.2511 Tm
(m)Tj
ET
BT
/T1_4 1 Tf
-0.011 Tc 0.392 Tw 9.5 0 0 9.5 326.615 105.2511 Tm
(mol/L \(55)Tj
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 9.5 0 0 9.5 371.057 105.2511 Tm
(m)Tj
ET
BT
/T1_4 1 Tf
-0.011 Tc 0.392 Tw 9.5 0 0 9.5 376.4357 105.2511 Tm
[(g/L\) on admission had signi\336cantly mor)20 (e)]TJ
0.021 Tw -7.32477 -1.28797 Td
[(complications and an incr)20 (eased mor)9 (t)-1 (a)-1 (l)-1 (i)-1 (t)-1 (y)134 (. )]TJ
0.321 Tw 1.19354 -1.28798 Td
(Sakr and co-workers)Tj
ET
BT
/T1_4 1 Tf
0 Tw 5.415 0 0 5.415 403.4335 84.4402 Tm
(11)Tj
ET
BT
/T1_4 1 Tf
0.321 Tw 9.5 0 0 9.5 414.3495 80.7796 Tm
(also examined selenium levels in)Tj
0.04201 Tw -11.31569 -1.28798 Td
[(r)19 (elation to sepsis and SIRS. On ICU admission, 92% of patients)]TJ
0.248 Tw 0 -1.28796 TD
(had plasma selenium levels below 74)Tj
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 9.5 0 0 9.5 463.1829 56.3081 Tm
(m)Tj
ET
BT
/T1_4 1 Tf
-0.011 Tc 0.248 Tw 9.5 0 0 9.5 468.5616 56.3081 Tm
[(g/L \320 their r)20 (efer)19 (ence)]TJ
ET
BT
/T1_0 1 Tf
-0.01401 Tc 0.02901 Tw 26 0 0 26 42.5197 730.3864 Tm
[(S)10 (elenium in critic)5 (ally ill p)8 (atien)4 (t)7 (s)]TJ
ET
BT
/T1_3 1 Tf
-0.00011 Tc 0 Tw 11.5 0 0 11.5 42.5197 700.2132 Tm
(S)Tj
0 Tc -0.04201 Tw 0.79213 0 Td
[(Strachan, D W)30 (yncoll)]TJ
ET
BT
/T1_1 1 Tf
-0.019 Tc 0.021 Tw 9.75 0 0 9.75 42.5197 658.3746 Tm
[(T)12 (her)25 (e is incr)25 (e)7 (asing e)20 (videnc)17 (e that p)8 (ar)-10 (tic)5 (ular nutritional sub)8 (s)10 (tr)35 (a)1 (t)20 (e)11 (s ma)15 (y be impor)-11 (t)16 (a)1 (n)5 (t in critic)17 (ally ill p)8 (atien)5 (t)8 (s and in r)24 (e)1 (c)18 (e)1 (n)6 (t)]TJ
0 Tc 0 -1.48718 TD
(y)Tj
-0.019 Tc 0.49149 -0.00001 Td
[(e)8 (ar)19 (s ther)25 (e has been gr)25 (o)18 (wing in)5 (t)21 (er)24 (e)11 (s)10 (t in s)10 (elenium. T)12 (his r)25 (e)20 (vie)20 (w aims t)20 (o outline the incidenc)17 (e)1 ( )1 (o)16 (f s)9 (elenium de)5 (f)5 (icienc)8 (y in)]TJ
-0.49149 -1.48717 Td
[(critic)17 (ally ill p)8 (atien)5 (t)7 (s)13 (, the c)17 (ons)9 (equenc)17 (e)11 (s)1 ( )1 (o)15 (f such a de)5 (f)5 (icienc)8 (y and pr)25 (e)10 (s)11 (e)1 (n)6 (t the e)19 (videnc)17 (e f)22 (or)125 (, and e)5 (f)15 (f)22 (ect o)15 (f)55 (, s)10 (elenium)]TJ
T*
[(supplemen)5 (t)15 (ation in the)10 (s)10 (e)1 ( )1 (p)9 (atien)5 (t)7 (s)13 (. S)8 (elenium le)20 (v)18 (els f)35 (all during periods o)14 (f o)20 (xidativ)18 (e)1 ( )1 (s)11 (tr)25 (e)10 (s)11 (s as oc)17 (c)5 (ur)20 (s in critic)17 (ally ill p)8 (atien)4 (t)8 (s)]TJ
T*
[(with c)17 (onditions such as s)10 (e)20 (v)19 (er)24 (e)1 ( )1 (s)11 (e)1 (p)9 (sis)12 (, burns)11 (, and f)22 (ollo)18 (wing tr)35 (auma. Dat)15 (a fr)25 (om individual s)9 (t)9 (udie)10 (s and me)8 (t)15 (a)1 (-)16 (ana)-1 (ly)20 (s)11 (e)10 (s)]TJ
0 -1.48719 TD
[(sugge)10 (s)10 (t)8 (s that s)10 (elenium is an impor)-10 (t)15 (a)1 (n)5 (t adjuv)28 (a)1 (n)6 (t ther)35 (a)1 (p)20 (y in c)17 (er)-10 (t)15 (ain critic)17 (ally ill p)8 (atien)5 (t)8 (s and supplemen)4 (t)16 (ation o)14 (f s)10 (elenium)]TJ
0 -1.48717 TD
[(m)1 (a)16 (y)1 ( )1 (o)15 (f)15 (f)23 (er a mor)-10 (t)15 (alit)20 (y bene)4 (f)6 (it)9 (. )]TJ
ET
0.125 w
/GS1 gs
42.52 536.697 m
292.302 536.697 l
S
BT
/GS3 gs
/T1_6 1 Tf
-0.011 Tc 0 Tw 9.5 0 0 9.5 42.5197 542.3668 Tm
[(Keywor)15 (ds:)]TJ
ET
BT
/T1_7 1 Tf
-0.00999 Tc -0.037 Tw 9.5 0 0 9.5 84.0935 542.3668 Tm
[(selenium; sepsis; septic shock; intensive car)50 (e; antioxidants)]TJ
ET
1 w
/GS1 gs
42.52 39.685 m
552.756 39.685 l
S
BT
0 g
/GS4 gs
/T1_8 1 Tf
0 Tc 0 Tw 5 0 0 5 301.10497 11 Tm
( by guest on September 2, 2015)Tj
0 0 1 rg
/GS4 gs
-7.55899 0 Td
(inc.sagepub.com)Tj
0 g
/GS4 gs
-8.11399 0 Td
(Downloaded from )Tj
ET
endstream
endobj
15 0 obj
<<
/OPM 1
/Type /ExtGState
>>
endobj
16 0 obj
<<
/OP true
/OPM 1
/SM 0.00999451
/Type /ExtGState
/op true
>>
endobj
17 0 obj
<<
/OP false
/OPM 1
/SM 0.00999451
/Type /ExtGState
/op false
>>
endobj
18 0 obj
<<
/FL 1
/OP true
/OPM 1
/SM 0.00999451
/Type /ExtGState
/op true
>>
endobj
19 0 obj
<<
/OP false
/OPM 0
/SM 1.0
/op false
>>
endobj
20 0 obj
<<
/BaseFont /MIAMIH+Interstate-Bold
/Encoding 162 0 R
/FirstChar 32
/FontDescriptor 163 0 R
/LastChar 121
/Subtype /Type1
/Type /Font
/Widths [290 0 0 0 0 0 0 0 370 370
500 613 0 407 272 470 688 385 683 645
695 0 0 0 702 663 0 0 0 0
0 584 0 750 0 670 707 0 0 698
747 340 0 0 0 835 747 714 680 0
714 661 632 737 0 881 0 0 0 0
0 0 0 0 0 556 562 537 562 538
370 562 584 282 0 0 282 881 584 555
562 562 428 537 442 584 570 742 574 590]
>>
endobj
21 0 obj
<<
/BaseFont /MXMCYF+Interstate-Light
/Encoding 164 0 R
/FirstChar 32
/FontDescriptor 165 0 R
/LastChar 213
/Subtype /Type1
/Type /Font
/Widths [260 0 0 0 0 0 0 0 348 348
500 577 240 322 240 425 642 312 569 563
625 605 614 556 636 614 0 0 0 577
0 561 836 678 626 628 658 0 548 659
688 272 0 642 575 788 688 0 618 0
650 592 588 678 0 0 0 0 628 0
0 0 0 0 0 539 559 495 559 540
356 559 567 251 251 505 251 848 567 566
559 559 407 467 372 567 522 730 504 531
492 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 836 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 469 469
0 252]
>>
endobj
22 0 obj
<<
/BaseFont /JLNEBO+Berkeley-Book
/Encoding 166 0 R
/FirstChar 32
/FontDescriptor 167 0 R
/LastChar 121
/Subtype /Type1
/Type /Font
/Widths [259 0 0 0 0 0 0 0 0 0
0 0 259 0 0 0 519 519 519 0
0 0 0 0 0 519 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 315 0 0 0 722 0 0 0
0 0 0 0 611 0 0 0 0 0
0 0 0 0 0 426 519 0 0 426
0 0 0 0 0 0 259 796 537 500
0 0 352 0 0 537 0 0 0 463]
>>
endobj
23 0 obj
<<
/BaseFont /TFXMNR+Berkeley-Black
/Encoding 168 0 R
/FirstChar 32
/FontDescriptor 169 0 R
/LastChar 121
/Subtype /Type1
/Type /Font
/Widths [278 0 0 0 0 0 0 0 0 0
0 0 278 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 685 741 0 0 0
0 370 370 0 0 0 0 0 0 0
0 556 0 0 0 981 0 0 0 0
0 0 0 0 0 524 0 460 0 455
0 0 574 301 0 0 301 0 574 537
574 0 407 0 352 574 0 0 0 500]
>>
endobj
24 0 obj
<<
/BaseFont /BFOTJG+Berkeley-Medium
/Encoding 170 0 R
/FirstChar 32
/FontDescriptor 171 0 R
/LastChar 223
/Subtype /Type1
/Type /Font
/Widths [259 0 0 0 0 759 870 0 389 389
0 0 259 333 259 278 519 519 519 519
519 519 519 519 519 519 259 259 519 519
519 444 0 648 549 685 704 593 574 722
722 333 333 667 556 852 741 741 556 0
611 478 611 704 648 963 648 0 593 0
0 0 0 500 0 444 519 444 537 444
296 481 556 278 278 537 278 815 556 519
537 519 370 389 315 556 481 722 519 481
444 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 500 0 0 800 800 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 500 0 0 0
0 185 0 0 0 0 0 0 0 0
556 556]
>>
endobj
25 0 obj
<<
/BaseFont /HGHDRU+Symbol
/Encoding 172 0 R
/FirstChar 32
/FontDescriptor 173 0 R
/LastChar 109
/Subtype /Type1
/Type /Font
/Widths [250 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 549 0 576]
>>
endobj
26 0 obj
<<
/BaseFont /YLPTDE+Berkeley-BlackItalic
/Encoding 174 0 R
/FirstChar 58
/FontDescriptor 175 0 R
/LastChar 121
/Subtype /Type1
/Type /Font
/Widths [268 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 667 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 519 444 0 0 0 0 0 0
0 0 0 500 0 0 389 407 0 0
0 648 0 444]
>>
endobj
27 0 obj
<<
/BaseFont /JMXSYX+Berkeley-Italic
/Encoding 176 0 R
/FirstChar 32
/FontDescriptor 177 0 R
/LastChar 120
/Subtype /Type1
/Type /Font
/Widths [250 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 250 0 0
0 0 0 611 574 648 685 574 556 704
0 315 315 648 537 815 704 685 537 0
574 500 593 0 0 0 0 0 574 0
0 0 0 0 0 481 0 407 481 407
0 463 500 278 0 500 278 741 500 463
481 0 389 370 296 500 444 0 461]
>>
endobj
28 0 obj
<<
/BaseFont /Helvetica
/Encoding /WinAnsiEncoding
/Subtype /Type1
/Type /Font
>>
endobj
29 0 obj
<<
/A 178 0 R
/Border [0 0 0]
/Rect [262.31 9.0 302.105 16.0]
/Subtype /Link
/Type /Annot
>>
endobj
30 0 obj
<<
/Length 16354
>>
stream
q
0 0.89 595 841 re
W n
1 g
/GS0 gs
0 841.89 0 0 re
f
Q
0 1 0.60001 0.27 k
/GS1 gs
575.433 785.718 28.346 64.676 re
f
0.27 0.06 0 0 k
-8.504 785.1971 581.9529 65.197 re
f
0.95 0.7 0.06 0 K
2 w
/GS2 gs
-8.112 785.8901 m
605.345 785.8901 l
S
BT
0 0 0 1 k
/GS3 gs
/T1_0 1 Tf
9.3 0 0 9.3 42.5197 28.8783 Tm
(JICS)Tj
ET
BT
/T1_1 1 Tf
8.5 0 0 8.5 65.9098 29.4783 Tm
(V)Tj
0.026 Tw 0.51587 0.00001 Td
(olume 10, Number 1)Tj
8.5376 -0.0706 Td
(,)Tj
0 Tw 0.52672 0.07059 Td
(Januar)Tj
-0.0002 Tc 2.60181 0.00001 Td
(y)Tj
0 Tc 0.74743 0 Td
(2009)Tj
ET
BT
/T1_2 1 Tf
9 0 0 9 540.9873 29.0855 Tm
(39)Tj
ET
1 w
/GS1 gs
42.52 39.685 m
552.756 39.685 l
S
BT
/GS3 gs
/T1_2 1 Tf
-0.021 Tc 0.02901 Tw 12.5 0 0 12.5 465.8717 793.7901 Tm
[(R)26 (e)24 (vie)21 (w ar)-18 (ticle)10 (s)]TJ
ET
BT
/T1_3 1 Tf
-0.0002 Tc 0 Tw 7 0 0 7 42.5197 793.7717 Tm
(\251)Tj
0 Tc 0.026 Tw 1.12159 0.00001 Td
[(T)12 (he In)5 (t)20 (ensiv)18 (e C)11 (ar)25 (e S)8 (ocie)8 (t)20 (y 2)18 (009)]TJ
ET
BT
/T1_4 1 Tf
-0.011 Tc 0.071 Tw 9.5 0 0 9.5 42.5197 744.4855 Tm
(level for healthy subjects. Plasma selenium levels subsequently)Tj
0.099 Tw 0 -1.27842 TD
[(decr)20 (eased in all patients with SIRS, especially when associated)]TJ
0.29201 Tw T*
(with sepsis, despite 100)Tj
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 9.5 0 0 9.5 144.2395 720.1955 Tm
(m)Tj
ET
BT
/T1_4 1 Tf
-0.011 Tc 0.29201 Tw 9.5 0 0 9.5 149.6182 720.1955 Tm
[(g/day of selenium. The degr)20 (ee of)]TJ
0.14301 Tw -11.27353 -1.27843 Td
[(or)29 (gan dysfunction appear)20 (ed to be a major determinant of the)]TJ
0.189 Tw T*
[(decline in selenium concentration, and the levels wer)20 (e again)]TJ
0.024 Tw T*
[(inversely r)20 (elated to the AP)74 (ACHE and SOF)60 (A scor)20 (es. A minimum)]TJ
0.07001 Tw T*
(plasma selenium level of 36)Tj
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 9.5 0 0 9.5 153.9312 671.6154 Tm
(m)Tj
ET
BT
/T1_4 1 Tf
-0.011 Tc 0.07001 Tw 9.5 0 0 9.5 159.3099 671.6154 Tm
[(g/L pr)20 (edicted ICU mor)9 (t)-1 (a)-1 (l)-1 (i)-1 (t)-1 (y)-1 ( )-1 (w)-1 (i)-1 (t)-1 (h)]TJ
-0.0105 Tc -12.29371 -1.27842 Td
(a)Tj
-0.00999 Tc 0.021 Tw 0.70271 -0.00001 Td
[(high sensitivity and speci\336c)1 (i)1 (t)1 (y)136 (.)1 ( )]TJ
-0.011 Tc 0.548 Tw 0.49083 -1.27843 Td
(These landmark studies on selenium kinetics in the)Tj
0.237 Tw -1.19354 -1.27842 Td
(critically ill demonstrated that the magnitude of the plasma)Tj
0.57899 Tw T*
[(selenium level negatively corr)19 (elates with the degr)20 (ee of)]TJ
0.25 Tw T*
[(oxidative str)20 (ess and may be pr)19 (edictive of outcome. Patients)]TJ
-0.00999 Tc 0.28999 Tw T*
(with sever)Tj
-0.0105 Tc 4.42348 0.00001 Td
(e)Tj
-0.011 Tc 0.97209 0 Td
[(sepsis and SIRS have the gr)20 (eatest r)19 (eduction in)]TJ
0.30299 Tw -5.39557 -1.27844 Td
[(selenium levels, which corr)19 (elates with the higher mor)10 (t)-1 (a)-1 (l)-1 (i)-1 (t)-1 (y)]TJ
0.086 Tw T*
(rates associated with these conditions. Since low plasma levels)Tj
-0.0105 Tc T*
(do)Tj
-0.011 Tc 0.075 Tw 1.35854 0 Td
[(not necessarily equate with de\336)-15.6 (ciency)145 (, selenium levels have)]TJ
0.388 Tw -1.35855 -1.27842 Td
[(been measur)20 (ed in conjunction with selenopr)19 (otein activity;)]TJ
0.808 Tw T*
[(r)19 (educed selenium levels ar)20 (e associated with r)20 (educed)]TJ
0.035 Tw 0 -1.27843 TD
[(glutathione per)20 (oxidase activity and ther)19 (efor)20 (e impairment of the)]TJ
-0.00999 Tc 0.83501 Tw T*
[(enzyme systems for which selenium is r)20 (e)1 (q)1 (u)1 (i)1 (r)20 (e)1 (d)1 ( )1 (i)1 (s)]TJ
-0.011 Tc 0 Tw 0 -1.27842 TD
(demonstrated.)Tj
ET
BT
/T1_4 1 Tf
-0.0106 Tc 5.415 0 0 5.415 97.6917 505.2458 Tm
(1)Tj
-0.011 Tc (2-14)Tj
ET
BT
/T1_4 1 Tf
-0.00999 Tc 0.54401 Tw 9.5 0 0 9.5 117.9845 501.5851 Tm
[(This )-1 (suggests )-1 (ther)20 (e)1 ( i)1 (s)1 ( a)1 ( d)1 (e)1 (\336)1 (c)1 (i)1 (e)1 (n)1 (c)1 (y)1 ( o)1 (f)]TJ
-0.011 Tc 0.23 Tw -7.94366 -1.27842 Td
(selenium in critically ill patients, especially in conditions of)Tj
0.021 Tw T*
(high oxidative str)Tj
0 Tw 7.11061 0 Td
(ess. )Tj
ET
BT
/T1_2 1 Tf
-0.01401 Tc -0.043 Tw 10.5 0 0 10.5 42.5197 459.4807 Tm
[(W)10 (hat happens during r)15 (enal r)14 (eplac)12 (emen)5 (t ther)25 (ap)20 (y)10 (?)]TJ
ET
BT
/T1_4 1 Tf
-0.011 Tc 0.151 Tw 9.5 0 0 9.5 42.5197 444.5011 Tm
[(Stor)-5 (y and colleagues)]TJ
ET
BT
/T1_4 1 Tf
0 Tw 5.415 0 0 5.415 124.1384 448.1617 Tm
(15)Tj
ET
BT
/T1_4 1 Tf
0.151 Tw 9.5 0 0 9.5 133.4381 444.5011 Tm
[(measur)20 (ed trace element elimination by)]TJ
0.291 Tw -9.57036 -1.27842 Td
[(continuous veno-venous haemo\336ltration, \336n)-1 (d)-1 (i)-1 (n)-1 (g)-1 ( )-1 (u)-1 (l)-1 (t)-1 (r)-1 (a)-1 (\336)-1 (ltrate)]TJ
0.144 Tw 0 -1.27843 TD
[(losses of vitamin C, copper and chr)20 (omium but not selenium.)]TJ
0.87 Tw 0 -1.27842 TD
[(However)70 (, animal studies have detected selenium in)]TJ
0 Tw T*
[(ultra\336)-3.1 (ltrate)]TJ
ET
BT
/T1_4 1 Tf
5.415 0 0 5.415 85.8317 399.5817 Tm
(16)Tj
ET
BT
/T1_4 1 Tf
-0.00999 Tc 0.16701 Tw 9.5 0 0 9.5 95.2859 395.921 Tm
(and some human studies have found signi\336)Tj
-0.011 Tc 0 Tw 18.60301 0.00001 Td
(cant)Tj
0.606 Tw -24.15735 -1.27843 Td
[(trace element losses in ICU patients under)30 (going r)19 (enal)]TJ
0.114 Tw T*
[(r)19 (eplacement therapy)]TJ
ET
BT
/T1_4 1 Tf
0 Tw 5.415 0 0 5.415 122.2457 375.2916 Tm
(17)Tj
ET
BT
/T1_4 1 Tf
-0.00999 Tc 0.114 Tw 9.5 0 0 9.5 131.1986 371.631 Tm
(in quantities suggesting selenium losses)Tj
-0.011 Tc 0 Tw -9.33462 -1.27842 Td
(ar)Tj
-0.0105 Tc 0.7732 0 Td
(e)Tj
-0.011 Tc 0.021 Tw 0.70261 0 Td
[(gr)20 (eater than standar)19 (d supplementation. )]TJ
ET
BT
0.95 0.7 0.06 0 k
/T1_2 1 Tf
-0.021 Tc 0.02299 Tw 11 0 0 11 42.5197 336.837 Tm
[(W)10 (h)20 (y migh)5 (t s)10 (elenium supplemen)5 (t)14 (ation be)]TJ
0 -1.28591 TD
[(bene)5 (f)4 (icial in s)10 (ep)8 (sis)52 (?)]TJ
ET
BT
0 0 0 1 k
/T1_4 1 Tf
-0.011 Tc 0.129 Tw 9.5 0 0 9.5 42.5197 307.7123 Tm
[(The pathophysiology of sepsis involves sever)20 (e oxidative str)19 (ess)]TJ
0.478 Tw 0 -1.27842 TD
[(and endothelial damage. Oxidant pr)20 (oduction is normally)]TJ
0.07401 Tw T*
(balanced by antioxidant systems \(enzyme scavengers and non-)Tj
0.05099 Tw T*
[(enzymatic dietar)-5 (y antioxidants\) \320 termed r)20 (edox balance. When)]TJ
0.07401 Tw 0 -1.27844 TD
[(the antioxidant system is unbalanced by either overpr)20 (oduction)]TJ
-0.0106 Tc 0 -1.27842 TD
(of)Tj
-0.011 Tc 0.742 Tw 1.78465 0 Td
[(r)20 (eactive oxygen species and fr)19 (ee radicals or the)]TJ
0.026 Tw -1.78465 -1.27842 Td
[(underpr)20 (oduction of antioxidants and destruction of scavengers,)]TJ
0.444 Tw T*
[(the situation is de\336)-9.8 (ned as oxidative str)10.2 (ess. In\337ammator)-5 (y)]TJ
0.17101 Tw T*
[(conditions such as sepsis pr)20 (omote periods of oxidative str)19 (ess)]TJ
0.02299 Tw 0 -1.27843 TD
(which leads to the development of complications of sepsis such)Tj
0.133 Tw 0 -1.27842 TD
[(as the acute r)20 (espirator)-5 (y distr)19 (e)-1 (s)-1 (s)-1 ( )-1 (s)-1 (y)-1 (n)-1 (d)-1 (r)19 (ome \(ARDS\) and multi-)]TJ
0.024 Tw T*
[(or)29 (gan failur)20 (e. The level of oxidative str)20 (ess is associated with the)]TJ
0.021 Tw T*
(severity of critical illness.)Tj
ET
BT
/T1_4 1 Tf
0 Tw 5.415 0 0 5.415 140.1166 165.6327 Tm
(18)Tj
ET
BT
/T1_2 1 Tf
-0.01401 Tc -0.043 Tw 10.5 0 0 10.5 42.5197 144.1579 Tm
[(Glut)15 (athione per)15 (o)21 (xidas)10 (e)10 (s \()37 (GP)15 (x)21 (\))]TJ
ET
BT
/T1_4 1 Tf
-0.011 Tc 0.313 Tw 9.5 0 0 9.5 42.5197 129.1781 Tm
[(Selenium limits oxidative str)20 (ess pr)19 (e)-1 (d)-1 (o)-1 (m)-1 (i)-1 (n)-1 (a)-1 (n)-1 (t)-1 (l)-1 (y)-1 ( )-1 (t)-1 (h)-1 (r)19 (ough the)]TJ
0.05 Tw T*
[(actions of glutathione per)6.3 (oxidase, pr)14.4 (obably the most impor)]TJ
-0.00999 Tc 0 Tw 24.28626 0.00003 Td
(tant)Tj
0.701 Tw -24.28626 -1.27844 Td
[(antioxidant enzyme system pr)20 (eventing injur)-5 (y)1 ( )1 (t)1 (o)1 ( )1 (c)1 (e)1 (l)1 (l)1 (s)1 (,)]TJ
-0.011 Tc 0.33501 Tw 0 -1.27843 TD
(including the endothelium. GPx ar)Tj
-0.0106 Tc 15.45664 0.00001 Td
(e)Tj
-0.011 Tc 0 Tw 1.01689 0 Td
(par)Tj
-0.0105 Tc 1.30974 0.00001 Td
(t)Tj
-0.011 Tc 0.33501 Tw 0.88801 0 Td
(of the scavenger)Tj
0.263 Tw -18.67129 -1.27844 Td
[(s)-1 (y)-1 (s)-1 (t)-1 (e)-1 (m)-1 ( )-1 (r)19 (esponsible for the cleavage of fr)19 (ee radicals and ar)20 (e)]TJ
0.52499 Tw 0 -1.27842 TD
[(selenium-dependent, with their activity r)-2.3 (egulated by the)]TJ
0.86301 Tw 0 -1.27841 TD
(availability of selenium. In critical illness, selenium)Tj
0.099 Tw 27.82429 72.43974 Td
[(r)19 (equir)20 (ements ar)20 (e initially incr)19 (eased as it is r)20 (edistributed to the)]TJ
0.116 Tw 0 -1.28338 TD
[(endothelium and or)30 (gans for metabolic use \(eg GPx synthesis\))]TJ
0.366 Tw T*
(giving rise to low blood selenium levels \320 despite which)Tj
0.12399 Tw 0 -1.28337 TD
[(plasma GPx activity is normal. GPx activity then decr)20 (eases as)]TJ
0.021 Tw 0 -1.28338 TD
(mismatching of supply and demand of selenium occurs. )Tj
ET
BT
/T1_2 1 Tf
-0.01401 Tc -0.043 Tw 10.5 0 0 10.5 306.8504 677.8558 Tm
[(Glut)15 (athione \()37 (G)10 (SH\))]TJ
ET
BT
/T1_4 1 Tf
-0.011 Tc 0.12 Tw 9.5 0 0 9.5 306.8504 662.8292 Tm
(GSH functions as an antioxidant, both as a component of the)Tj
-0.00999 Tc 0.776 Tw T*
[(GPx enzyme system and independently)135 (.)]TJ
ET
BT
/T1_4 1 Tf
-0.011 Tc 0 Tw 5.415 0 0 5.415 489.2641 654.2977 Tm
(19)Tj
ET
BT
/T1_4 1 Tf
0.776 Tw 9.5 0 0 9.5 504.5049 650.637 Tm
(It contains)Tj
0.424 Tw -20.80574 -1.28338 Td
(glutamine, cysteine and glycine. Supplementation with n-)Tj
-0.00999 Tc 0.368 Tw 0 -1.28336 TD
[(acetylcysteine )-1 (and )-1 (glutamine )-1 (ar)20 (e)1 ( s)1 (t)1 (r)1 (a)1 (t)1 (e)1 (g)1 (i)1 (e)1 (s)1 ( t)1 (h)1 (a)1 (t)1 ( h)1 (a)1 (v)1 (e)1 ( b)1 (e)1 (e)1 (n)]TJ
-0.011 Tc 0.239 Tw 0 -1.28338 TD
(employed to enhance this aspect of the antioxidant defence)Tj
0.021 Tw T*
(system in critically ill patients.)Tj
ET
BT
/T1_2 1 Tf
-0.01401 Tc -0.043 Tw 10.5 0 0 10.5 306.8504 584.0073 Tm
[(Other s)10 (elenopr)15 (o)4 (t)21 (eins)]TJ
ET
BT
/T1_4 1 Tf
-0.011 Tc 0.44901 Tw 9.5 0 0 9.5 306.8504 568.9806 Tm
[(Ther)20 (e ar)19 (e appr)20 (oximately 25 known selenopr)19 (oteins whose)]TJ
0.677 Tw T*
[(antioxidant/immune functions r)20 (esult fr)19 (om r)20 (egulation of)]TJ
0.522 Tw 0 -1.28336 TD
(intracellular pathways, eg NF-)Tj
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 9.5 0 0 9.5 437.986 544.5966 Tm
(k)Tj
ET
BT
/T1_4 1 Tf
-0.0105 Tc 9.5 0 0 9.5 443.1049 544.5966 Tm
(B)Tj
-0.011 Tc 0.522 Tw 1.30922 0 Td
(transcription activation,)Tj
0.021 Tw -15.6518 -1.28339 Td
(arachidonic acid cascade, and mitochondrial functions. )Tj
ET
BT
0.95 0.7 0.06 0 k
/T1_2 1 Tf
-0.021 Tc 0.02299 Tw 11 0 0 11 306.8504 509.7085 Tm
[(Ho)19 (w c)4 (an supplemen)5 (t)15 (ation be achie)25 (v)17 (ed?)]TJ
ET
BT
0 0 0 1 k
/T1_4 1 Tf
-0.011 Tc 0.12399 Tw 9.5 0 0 9.5 306.8504 494.6816 Tm
(Selenium is inexpensive, safe and can be supplemented orally)Tj
0.14999 Tw 0 -1.28337 TD
(or intravenously as sodium selenite, eg Selenase)Tj
ET
BT
/T1_4 1 Tf
0 Tc 0 Tw 5.415 0 0 5.415 499.1356 486.1502 Tm
(\250)Tj
ET
BT
/T1_4 1 Tf
9.5 0 0 9.5 503.4104 482.4896 Tm
(.)Tj
ET
BT
/T1_4 1 Tf
-0.0108 Tc 5.415 0 0 5.415 505.7704 486.1502 Tm
(20)Tj
ET
BT
/T1_4 1 Tf
-0.011 Tc 0.14999 Tw 9.5 0 0 9.5 515.0601 482.4896 Tm
[(Ther)20 (e ar)19 (e)]TJ
0.157 Tw -21.91681 -1.28338 Td
[(no clear r)20 (ecommendations r)19 (egar)20 (ding r)20 (outine supplementation)]TJ
0.07201 Tw 0 -1.28338 TD
[(of selenium in TPN \(compar)8.3 (ed with other trace elements such)]TJ
0.217 Tw 0 -1.28339 TD
[(as zinc, ir)20 (on, copper)69 (, chr)20 (omium, manganese, and iodine\). It)]TJ
0.18401 Tw 0 -1.28337 TD
[(should be administer)20 (ed as a continuous infusion since bolus)]TJ
0.021 Tw 0 -1.28338 TD
[(dosing leads to rapid urinar)-5 (y excr)20 (etion.)]TJ
ET
BT
0.95 0.7 0.06 0 k
/T1_2 1 Tf
-0.021 Tc 0.02299 Tw 11 0 0 11 306.8504 398.8332 Tm
[(Is ther)15 (e an)21 (y e)24 (videnc)12 (e that s)10 (elenium)]TJ
0 -1.29019 TD
[(supplemen)5 (t)14 (ation in IC)10 (U p)8 (atien)5 (t)7 (s is bene)4 (f)5 (icial?)]TJ
ET
BT
0 0 0 1 k
/T1_4 1 Tf
-0.0105 Tc 0 Tw 9.5 0 0 9.5 306.8504 369.6144 Tm
(A)Tj
-0.011 Tc 0.097 Tw 0.98328 0 Td
(number of small studies on selenium supplementation fr)Tj
0 Tw 23.57815 0 Td
(om)Tj
0.254 Tw -24.56143 -1.28338 Td
[(Eur)20 (ope \(as sodium selenite\) and Japan \(as ebselen, an oral)]TJ
0.15601 Tw 0 -1.28338 TD
[(synthetic seleno-or)30 (ganic compound which mimics GPx\) have)]TJ
0.043 Tw T*
[(been published following the demonstration of r)20 (educed plasma)]TJ
0.021 Tw 0 -1.28337 TD
(selenium levels on admission to ICU. )Tj
ET
BT
/T1_2 1 Tf
-0.01401 Tc -0.043 Tw 10.5 0 0 10.5 306.8504 302.9848 Tm
(In s)Tj
-0.0141 Tc 1.642 0.00001 Td
(ep)Tj
-0.01401 Tc 0 Tw 1.06405 0.00001 Td
(sis )Tj
ET
BT
/T1_4 1 Tf
-0.011 Tc 0.353 Tw 9.5 0 0 9.5 306.8504 287.958 Tm
[(Ther)20 (e have been \336)-1 (ve studies to date looking at selenium)]TJ
0.295 Tw 0 -1.28338 TD
[(supplementation in critically ill patients with sever)20 (e sepsis,)]TJ
0.10001 Tw T*
(septic shock and SIRS, investigating a total of 431 patients. In)Tj
0.565 Tw T*
(1997, Zimmermann and colleagues)Tj
ET
BT
/T1_4 1 Tf
0 Tw 5.415 0 0 5.415 458.6809 255.0424 Tm
(21)Tj
ET
BT
/T1_4 1 Tf
0.565 Tw 9.5 0 0 9.5 471.9185 251.3817 Tm
(published the \336rst )Tj
0.256 Tw -17.37559 -1.28337 Td
(study of selenium administration in patients with SIRS and)Tj
0 Tw T*
(multi-or)Tj
0.304 Tw 3.35014 0.00001 Td
(gan failur)Tj
-0.0105 Tc 4.14129 0.00001 Td
(e)Tj
-0.011 Tc 0 Tw 0.98603 0 Td
(\(AP)Tj
0.304 Tw 1.48665 0.00001 Td
[(ACHE II >15\). They administer)5.6 (ed a)]TJ
0.21001 Tw -9.96411 -1.28339 Td
(bolus of 1,000)Tj
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 9.5 0 0 9.5 368.1232 214.8056 Tm
(m)Tj
ET
BT
/T1_4 1 Tf
-0.0105 Tc 9.5 0 0 9.5 373.5019 214.8056 Tm
(g)Tj
-0.011 Tc 0.92864 0 Td
(par)Tj
0.21001 Tw 1.29978 0.00001 Td
(enteral sodium selenite followed by an)Tj
0.414 Tw -9.24436 -1.28339 Td
(infusion of 1,000)Tj
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 9.5 0 0 9.5 382.7929 202.6134 Tm
(m)Tj
ET
BT
/T1_4 1 Tf
-0.011 Tc 0.414 Tw 9.5 0 0 9.5 388.1716 202.6134 Tm
(g/day to 20 patients for 28 days and)Tj
0.19099 Tw -8.56012 -1.28338 Td
[(compar)20 (ed the r)19 (esults with 20 contr)20 (ols. They demonstrated a)]TJ
0.82401 Tw 0 -1.28337 TD
[(non-signi\336cant mor)10 (tality b)-1 (ene\336t fr)20 (om selenium supp-)]TJ
0.097 Tw 0 -1.28338 TD
[(l)-1 (e)-1 (m)-1 (e)-1 (n)-1 (t)-1 (a)-1 (t)-1 (i)-1 (o)-1 (n)-1 ( )-1 (\()-1 (s)-1 (u)-1 (p)-1 (p)-1 (l)-1 (e)-1 (m)-1 (e)-1 (n)-1 (t)-1 (e)-1 (d)-1 ( )-1 (g)-1 (r)19 (oup 3/20 patients versus contr)19 (ol)]TJ
0.021 Tw T*
[(gr)20 (oup 8/20 patients\).)]TJ
-0.00999 Tc 0.08099 Tw 1.19354 -1.28338 Td
[(At the same time, Angstwurm)1 ( )]TJ
ET
BT
/T1_6 1 Tf
0.078 Tw 9.5 0 0 9.5 439.2012 141.653 Tm
(et al)Tj
ET
BT
/T1_4 1 Tf
-0.011 Tc 0 Tw 5.415 0 0 5.415 455.7283 145.3137 Tm
(12)Tj
ET
BT
/T1_4 1 Tf
0.08099 Tw 9.5 0 0 9.5 464.3617 141.653 Tm
(studied 42 critically ill)Tj
0.121 Tw -16.58014 -1.28337 Td
[(p)-1 (a)-1 (t)-1 (i)-1 (e)-1 (n)-1 (t)-1 (s)-1 ( )-1 (\()-1 (A)-1 (P)74 (ACHE II >15\) with SIRS secondar)-5 (y to sepsis, and)]TJ
0.036 Tw T*
[(supplemented one gr)20 (oup with a r)19 (educing r)20 (egimen of par)20 (enteral)]TJ
0.317 Tw T*
(sodium selenite \(535)Tj
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 9.5 0 0 9.5 395.9579 105.0769 Tm
(m)Tj
ET
BT
/T1_4 1 Tf
-0.011 Tc 0.317 Tw 9.5 0 0 9.5 401.3366 105.0769 Tm
[(g/day for thr)20 (ee days, 285)]TJ
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 9.5 0 0 9.5 510.3429 105.0769 Tm
(m)Tj
ET
BT
/T1_4 1 Tf
-0.011 Tc 0.317 Tw 9.5 0 0 9.5 515.7216 105.0769 Tm
(g/day for)Tj
0 Tw -21.98644 -1.28338 Td
(thr)Tj
0.17 Tw 1.18984 0.00001 Td
(ee days and 155)Tj
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 9.5 0 0 9.5 386.6591 92.8848 Tm
(m)Tj
ET
BT
/T1_4 1 Tf
-0.011 Tc 0.17 Tw 9.5 0 0 9.5 392.0378 92.8848 Tm
[(g/day for thr)13.3 (ee days\); the contr)10.4 (ol gr)]TJ
0 Tw 15.32687 0.00003 Td
(oup)Tj
0.386 Tw -24.29396 -1.2834 Td
[(r)19 (eceived 35)]TJ
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 9.5 0 0 9.5 356.6181 80.6926 Tm
(m)Tj
ET
BT
/T1_4 1 Tf
-0.011 Tc 0.386 Tw 9.5 0 0 9.5 361.9968 80.6926 Tm
[(g/day)135 (. Plasma selenium and GPx levels wer)19 (e)]TJ
0.103 Tw -5.80488 -1.28337 Td
[(normalised within thr)19 (ee days by the supplementation r)20 (egimen)]TJ
0.50101 Tw T*
[(compar)20 (ed with the contr)19 (ols whose levels r)20 (emained low)125 (. )]TJ
ET
0.27 0.06 0 0 k
/GS2 gs
-573.449 785.1971 581.9529 65.197 re
f
2 w
-603.388 785.8901 m
10.07 785.8901 l
S
BT
0 g
/GS4 gs
/T1_7 1 Tf
0 Tc 0 Tw 5 0 0 5 301.10497 11 Tm
( by guest on September 2, 2015)Tj
0 0 1 rg
/GS4 gs
-7.55899 0 Td
(inc.sagepub.com)Tj
0 g
/GS4 gs
-8.11399 0 Td
(Downloaded from )Tj
ET
endstream
endobj
31 0 obj
<<
/OP true
/OPM 1
/SM 0.00999451
/Type /ExtGState
/op true
>>
endobj
32 0 obj
<<
/OP false
/OPM 1
/SM 0.00999451
/Type /ExtGState
/op false
>>
endobj
33 0 obj
<<
/FL 1
/OP true
/OPM 1
/SM 0.00999451
/Type /ExtGState
/op true
>>
endobj
34 0 obj
<<
/OP false
/OPM 0
/SM 1.0
/op false
>>
endobj
35 0 obj
<<
/A 179 0 R
/Border [0 0 0]
/Rect [262.31 9.0 302.105 16.0]
/Subtype /Link
/Type /Annot
>>
endobj
36 0 obj
<<
/Length 17829
>>
stream
q
0 0.89 595 841 re
W n
1 g
/GS0 gs
0 841.89 0 0 re
f
Q
0 1 0.60001 0.27 k
/GS1 gs
-8.504 785.718 28.346 64.676 re
f
0.27 0.06 0 0 k
21.901 785.1971 573.374 65.197 re
f
0.95 0.7 0.06 0 K
2 w
/GS2 gs
-8.504 785.889 m
595.276 785.889 l
S
BT
0 0 0 1 k
/GS3 gs
/T1_0 1 Tf
8.5 0 0 8.5 401.6363 29.4783 Tm
(V)Tj
0.026 Tw 0.51587 0.00001 Td
(olume 10, Number 1)Tj
8.5376 -0.0706 Td
(,)Tj
0 Tw 0.52672 0.07059 Td
(Januar)Tj
-0.0002 Tc 2.6018 0.00001 Td
(y)Tj
0 Tc 0.74743 0 Td
(2009)Tj
ET
BT
/T1_1 1 Tf
9.3 0 0 9.3 534.3687 28.8783 Tm
(JICS)Tj
ET
BT
/T1_2 1 Tf
9 0 0 9 42.5197 29.0855 Tm
(40)Tj
ET
BT
/T1_3 1 Tf
-0.0105 Tc 9.5 0 0 9.5 42.5197 744.4855 Tm
(A)Tj
-0.011 Tc 1.386 Tw 2.27172 0 Td
[(non-signi\336cant mor)9 (tality bene\336t of selenium)]TJ
-0.00999 Tc 0.23599 Tw -2.27172 -1.27758 Td
[(supplementation was seen \(supplemented gr)20 (o)1 (u)1 (p)1 ( )1 (3)1 (3)1 (%)1 ( )1 (v)1 (e)1 (r)1 (s)1 (u)1 (s)]TJ
-0.011 Tc 0.028 Tw 0 -1.27759 TD
[(contr)20 (ol gr)19 (oup 52%, p=0.135\). Ther)20 (e was a signi\336cant r)19 (eduction)]TJ
0.069 Tw 0 -1.27758 TD
[(in AP)75 (ACHE III scor)19 (e and r)20 (equir)20 (ement for haemo\336ltrat)-1 (ion. )]TJ
ET
BT
/T1_4 1 Tf
-0.00999 Tc 0 Tw 9.5 0 0 9.5 272.8875 708.0745 Tm
(Post)Tj
-24.24924 -1.27758 Td
(hoc)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 0.04601 Tw 9.5 0 0 9.5 58.0492 695.9374 Tm
[(subgr)20 (oup analysis of 20 patients with an AP)74 (ACHE III scor)20 (e)]TJ
0.166 Tw -1.63468 -1.27758 Td
[(>53 \(the median scor)20 (e)-1 (\))-1 ( )-1 (s)-1 (u)-1 (g)-1 (g)-1 (e)-1 (s)-1 (t)-1 (e)-1 (d)-1 ( )-1 (t)-1 (h)-1 (e)-1 (r)18 (e might be a mor)10 (t)-1 (a)-1 (l)-1 (i)-1 (t)-1 (y)]TJ
0.021 Tw T*
(bene\336t in those most de\336cient.)Tj
-0.0105 Tc 1.19354 -1.27759 Td
(In)Tj
-0.011 Tc 0.16 Tw 1.27669 0 Td
(2007, Mishra and co-workers)Tj
ET
BT
/T1_3 1 Tf
0 Tw 5.415 0 0 5.415 183.6113 663.1871 Tm
(13)Tj
ET
BT
/T1_3 1 Tf
0.16 Tw 9.5 0 0 9.5 193.0004 659.5264 Tm
(published a randomised)Tj
0.209 Tw -15.84007 -1.27758 Td
[(contr)20 (olled trial of 40 critically ill patients with sever)19 (e sepsis)]TJ
0.028 Tw T*
[(\()-1 (A)-1 (P)74 (ACHE II >15\). Eighteen patients r)20 (eceived a r)19 (educing course)]TJ
0.056 Tw T*
[(of par)20 (enteral selenium for nine days using a r)19 (egimen similar to)]TJ
0.442 Tw 0 -1.27759 TD
[(A)-1 (n)-1 (g)-1 (s)-1 (t)-1 (w)-1 (u)-1 (r)-1 (m\325)90 (s study; the contr)19 (ol gr)20 (oup r)19 (eceived 32)]TJ
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 9.5 0 0 9.5 261.2664 610.9782 Tm
(m)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 9.5 0 0 9.5 266.6451 610.9782 Tm
[(g/day)135 (.)]TJ
0.02901 Tw -23.59215 -1.27758 Td
[(Plasma selenium levels and GPx activity wer)20 (e again r)19 (educed on)]TJ
0.08099 Tw 0 -1.27758 TD
[(admission but incr)20 (eased signi\336cantly by day thr)19 (ee in the high-)]TJ
0.52 Tw T*
[(dose supplementation gr)7.9 (oup. The SOF)60 (A scor)19 (e decr)20 (eased)]TJ
-0.00999 Tc 0.263 Tw 0 -1.27759 TD
[(signi\336cantly in the selenium-supplemented gr)20 (o)1 (u)1 (p)1 (,)1 ( )1 (b)1 (u)1 (t)1 ( )1 (t)1 (h)1 (e)1 (r)20 (e)]TJ
-0.011 Tc 0.198 Tw 0 -1.27758 TD
[(was no dif)10 (fer)19 (ence in r)20 (enal r)19 (eplacement therapy r)20 (equir)20 (e)-1 (m)-1 (e)-1 (n)-1 (t)-1 (s)]TJ
0.381 Tw T*
[(and no mor)10 (tality bene\336)-1 (t seen \(contr)20 (ol gr)20 (oup 50% versus)]TJ
0.021 Tw T*
[(s)-1 (u)-1 (p)-1 (p)-1 (l)-1 (e)-1 (m)-1 (e)-1 (n)-1 (t)-1 (e)-1 (d)-1 ( )-1 (g)-1 (r)19 (oup 44%, p=0.94\).)]TJ
0.036 Tw 1.19354 -1.27758 Td
[(For)40 (ceville\325)89 (s gr)20 (oup)]TJ
ET
BT
/T1_3 1 Tf
0 Tw 5.415 0 0 5.415 121.3382 517.5427 Tm
(22)Tj
ET
BT
/T1_3 1 Tf
0.036 Tw 9.5 0 0 9.5 129.5433 513.882 Tm
[(published a randomised contr)20 (olled study)]TJ
0.155 Tw -9.16038 -1.27758 Td
[(of 60 patients, on the ef)10 (fects of selenium supplementation in)]TJ
0.089 Tw T*
[(septic shock \(SAPS scor)20 (e >25\). The selenium gr)19 (oup was given)]TJ
-0.0106 Tc T*
(a)Tj
-0.011 Tc 0 Tw 0.77692 0 Td
(4,000)Tj
ET
BT
/T1_5 1 Tf
0 Tc 9.5 0 0 9.5 73.9474 477.471 Tm
(m)Tj
ET
BT
/T1_3 1 Tf
-0.0105 Tc 9.5 0 0 9.5 79.3261 477.471 Tm
(g)Tj
-0.011 Tc 0.095 Tw 0.81407 0 Td
[(loading dose of par)10.3 (enteral sodium selenite in an to)]TJ
0.036 Tw -4.68843 -1.27759 Td
[(attempt to use the pr)20 (o-oxidant pr)19 (oper)10 (ties of seleno-compounds)]TJ
0.11 Tw T*
(to inhibit NF-)Tj
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 9.5 0 0 9.5 98.1308 453.1969 Tm
(k)Tj
ET
BT
/T1_3 1 Tf
-0.0105 Tc 9.5 0 0 9.5 103.2497 453.1969 Tm
(B)Tj
-0.011 Tc 0.11 Tw 0.89742 0 Td
(binding to DNA and pr)Tj
-0.00999 Tc 9.81328 0 Td
(event the subsequent)Tj
-0.011 Tc 0.884 Tw -17.10334 -1.27758 Td
[(initiation of the in\337ammator)-5 (y cascade, followed by)]TJ
0 Tw T*
(1,000)Tj
ET
BT
/T1_5 1 Tf
0 Tc 9.5 0 0 9.5 66.5658 428.9229 Tm
(m)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 0.16701 Tw 9.5 0 0 9.5 71.9444 428.9229 Tm
(g/day as an intravenous infusion for nine days. Ther)Tj
0 Tc 22.34359 0 Td
(e)Tj
-0.011 Tc 0.02499 Tw -25.44093 -1.27759 Td
[(was no signi\336)-6.1 (cant dif)]TJ
0 Tw 8.65909 0.00001 Td
(fer)Tj
0.02499 Tw 1.05874 0 Td
(ence in the primar)Tj
-0.0105 Tc 7.5181 0 Td
(y)Tj
-0.011 Tc 0.74376 0 Td
(endpoint of time to)Tj
0.145 Tw -17.97969 -1.27759 Td
[(vasopr)20 (essor withdrawal, nor was ther)19 (e a signi\336cant dif)10 (fer)19 (ence)]TJ
0.021 Tw T*
[(in sur)-12.5 (vival \(45%)]TJ
-0.00999 Tc 0 Tw 6.94703 0 Td
(versus)Tj
-0.011 Tc 0.021 Tw 2.81523 0 Td
(45%, p=0.59 at 28)Tj
0 Tw 7.63364 0 Td
(days\). )Tj
0.24001 Tw -16.20237 -1.27759 Td
[(The lar)26.3 (gest selenium supplementation trial to date is the)]TJ
0.231 Tw -1.19353 -1.27758 Td
[(Selenium in Intensive Car)20 (e \(SIC\) study)134 (.)]TJ
ET
BT
/T1_3 1 Tf
-0.0108 Tc 0 Tw 5.415 0 0 5.415 205.1324 371.8984 Tm
(14)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 0.231 Tw 9.5 0 0 9.5 215.1906 368.2378 Tm
(This was a multi-)Tj
0.069 Tw -18.17588 -1.27759 Td
[(centr)20 (e, randomised contr)19 (olled trial involving 249 patients with)]TJ
0.237 Tw T*
[(sever)20 (e SIRS, sepsis and septic shock \(AP)74 (ACHE III>70\). The)]TJ
0 Tc T*
(r)Tj
-0.011 Tc 0.425 Tw 0.33973 0.00001 Td
(egimen involved a 1,000)Tj
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 9.5 0 0 9.5 154.3402 331.8267 Tm
(m)Tj
ET
BT
/T1_3 1 Tf
-0.0105 Tc 9.5 0 0 9.5 159.7188 331.8267 Tm
(g)Tj
-0.011 Tc 0.425 Tw 1.14423 0 Td
(selenium bolus followed by)Tj
0 Tw -13.48097 -1.27758 Td
(1,000)Tj
ET
BT
/T1_5 1 Tf
0 Tc 9.5 0 0 9.5 66.5658 319.6897 Tm
(m)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 0.16901 Tw 9.5 0 0 9.5 71.9444 319.6897 Tm
(g/day for two weeks. Patients wer)Tj
-0.0105 Tc 14.36376 0.00001 Td
(e)Tj
-0.011 Tc 0.85099 0 Td
(either enterally or)Tj
0.10699 Tw -18.31208 -1.2776 Td
[(par)20 (enterally fed, and glutamine and other trace elements wer)19 (e)]TJ
0.09399 Tw T*
[(not speci\336)-4.6 (cally given but wer)20 (e not disallowed or documented.)]TJ
-0.0105 Tc T*
(A)Tj
-0.011 Tc 0 Tw 1.00475 0 Td
(tr)Tj
0.119 Tw 0.64433 0.00001 Td
[(end towar)15.5 (ds the primar)-5 (y end-point of mor)10 (tality bene\336t in)]TJ
-0.00999 Tc 0.74899 Tw -1.64909 -1.27759 Td
[(the selenium supplementation gr)20 (o)1 (u)1 (p)1 ( )1 (w)1 (a)1 (s)1 ( )1 (a)1 (g)1 (a)1 (i)1 (n)1 ( )1 (s)1 (e)1 (e)1 (n)1 (,)]TJ
-0.011 Tc 0.151 Tw T*
[(s)-1 (u)-1 (p)-1 (p)-1 (l)-1 (e)-1 (m)-1 (e)-1 (n)-1 (t)-1 (e)-1 (d)-1 ( )-1 (g)-1 (r)19 (oup 40% \(46/116\) versus contr)19 (ol gr)20 (oup 50%)]TJ
0.034 Tw T*
(\(61/122\), but was not signi\336cant despite \337aws in the intention-)Tj
0 Tw 0 -1.27757 TD
(to-tr)Tj
0.353 Tw 1.7797 0.00001 Td
(eat analysis. The pr)Tj
0 Tw 8.84553 0.00001 Td
(ede\336)Tj
0.353 Tw 1.93899 0.00001 Td
[(ned sub-gr)14.7 (oup analysis of the)]TJ
0.19701 Tw -12.56421 -1.2776 Td
[(p)-1 (a)-1 (t)-1 (i)-1 (e)-1 (n)-1 (t)-1 (s)-1 ( )-1 (w)-1 (i)-1 (t)-1 (h)-1 ( )-1 (A)-1 (P)74 (ACHE III scor)19 (es >102 \(the highest quar)10 (tile\))]TJ
0.17 Tw 0 -1.27758 TD
[(gave rise to a signi\336)-10.6 (cant dif)10 (fer)19 (ence in mor)10 (tality \(p=0.04\) but)]TJ
0.638 Tw T*
[(wer)20 (e for a small pr)19 (opor)10 (tion of the study population)]TJ
-0.00999 Tc 0.552 Tw 0 -1.27757 TD
(\(supplemented gr)Tj
-0.011 Tc 7.7152 0.00001 Td
[(oup 15/27 versus contr)9.8 (ols 22/27\); this)]TJ
0.147 Tw -7.7152 -1.27759 Td
[(concurr)19 (ed with the analysis of those patients with mor)20 (e than)]TJ
0 Tw 0 -1.27758 TD
(thr)Tj
0.021 Tw 1.18983 0.00001 Td
[(ee or)27.8 (gan failur)]TJ
0 Tw 5.83216 0.00002 Td
(es.)Tj
ET
BT
/T1_2 1 Tf
-0.01401 Tc -0.043 Tw 10.5 0 0 10.5 42.5197 144.102 Tm
(In burns)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 0.136 Tw 9.5 0 0 9.5 42.5197 129.1304 Tm
[(P)-1 (a)-1 (t)-1 (i)-1 (e)-1 (n)-1 (t)-1 (s)-1 ( )-1 (w)-1 (i)-1 (t)-1 (h)-1 ( )-1 (g)-1 (r)19 (eater than 20% body sur)9 (face ar)20 (ea burns incur)]TJ
0.627 Tw 0 -1.27759 TD
[(s)-1 (i)-1 (g)-1 (n)-1 (i)-1 (\336)-1 (cant trace element losses, with selenium lost in)]TJ
0.145 Tw 0 -1.27758 TD
(quantities of up to 600)Tj
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 9.5 0 0 9.5 137.6543 104.8563 Tm
(m)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 9.5 0 0 9.5 143.033 104.8563 Tm
(g/day)Tj
0 Tc 2.03384 0.00001 Td
(.)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 5.415 0 0 5.415 164.7145 108.517 Tm
(23)Tj
ET
BT
/T1_3 1 Tf
0.145 Tw 9.5 0 0 9.5 173.9539 104.8563 Tm
[(Oxidative str)13.6 (ess is also high,)]TJ
0 Tc -13.83518 -1.27757 Td
(r)Tj
-0.011 Tc 0.86 Tw 0.33973 0.00001 Td
[(esulting in decr)12.2 (eased antioxidant capacity)]TJ
-0.0106 Tc 20.20133 0.00002 Td
(,)Tj
-0.011 Tc 0 Tw 1.35664 0 Td
[(depr)17.8 (essed)]TJ
0.099 Tw -21.89769 -1.27759 Td
[(i)-1 (m)-1 (m)-1 (u)-1 (n)-1 (i)-1 (t)-1 (y)144 (, and a pr)19 (opensity for developing infection. Infection)]TJ
0 Tc 0 -1.27759 TD
(r)Tj
-0.011 Tc 0.12801 Tw 0.33973 0.00001 Td
(emains the leading cause of death after major burns, but the)Tj
0 Tw -0.33973 -1.27758 Td
(mor)Tj
0.257 Tw 1.66274 0.00001 Td
[(tality r)16 (emains r)16.1 (elatively low)125 (. Ber)29 (ger and colleagues have)]TJ
0.052 Tw 26.16155 72.43972 Td
(published a number of studies on trace element substitution in)Tj
0.66901 Tw 0 -1.26826 TD
(burned patients including some of the \336rst selenium)Tj
-0.00999 Tc 0.373 Tw 0 -1.26825 TD
(supplementation studies.)Tj
ET
BT
/T1_3 1 Tf
-0.0106 Tc 0 Tw 5.415 0 0 5.415 406.8903 724.0492 Tm
(2)Tj
-0.011 Tc (4-26)Tj
ET
BT
/T1_3 1 Tf
0.373 Tw 9.5 0 0 9.5 425.5558 720.3886 Tm
(In these studies, supplemental)Tj
0.082 Tw -12.4953 -1.26826 Td
[(selenium normalised plasma selenium levels r)20 (esulting in fewer)]TJ
0.36301 Tw 0 -1.26826 TD
[(infections compar)20 (ed with the contr)19 (ol gr)20 (oups whose levels)]TJ
0.021 Tw 0 -1.26825 TD
[(r)19 (emained low)125 (.)]TJ
ET
BT
/T1_2 1 Tf
-0.01401 Tc -0.043 Tw 10.5 0 0 10.5 306.8504 666.5255 Tm
[(In tr)25 (auma )]TJ
ET
BT
/T1_3 1 Tf
-0.011 Tc 0 Tw 9.5 0 0 9.5 306.8504 651.6423 Tm
[(Por)10 (ter )]TJ
ET
BT
/T1_4 1 Tf
-0.00999 Tc 0.47501 Tw 9.5 0 0 9.5 337.6481 651.6423 Tm
(et al)Tj
ET
BT
/T1_3 1 Tf
-0.0108 Tc 0 Tw 5.415 0 0 5.415 357.9512 655.303 Tm
(27)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 0.492 Tw 9.5 0 0 9.5 370.4933 651.6423 Tm
(in 1999 studied 18 adult trauma victims )Tj
-0.00999 Tc 0.03101 Tw -6.69925 -1.26825 Td
[(with principally gunshot wounds, supplementing the tr)20 (eatment)]TJ
-0.011 Tc 0.97 Tw 0 -1.26826 TD
[(gr)20 (oup with selenium, vitamin C, vitamin E and )]TJ
0.535 Tw T*
[(n-acetylcysteine. The tr)20 (eated gr)19 (oup had fewer infections)]TJ
0.05701 Tw T*
[(compar)20 (ed with the placebo gr)19 (oup and a signi\336cantly decr)20 (eased)]TJ
0.548 Tw T*
[(ICU and hospital length of stay)135 (. In 2001, Ber)29 (ger and )]TJ
0.15199 Tw 0 -1.26825 TD
(colleagues studied the impact of antioxidant supplementation)Tj
0.87801 Tw 0 -1.26826 TD
(on blood antioxidant status)Tj
ET
BT
/T1_3 1 Tf
-0.0108 Tc 0 Tw 5.415 0 0 5.415 437.4037 570.9637 Tm
(28)Tj
ET
BT
/T1_3 1 Tf
-0.00999 Tc 0.87801 Tw 9.5 0 0 9.5 453.6087 567.3031 Tm
(and thyr)Tj
-0.011 Tc 4.29212 0.00001 Td
(oid hormone)Tj
0 Tw -19.74035 -1.26827 Td
(metabolism)Tj
ET
BT
/T1_3 1 Tf
5.415 0 0 5.415 351.6049 558.9153 Tm
(29)Tj
ET
BT
/T1_3 1 Tf
0.209 Tw 9.5 0 0 9.5 361.4585 555.2546 Tm
[(in 32 adult trauma patients. The patients wer)20 (e)]TJ
0.021 Tw -5.74822 -1.26825 Td
[(divided into thr)20 (ee gr)19 (oups:)]TJ
T*
[(\245)-705 (a selenium-supplemented gr)20 (oup)]TJ
0.08501 Tw T*
[(\245)-705 (an antioxidant-supplemented gr)20 (oup \(selenium, copper)70 (, zinc)]TJ
0.021 Tw 1.19354 -1.26825 Td
(and vitamin E\))Tj
-1.19354 -1.26826 Td
[(\245)-705 (a placebo gr)20 (oup, who r)20 (eceived no supplemental selenium. )]TJ
0 Tw 0 -1.26825 TD
(Ther)Tj
-0.0105 Tc 1.91921 0 Td
(e)Tj
-0.011 Tc 0.76261 0 Td
(wer)Tj
-0.0105 Tc 1.48475 0 Td
(e)Tj
-0.011 Tc 0.08099 Tw 0.76266 0 Td
[(no signi\336)-4.2 (cant dif)6.1 (fer)20 (ences in the clinical end-points)]TJ
0.30499 Tw -4.92924 -1.26827 Td
[(measur)20 (ed. Plasma selenium levels and plasma GPx activity)]TJ
0.50101 Tw 0 -1.26826 TD
[(wer)20 (e incr)19 (eased by 500)]TJ
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 9.5 0 0 9.5 408.6197 458.8669 Tm
(m)Tj
ET
BT
/T1_3 1 Tf
-0.00999 Tc 0.50101 Tw 9.5 0 0 9.5 413.9984 458.8669 Tm
[(g/day selenium and the thyr)20 (o)1 (i)1 (d)]TJ
-0.011 Tc 0.021 Tw -11.27874 -1.26825 Td
(hormones demonstrated only modest change.)Tj
ET
BT
/T1_2 1 Tf
-0.01401 Tc -0.043 Tw 10.5 0 0 10.5 306.8504 429.1007 Tm
[(In p)8 (ancr)15 (e)7 (atitis )]TJ
ET
BT
/T1_3 1 Tf
-0.011 Tc 0.02499 Tw 9.5 0 0 9.5 306.8504 414.2176 Tm
[(Selenium has been r)20 (outinely supplemented in several Eur)19 (opean)]TJ
0 Tw T*
(centr)Tj
0.082 Tw 2.05679 0 Td
(es for some time for patients with either acute or chr)Tj
0 Tw 22.0627 0 Td
(onic)Tj
0.04201 Tw -24.11949 -1.26826 Td
[(pancr)20 (eatitis as it was thought to of)9 (fer a mor)10 (t)-1 (a)-1 (l)-1 (i)-1 (t)-1 (y)-1 ( )-1 (a)-1 (d)-1 (v)-1 (a)-1 (n)-1 (t)-1 (a)-1 (g)-1 (e)-1 (.)]TJ
ET
BT
/T1_3 1 Tf
-0.0106 Tc 0 Tw 5.415 0 0 5.415 539.9414 393.7813 Tm
(3)Tj
-0.011 Tc (0-32)Tj
ET
BT
/T1_3 1 Tf
9.5 0 0 9.5 306.8504 378.0722 Tm
(However)Tj
-0.0105 Tc 3.55876 0 Td
(,)Tj
-0.011 Tc 0.54601 Tw 1.04285 0 Td
[(this assumption has r)9.7 (ecently been challenged.)]TJ
0 Tw -4.60161 -1.26826 Td
(Lindner )Tj
ET
BT
/T1_4 1 Tf
-0.00999 Tc 0.28799 Tw 9.5 0 0 9.5 342.6708 366.0238 Tm
(et al)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 0 Tw 5.415 0 0 5.415 361.1972 369.6844 Tm
(33)Tj
ET
BT
/T1_3 1 Tf
0.299 Tw 9.5 0 0 9.5 371.9002 366.0238 Tm
[(in Ger)-2.6 (many studied 70 patients with acute)]TJ
0.535 Tw -6.84734 -1.26827 Td
[(pancr)20 (eatitis and demonstrated no bene\336)-1 (t fr)20 (om selenium)]TJ
0.47 Tw T*
[(supplementation. Siriwar)20 (dena and colleagues)]TJ
ET
BT
/T1_3 1 Tf
0 Tw 5.415 0 0 5.415 493.9302 345.5875 Tm
(34)Tj
ET
BT
/T1_3 1 Tf
0.47 Tw 9.5 0 0 9.5 506.2623 341.9268 Tm
(in the UK)Tj
0.052 Tw -20.99073 -1.26825 Td
[(per)10 (for)-1 (med a randomised, double-blind, placebo-contr)20 (olled trial)]TJ
0.312 Tw T*
[(of intravenous antioxidant supplementation in sever)20 (e acute)]TJ
0 Tw 0 -1.26825 TD
(pancr)Tj
0.147 Tw 2.27871 0.00001 Td
[(eatitis and found no statistical dif)-8.5 (fer)20 (ence in the primar)-5 (y)]TJ
0.021 Tw -2.27871 -1.26826 Td
[(end-point of the pr)11.4 (esence of or)30 (gan dysfunction at seven days. )]TJ
ET
BT
/T1_2 1 Tf
-0.01401 Tc 0 Tw 10.5 0 0 10.5 306.8504 276.0152 Tm
[(Me)8 (t)15 (a-)14 (analy)23 (s)10 (e)10 (s)]TJ
ET
BT
/T1_3 1 Tf
-0.011 Tc 0.39101 Tw 9.5 0 0 9.5 306.8504 261.1321 Tm
[(A)69 (venell and co-workers)]TJ
ET
BT
/T1_3 1 Tf
0 Tw 5.415 0 0 5.415 404.8089 264.7928 Tm
(35)Tj
ET
BT
/T1_3 1 Tf
0.39101 Tw 9.5 0 0 9.5 416.3874 261.1321 Tm
[(per)10 (for)-1 (med a r)20 (eview of selenium)]TJ
0.43201 Tw -11.53021 -1.26825 Td
(supplementation for critically ill adults for the Cochrane)Tj
0.32201 Tw 0 -1.26826 TD
(Collaboration, updated in 2008 to include ten randomised)Tj
0.039 Tw T*
(trials of either selenium or ebselen supplementation. The study)Tj
0.629 Tw 0 -1.26825 TD
[(gr)20 (oup included 1,172 patients fr)19 (om pr)20 (e)-1 (d)-1 (o)-1 (m)-1 (i)-1 (n)-1 (a)-1 (n)-1 (t)-1 (l)-1 (y)-1 ( )-1 (t)-1 (h)-1 (e)]TJ
0.274 Tw 0 -1.26826 TD
[(Japanese, ebselen in neur)20 (o-intensive car)19 (e studies; the meta-)]TJ
0.093 Tw 0 -1.26825 TD
(analysis population also included patients with burns, trauma,)Tj
0.164 Tw 0 -1.26826 TD
(and post-major sur)Tj
0 Tw 7.99804 0.00001 Td
(ger)Tj
0 Tc 1.26845 0.00001 Td
(y)Tj
-0.0105 Tc 0.33582 0.00001 Td
(.)Tj
-0.011 Tc 0.164 Tw 0.66094 0 Td
(The data wer)Tj
-0.0105 Tc 5.58701 0.00001 Td
(e)Tj
-0.011 Tc 0.84596 0 Td
(analysed for mor)Tj
-0.00999 Tc 0 Tw 7.13006 0.00001 Td
(tality)Tj
-0.011 Tc -23.82628 -1.2683 Td
(bene\336)Tj
-0.0105 Tc 2.46646 0.00001 Td
(t)Tj
-0.011 Tc 0.215 Tw 0.76775 0 Td
(and infection risk. The authors concluded that ther)Tj
0 Tc 22.20671 0.00001 Td
(e)Tj
-0.011 Tc 0.42999 Tw -25.44092 -1.26826 Td
[(was limited evidence to r)7.9 (ecommend selenium or ebselen)]TJ
0.106 Tw T*
(supplementation in critically ill adults and commented on the)Tj
0.114 Tw 0 -1.26827 TD
[(poor quality of trials, the heter)20 (ogeneous natur)19 (e of the gr)20 (oups,)]TJ
0.021 Tw 0 -1.26825 TD
(and the small populations studied.)Tj
0 Tw 1.19354 -1.26826 Td
(Heyland )Tj
ET
BT
/T1_4 1 Tf
-0.00999 Tc 0.07001 Tw 9.5 0 0 9.5 353.4256 104.5021 Tm
(et al)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 0 Tw 5.415 0 0 5.415 369.8735 108.1628 Tm
(36)Tj
ET
BT
/T1_3 1 Tf
0.07201 Tw 9.5 0 0 9.5 378.4249 104.5021 Tm
(included eight studies in the 2007 update of)Tj
0.123 Tw -7.53416 -1.26825 Td
[(the meta-analysis of selenium supplementation in critical car)20 (e)]TJ
0.175 Tw 0 -1.26826 TD
[(fr)20 (om the Canadian Critical Car)19 (e Nutrition Gr)20 (oup. The study)]TJ
0.151 Tw T*
[(population consisted of 424 patients with pancr)20 (eatitis, sepsis,)]TJ
0.16701 Tw 0 -1.26825 TD
[(SIRS, bur)-3.9 (ns, major sur)23.7 (ger)-5 (y and trauma. They concluded that)]TJ
ET
1 w
/GS1 gs
42.52 39.685 m
552.756 39.685 l
S
BT
/GS3 gs
/T1_2 1 Tf
-0.021 Tc 0.02901 Tw 12.5 0 0 12.5 42.5197 793.7901 Tm
[(R)26 (e)24 (vie)21 (w ar)-18 (ticle)10 (s)]TJ
ET
BT
0 g
/GS4 gs
/T1_6 1 Tf
0 Tc 0 Tw 5 0 0 5 301.10497 11 Tm
( by guest on September 2, 2015)Tj
0 0 1 rg
/GS4 gs
-7.55899 0 Td
(inc.sagepub.com)Tj
0 g
/GS4 gs
-8.11399 0 Td
(Downloaded from )Tj
ET
endstream
endobj
37 0 obj
<<
/OP true
/OPM 1
/SM 0.00999451
/Type /ExtGState
/op true
>>
endobj
38 0 obj
<<
/OP false
/OPM 1
/SM 0.00999451
/Type /ExtGState
/op false
>>
endobj
39 0 obj
<<
/FL 1
/OP true
/OPM 1
/SM 0.00999451
/Type /ExtGState
/op true
>>
endobj
40 0 obj
<<
/OP false
/OPM 0
/SM 1.0
/op false
>>
endobj
41 0 obj
<<
/A 180 0 R
/Border [0 0 0]
/Rect [262.31 9.0 302.105 16.0]
/Subtype /Link
/Type /Annot
>>
endobj
42 0 obj
<<
/Length 17065
>>
stream
q
0 0.89 595 841 re
W n
1 g
/GS0 gs
0 841.89 0 0 re
f
Q
0 1 0.60001 0.27 k
/GS1 gs
575.433 785.718 28.346 64.676 re
f
0.27 0.06 0 0 k
0 785.1971 573.449 65.197 re
f
0.95 0.7 0.06 0 K
2 w
/GS2 gs
0 785.889 m
603.78 785.889 l
S
BT
0 0 0 1 k
/GS3 gs
/T1_0 1 Tf
9.3 0 0 9.3 42.5509 28.8783 Tm
(JICS)Tj
ET
BT
/T1_1 1 Tf
8.5 0 0 8.5 65.941 29.4783 Tm
(V)Tj
0.026 Tw 0.51587 0.00001 Td
(olume 10, Number 1)Tj
8.5376 -0.0706 Td
(,)Tj
0 Tw 0.52672 0.07059 Td
(Januar)Tj
-0.0002 Tc 2.60181 0.00001 Td
(y)Tj
0 Tc 0.74743 0 Td
(2009)Tj
ET
BT
/T1_2 1 Tf
9 0 0 9 543.0396 29.0855 Tm
(41)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 9.5 0 0 9.5 42.5197 198.1667 Tm
(ther)Tj
-0.0105 Tc 1.62332 0.00001 Td
(e)Tj
-0.011 Tc 0.341 Tw 1.0231 0 Td
[(was a bene\336)-5.6 (cial mor)]TJ
-0.00999 Tc 0.34 Tw 9.25683 0.00002 Td
[(t)1 (a)1 (l)1 (i)1 (t)1 (y)1 ( e)1 (f)11 (f)1 (e)1 (c)1 (t)1 ( f)1 (r)20 (om )-1 (supplementing)]TJ
-0.011 Tc 0.17599 Tw -11.90324 -1.27614 Td
(selenium in the critically ill \(risk ratio 0.69, 95% con\336)Tj
0 Tw 23.50195 0.00001 Td
(dence)Tj
-23.50195 -1.27613 Td
(inter)Tj
0.021 Tw 1.92032 0.00001 Td
(val 0.59-0.82\) \()Tj
ET
BT
/T1_2 1 Tf
0 Tc 0 Tw 8.5 0 0 8.5 120.9611 173.9203 Tm
(T)Tj
-0.01401 Tc 0.02299 Tw 0.50309 0.00001 Td
(able 1)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 0 Tw 9.5 0 0 9.5 146.9356 173.9203 Tm
(\). )Tj
ET
BT
/T1_2 1 Tf
-0.01401 Tc -0.043 Tw 10.5 0 0 10.5 42.5197 156.1278 Tm
[(Ongoing clinic)5 (al trials)]TJ
ET
BT
/T1_3 1 Tf
-0.011 Tc 0.021 Tw 9.5 0 0 9.5 42.5197 141.17 Tm
[(T)129 (wo randomised contr)20 (olled trials ar)20 (e curr)19 (ently ongoing: )]TJ
0 Tw 0 -1.27613 TD
(SIGNET)Tj
ET
BT
/T1_3 1 Tf
5.415 0 0 5.415 74.9606 132.7075 Tm
(37)Tj
ET
BT
/T1_3 1 Tf
0 Tc 9.5 0 0 9.5 86.0903 129.0468 Tm
(\()Tj
ET
BT
/T1_4 1 Tf
9.5 0 0 9.5 89.6864 129.0468 Tm
(S)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 9.5 0 0 9.5 94.6847 129.0468 Tm
(cottish )Tj
ET
BT
/T1_4 1 Tf
0 Tc 9.5 0 0 9.5 126.3627 129.0468 Tm
(I)Tj
ET
BT
/T1_3 1 Tf
-0.00999 Tc 9.5 0 0 9.5 129.6029 129.0468 Tm
(ntensive )Tj
ET
BT
/T1_4 1 Tf
0 Tc 9.5 0 0 9.5 167.3287 129.0468 Tm
(C)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 9.5 0 0 9.5 173.9134 129.0468 Tm
[(ar)19 (e )]TJ
ET
BT
/T1_4 1 Tf
0 Tc 9.5 0 0 9.5 191.0002 129.0468 Tm
(G)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 0.34399 Tw 9.5 0 0 9.5 197.9374 129.0468 Tm
(lutamine or sele)Tj
ET
BT
/T1_4 1 Tf
0 Tc 0 Tw 9.5 0 0 9.5 266.0225 129.0468 Tm
(N)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 9.5 0 0 9.5 272.9598 129.0468 Tm
(ium)Tj
ET
BT
/T1_4 1 Tf
0 Tc 9.5 0 0 9.5 42.5197 116.9237 Tm
(E)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 9.5 0 0 9.5 48.0491 116.9237 Tm
(valuative )Tj
ET
BT
/T1_4 1 Tf
0 Tc 9.5 0 0 9.5 89.652 116.9237 Tm
(T)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 0.504 Tw 9.5 0 0 9.5 95.5339 116.9237 Tm
[(rial\) will examine the ef)10 (fects of 500)]TJ
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 9.5 0 0 9.5 262.3461 116.9237 Tm
(m)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 9.5 0 0 9.5 267.7248 116.9237 Tm
(g/day)Tj
0.244 Tw -23.7058 -1.27612 Td
[(selenium and/or glutamine par)20 (enterally in 500 ICU patients)]TJ
0.306 Tw T*
[(who ar)20 (e being par)19 (enterally fed. The primar)-5 (y outcomes ar)20 (e)]TJ
0.3 Tw 0 -1.27612 TD
[(length of ICU and hospital stay)145 (, mor)9 (tality and episodes of)]TJ
0.021 Tw 0 -1.27613 TD
(sepsis. It is due to complete in 2009.)Tj
0.30099 Tw 0 -1.27612 TD
(The REDOXS)Tj
ET
BT
/T1_3 1 Tf
0 Tw 5.415 0 0 5.415 98.0096 59.9685 Tm
(38)Tj
ET
BT
/T1_3 1 Tf
0 Tc 9.5 0 0 9.5 108.7371 56.3078 Tm
(\()Tj
ET
BT
/T1_4 1 Tf
9.5 0 0 9.5 112.3333 56.3078 Tm
(R)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 9.5 0 0 9.5 118.2153 56.3078 Tm
(educing )Tj
ET
BT
/T1_4 1 Tf
0 Tc 9.5 0 0 9.5 154.051 56.3078 Tm
(D)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 0.30099 Tw 9.5 0 0 9.5 160.8073 56.3078 Tm
(eaths due to )Tj
ET
BT
/T1_4 1 Tf
0 Tw 9.5 0 0 9.5 218.4052 56.3078 Tm
(OX)Tj
ET
BT
/T1_3 1 Tf
9.5 0 0 9.5 231.396 56.3078 Tm
(idative )Tj
ET
BT
/T1_4 1 Tf
0 Tc 9.5 0 0 9.5 262.3008 56.3078 Tm
(S)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 9.5 0 0 9.5 267.2991 56.3078 Tm
[(tr)20 (ess\))]TJ
0.045 Tw 4.1633 14.93252 Td
[(study will examine the ef)-3.1 (fects of glutamine and/or antioxidants)]TJ
0.38499 Tw 0 -1.35285 TD
(in 1,200 mechanically-ventilated critically ill patients with)Tj
0.22099 Tw 0 -1.35284 TD
[(evidence of acute or)30 (gan failur)19 (e. The antioxidant supplement)]TJ
0.067 Tw T*
(will include 500)Tj
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 9.5 0 0 9.5 372.7626 159.6106 Tm
(m)Tj
ET
BT
/T1_3 1 Tf
-0.0105 Tc 9.5 0 0 9.5 378.1413 159.6106 Tm
(g)Tj
-0.011 Tc 0.067 Tw 0.78577 0 Td
[(selenium par)20 (enterally and 300)]TJ
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 9.5 0 0 9.5 506.4158 159.6106 Tm
(m)Tj
ET
BT
/T1_3 1 Tf
-0.0105 Tc 9.5 0 0 9.5 511.7945 159.6106 Tm
(g)Tj
-0.011 Tc 0.78578 0 Td
(enterally)Tj
0.161 Tw -22.35884 -1.35285 Td
[(\(in addition to zinc, vitamins A, C and E\). The primar)-5 (y end)]TJ
0.021 Tw T*
(point is 28-day mor)Tj
-0.00999 Tc 0 Tw 8.03843 0.00001 Td
(tality)Tj
-0.0106 Tc 1.90336 0.00001 Td
(,)Tj
-0.011 Tc 0.021 Tw 0.51759 0 Td
[(and r)17.7 (esults ar)]TJ
-0.0105 Tc 5.46479 0.00002 Td
(e)Tj
-0.011 Tc 0.70261 0 Td
(expected in 2010.)Tj
ET
BT
0.95 0.7 0.06 0 k
/T1_2 1 Tf
-0.021 Tc 0.02299 Tw 11 0 0 11 306.8504 110.5505 Tm
[(Single v)17 (er)21 (sus multiple an)5 (tio)21 (xidan)5 (t)7 (s)]TJ
ET
BT
0 0 0 1 k
/T1_3 1 Tf
-0.011 Tc 0.02699 Tw 9.5 0 0 9.5 306.8504 94.8639 Tm
[(The studies mentioned above dif)-6.2 (fer in the appr)12 (oaches they take)]TJ
0.20399 Tw T*
[(to antioxidant supplementation; some examine the ef)-16.4 (fects of)]TJ
0.12399 Tw 0 -1.35285 TD
(selenium alone, others examine combinations of antioxidants.)Tj
0.384 Tw 0 -1.35284 TD
(Study of a single nutrient allows any consequence to be)Tj
ET
1 w
/GS1 gs
42.52 39.685 m
552.756 39.685 l
S
BT
/GS3 gs
/T1_2 1 Tf
-0.021 Tc 0.02901 Tw 12.5 0 0 12.5 465.8717 793.7901 Tm
[(R)26 (e)24 (vie)21 (w ar)-18 (ticle)10 (s)]TJ
ET
0.06 0.08501 0.23 0 k
/GS1 gs
42.52 245.035 510.236 506.146 re
f
BT
0 0 0 1 k
/GS3 gs
/T1_2 1 Tf
-0.01401 Tc 8 0 0 8 48.189 737.874 Tm
[(A)25 (uthor and y)25 (e)7 (ar)-4594 (Critic)5 (al illne)10 (s)12 (s)-2801 (No)23 (. o)15 (f p)8 (atien)4 (t)7 (s)-2760 (D)4 (aily S)10 (e)26 (/)95 (eb)8 (s)9 (elen)-3711 (Mor)-18 (t)15 (alit)21 (y)-2615 (Included in me)8 (t)14 (a-)15 (analy)23 (sis)]TJ
ET
BT
/T1_2 1 Tf
0 Tc 0 Tw 4.56 0 0 4.56 537.2169 741.6152 Tm
(*)Tj
ET
0 0 0 1 K
0.125 w
/GS1 gs
48.189 721.2051 m
547.087 721.2051 l
S
BT
/GS3 gs
/T1_2 1 Tf
-0.01401 Tc 0.02901 Tw 8 0 0 8 386.4088 726.874 Tm
[(S)10 (e+ S)10 (e- )]TJ
ET
BT
/T1_6 1 Tf
-0.013 Tc 0.026 Tw 8 0 0 8 48.189 710.7715 Tm
[(K)30 (uklinski 199)-15 (1)]TJ
ET
BT
/T1_6 1 Tf
-0.02299 Tc 0 Tw 4.56 0 0 4.56 95.7664 714.5127 Tm
(31)Tj
ET
BT
/T1_6 1 Tf
-0.013 Tc 0.026 Tw 8 0 0 8 150.1234 710.7715 Tm
[(P)30 (ancr)25 (e)7 (atitis)]TJ
11.63399 0 Td
(17)Tj
7.967 0 Td
[(S)8 (e 500)]TJ
ET
BT
/T1_6 1 Tf
0 Tw 8 0 0 8 339.6807 710.7715 Tm
[(g)-4599 (0)55 (/)65 (8)-2797 (8)35 (/)30 (9)]TJ
17.526 0 Td
[(A)59 (v)18 (enell)]TJ
ET
/GS1 gs
48.189 694.1021 m
547.087 694.1021 l
S
BT
/GS3 gs
/T1_6 1 Tf
8 0 0 8 313.8681 699.7715 Tm
(8)Tj
0.026 Tw 0.89594 0 Td
[(da)15 (y)20 (s)-16542 (He)20 (yland \(+/-\))]TJ
-34.10582 -2.01279 Td
[(Zimmerman 199)5 (7)]TJ
ET
BT
/T1_6 1 Tf
0 Tw 4.56 0 0 4.56 109.5613 687.4104 Tm
(21)Tj
ET
BT
/T1_6 1 Tf
0.026 Tw 8 0 0 8 162.7089 683.6692 Tm
(SIRS)Tj
9.861 0 Td
(40)Tj
7.998 0 Td
[(S)8 (e 1000)]TJ
ET
BT
/T1_6 1 Tf
8 0 0 8 341.0239 683.6692 Tm
[(g)-4179 (3)40 (/)40 (2)18 (0)-2266 (8)35 (/)40 (2)18 (0)]TJ
17.358 0 Td
[(A)59 (v)18 (enell )]TJ
-22.83011 -1.375 Td
(bolus + 1000)Tj
ET
BT
/T1_6 1 Tf
0 Tw 8 0 0 8 349.3614 672.6693 Tm
(g)Tj
16.124 0 Td
[(He)20 (yland)]TJ
ET
/GS1 gs
48.189 656 m
547.087 656 l
S
BT
/GS3 gs
/T1_6 1 Tf
0.026 Tw 8 0 0 8 311.8042 661.6693 Tm
[(2)40 (8 da)15 (y)20 (s)]TJ
-32.9519 -2.0128 Td
[(B)8 (er)28 (ger 199)10 (8)]TJ
ET
BT
/T1_6 1 Tf
-0.08299 Tc 0 Tw 4.56 0 0 4.56 91.006 649.308 Tm
(24)Tj
ET
BT
/T1_6 1 Tf
-0.013 Tc 0.026 Tw 8 0 0 8 160.6802 645.5668 Tm
[(B)8 (urns)]TJ
10.152 0 Td
[(2)18 (0)]TJ
8.323 0 Td
[(S)8 (e 15)30 (9)]TJ
ET
BT
/T1_6 1 Tf
0 Tw 8 0 0 8 338.128 645.5668 Tm
[(g)-4746 (1/10)-2578 (0)55 (/10)]TJ
17.529 0 Td
[(He)20 (yland)]TJ
ET
/GS1 gs
48.189 628.898 m
547.087 628.898 l
S
BT
/GS3 gs
/T1_6 1 Tf
8 0 0 8 313.8681 634.5668 Tm
[(8)-272.9 (da)15 (y)20 (s)]TJ
0.026 Tw -33.20988 -2.01278 Td
[(Angs)10 (t)17 (wurm 1999)]TJ
ET
BT
/T1_6 1 Tf
0 Tw 4.56 0 0 4.56 107.5984 622.2057 Tm
(12)Tj
ET
BT
/T1_6 1 Tf
0.026 Tw 8 0 0 8 150.1492 618.4645 Tm
[(S)8 (ep)8 (sis)20 (/)34 (SIRS)]TJ
11.47599 0 Td
[(4)15 (2)]TJ
8.204 0 Td
[(S)8 (e 5)20 (3)28 (5)]TJ
ET
BT
/T1_6 1 Tf
8 0 0 8 339.0254 618.4645 Tm
[(g)-4658 (7)180 (/)40 (21)-2647 (11/)39 (21)]TJ
17.609 0 Td
[(A)59 (v)18 (enell )]TJ
-21.48782 -1.375 Td
[(f)22 (or 3 da)15 (y)20 (s )]TJ
21.296 0 Td
[(He)20 (yland)]TJ
ET
/GS1 gs
48.189 590.795 m
547.087 590.795 l
S
BT
/GS3 gs
/T1_6 1 Tf
8 0 0 8 301.1541 596.4645 Tm
[(then r)25 (educing)]TJ
0 Tc -31.62064 -2.0128 Td
(P)Tj
-0.013 Tc 0.588 0.00001 Td
[(or)-10 (t)20 (er 1999)]TJ
ET
BT
/T1_6 1 Tf
-0.03799 Tc 0 Tw 4.56 0 0 4.56 89.629 584.1033 Tm
(27)Tj
ET
BT
/T1_6 1 Tf
0 Tc 8 0 0 8 157.7637 580.3621 Tm
(T)Tj
-0.013 Tc 0.026 Tw 0.4901 0.00001 Td
[(r)35 (auma)-7349 (18)-7112 (S)8 (e 2)18 (00)]TJ
ET
BT
/T1_6 1 Tf
0 Tc 0 Tw 8 0 0 8 339.4639 580.3621 Tm
(g)Tj
-0.013 Tc 5.16559 0.00001 Td
[(0)55 (/)30 (9)-2797 (0)54 (/)30 (9)-6284 (He)20 (yland)]TJ
ET
/GS1 gs
48.189 563.6931 m
547.087 563.6931 l
S
BT
/GS3 gs
/T1_6 1 Tf
-0.01311 Tc 8 0 0 8 314.1688 569.3622 Tm
(?)Tj
-0.013 Tc 0.8208 0 Td
[(da)15 (y)20 (s)]TJ
0.026 Tw -34.06828 -2.01281 Td
[(B)8 (er)28 (ger 2)18 (001)]TJ
ET
BT
/T1_6 1 Tf
4.56 0 0 4.56 90.8536 557.001 Tm
[(2)40 (8, 2)25 (9**)]TJ
ET
BT
/T1_6 1 Tf
8 0 0 8 157.7637 553.2597 Tm
[(T)85 (r)35 (auma)]TJ
10.559 0 Td
[(3)24 (2)]TJ
8.087 0 Td
[(S)9 (e 500)]TJ
ET
BT
/T1_6 1 Tf
0 Tw 8 0 0 8 339.6807 553.2597 Tm
[(g)-4331 (2)15 (/)40 (2)18 (0)-2532 (1/12)]TJ
17.335 0 Td
[(He)20 (yland)]TJ
ET
/GS1 gs
48.189 536.59 m
547.087 536.59 l
S
BT
/GS3 gs
/T1_6 1 Tf
8 0 0 8 313.9921 542.2598 Tm
[(5)-272.9 (da)15 (y)20 (s)]TJ
0 Tc -33.22538 -2.01279 Td
(B)Tj
-0.013 Tc 0.026 Tw 0.60509 0.00001 Td
[(er)28 (ger 2)18 (001)]TJ
ET
BT
/T1_6 1 Tf
0 Tw 4.56 0 0 4.56 90.8536 529.8986 Tm
[(2)40 (8**)]TJ
ET
BT
/T1_6 1 Tf
0 Tc 8 0 0 8 157.7637 526.1574 Tm
(T)Tj
-0.013 Tc 0.026 Tw 0.4901 0.00001 Td
[(r)35 (auma)-7382 (21)-7119 (S)8 (e 500)]TJ
ET
BT
/T1_6 1 Tf
0 Tc 0 Tw 8 0 0 8 339.6807 526.1574 Tm
(g)Tj
-0.013 Tc 5.15498 0.00001 Td
[(2)15 (/)30 (9)-2938 (1/11)-6600 (A)59 (v)18 (enell)]TJ
ET
/GS1 gs
48.189 509.488 m
547.087 509.488 l
S
BT
/GS3 gs
/T1_6 1 Tf
8 0 0 8 313.9921 515.1575 Tm
[(5)-272.9 (da)15 (y)20 (s)]TJ
0.026 Tw -33.22538 -2.0128 Td
[(B)8 (er)28 (ger 2)18 (004)]TJ
ET
BT
/T1_6 1 Tf
0 Tw 4.56 0 0 4.56 93.3595 502.7962 Tm
[(***2)40 (6)]TJ
ET
BT
/T1_6 1 Tf
0.026 Tw 8 0 0 8 160.6802 499.0551 Tm
[(B)8 (urns)]TJ
10.308 0 Td
(21)Tj
8.005 0 Td
[(S)8 (e 3)15 (80)]TJ
ET
BT
/T1_6 1 Tf
0 Tw 8 0 0 8 339.4297 499.0551 Tm
[(g)-4748 (1/11)-2881 (1/10)]TJ
17.367 0 Td
[(He)20 (yland)]TJ
ET
/GS1 gs
48.189 482.386 m
547.087 482.386 l
S
BT
/GS3 gs
/T1_6 1 Tf
8 0 0 8 308.3204 488.0551 Tm
(14)Tj
0 Tc 0.89621 0 Td
(-)Tj
-0.013 Tc 0.026 Tw 0.2589 0 Td
(21 da)Tj
0 Tc 2.18497 0 Td
[(y)33.1 (s)]TJ
-0.013 Tc -35.85651 -2.0128 Td
(Lindner 2)Tj
0 Tw 4.18637 0 Td
(004)Tj
ET
BT
/T1_6 1 Tf
-0.028 Tc 4.56 0 0 4.56 96.6416 475.6939 Tm
(33)Tj
ET
BT
/T1_6 1 Tf
0 Tc 8 0 0 8 150.1234 471.9528 Tm
(P)Tj
-0.013 Tc 0.57506 0 Td
(ancr)Tj
0 Tc 1.93134 0 Td
(e)Tj
-0.013 Tc 0.51989 0 Td
(atitis)Tj
0 Tc 8.46761 0 Td
[(7)63 (0)]TJ
6.51014 0 Td
(S)Tj
-0.01311 Tc 0.57092 0 Td
(e)Tj
-0.013 Tc 0.79974 0 Td
[(2)18 (000)]TJ
ET
BT
/T1_6 1 Tf
8 0 0 8 331.5072 471.9528 Tm
[(g)-273 (bolus)]TJ
0 Tc 5.90951 0 Td
[(5)42.9 (/)43 (3)40.9 (5)-2309.3 (3)52.9 (/)]TJ
-0.013 Tc 5.27256 0 Td
[(3)28 (5)-6251 (A)59 (v)17 (enell)]TJ
ET
/GS1 gs
48.189 455.2831 m
547.087 455.2831 l
S
BT
/GS3 gs
/T1_6 1 Tf
8 0 0 8 295.3282 460.9527 Tm
[(+)-272.9 (1000)]TJ
ET
BT
/T1_6 1 Tf
8 0 0 8 326.4972 460.9527 Tm
[(g)-272.9 (7)-272.9 (da)15 (y)20 (s)]TJ
-34.78852 -2.0128 Td
(Mishr)Tj
-0.01311 Tc 2.38042 0 Td
(a)Tj
-0.03101 Tc 0.79875 0 Td
[(20)-18 (0)-7 (7)]TJ
ET
BT
/T1_6 1 Tf
-0.013 Tc 4.56 0 0 4.56 92.2404 448.5916 Tm
(13)Tj
ET
BT
/T1_6 1 Tf
0 Tc 8 0 0 8 150.1492 444.8503 Tm
(S)Tj
-0.013 Tc 0.026 Tw 0.57091 0 Td
[(ep)8 (sis)20 (/)34 (SIR)-1 (S)-6237 (40)-5861 (S)8 (e 4)24 (7)130 (4)]TJ
ET
BT
/T1_6 1 Tf
0 Tw 8 0 0 8 329.273 444.8503 Tm
[(g)-272.9 (f)]TJ
0.026 Tw 1.14008 0 Td
[(or 3 )-3069 (11/18)-2226 (15)30 (/)40 (2)20 (2)-6092 (A)59 (v)18 (enell )]TJ
ET
/GS1 gs
48.189 428.181 m
547.087 428.181 l
S
BT
/GS3 gs
/T1_6 1 Tf
8 0 0 8 292.0265 433.8503 Tm
[(da)15 (y)20 (s then r)24 (educing)]TJ
-30.47969 -2.01279 Td
[(F)81 (or)25 (c)17 (e)20 (ville 2)18 (00)12 (7)]TJ
ET
BT
/T1_6 1 Tf
-0.033 Tc 0 Tw 4.56 0 0 4.56 101.779 421.4892 Tm
(22)Tj
ET
BT
/T1_6 1 Tf
-0.013 Tc 0.026 Tw 8 0 0 8 148.8203 417.748 Tm
[(S)8 (ep)5 (tic shock)]TJ
11.603 0 Td
(60)Tj
9.93199 0 Td
[(S)8 (e)]TJ
7.187 0 Td
[(14)25 (/)30 (3)10 (1)-2144 (13)40 (/)40 (2)25 (9)]TJ
13.639 0 Td
(No)Tj
0 Tw -22.92672 -1.375 Td
(4000)Tj
ET
BT
/T1_6 1 Tf
8 0 0 8 331.2734 406.748 Tm
[(g)-272.9 (on )]TJ
0 Tc -3.73345 -1.375 Td
(f)Tj
-0.013 Tc 0.33824 0 Td
(ir)Tj
0 Tc 0.61228 0 Td
(s)Tj
-0.01311 Tc 0.44396 0 Td
(t)Tj
-0.013 Tc 0.63182 0 Td
(da)Tj
0.026 Tw 1.05719 0 Td
[(y)75 (, then )]TJ
0 Tw -2.82824 -1.37502 Td
(1000)Tj
ET
BT
/T1_6 1 Tf
8 0 0 8 327.9208 384.748 Tm
[(g/)82 (da)14 (y )]TJ
ET
/GS1 gs
48.189 368.079 m
547.087 368.079 l
S
BT
/GS3 gs
/T1_6 1 Tf
-0.01311 Tc 8 0 0 8 313.9569 373.748 Tm
(9)Tj
-0.013 Tc 0.87378 0 Td
(da)Tj
0 Tc 1.05718 0 Td
[(y)33.1 (s)]TJ
-0.013 Tc -35.15195 -2.01281 Td
(Angs)Tj
0.026 Tw 2.20917 0 Td
[(t)17 (wurm 2)18 (00)12 (7)]TJ
ET
BT
/T1_6 1 Tf
0 Tw 4.56 0 0 4.56 109.4012 361.3868 Tm
(14)Tj
ET
BT
/T1_6 1 Tf
0 Tc 8 0 0 8 150.1492 357.6457 Tm
(S)Tj
-0.013 Tc 0.57091 0 Td
[(ep)8 (sis)20 (/)34 (SIR)-1 (S)-6025 (2)70 (4)35 (9)-8485 (S)8 (e)-5740 (46)20 (/116)-1609 (6)15 (1/12)20 (2)-5911 (A)59 (v)18 (enell)]TJ
18.23481 -1.37501 Td
(1000)Tj
ET
BT
/T1_6 1 Tf
8 0 0 8 325.068 346.6456 Tm
(g)Tj
15.75 Tw 0.81898 0 Td
[(bolus He)20 (yland)]TJ
0.026 Tw -4.65501 -1.375 Td
(then 1000)Tj
ET
BT
/T1_6 1 Tf
0 Tw 8 0 0 8 336.9889 335.6456 Tm
[(g/)82 (da)14 (y)]TJ
ET
/GS1 gs
48.189 318.976 m
547.087 318.976 l
S
BT
/GS3 gs
/T1_6 1 Tf
0.026 Tw 8 0 0 8 312.7163 324.6457 Tm
[(14 da)15 (y)20 (s)]TJ
ET
BT
/T1_6 1 Tf
0 Tc 0 Tw 4.56 0 0 4.56 48.189 312.2845 Tm
(*)Tj
ET
BT
/T1_6 1 Tf
-0.013 Tc 8 0 0 8 52.5938 308.5432 Tm
[(A)59 (v)18 (enell)]TJ
ET
BT
/T1_6 1 Tf
-0.041 Tc 4.56 0 0 4.56 78.0452 312.2845 Tm
(35)Tj
ET
BT
/T1_6 1 Tf
-0.013 Tc 0.026 Tw 8 0 0 8 85.3095 308.5432 Tm
[(analy)20 (s)10 (ed s)10 (t)8 (udie)10 (s on s)9 (elenium or eb)8 (s)10 (elen alone)25 (, He)20 (yland)]TJ
ET
BT
/T1_6 1 Tf
-0.028 Tc 0 Tw 4.56 0 0 4.56 280.2292 312.2845 Tm
(36)Tj
ET
BT
/T1_6 1 Tf
-0.013 Tc 0.026 Tw 8 0 0 8 287.5937 308.5432 Tm
[(analy)20 (s)10 (ed s)10 (t)8 (udie)10 (s on s)9 (elenium either alone or as one o)15 (f a number o)15 (f)]TJ
0 Tw -29.92559 -1.375 Td
[(an)5 (tio)20 (xidan)4 (t)7 (s)12 (.)]TJ
ET
BT
/T1_6 1 Tf
4.56 0 0 4.56 48.189 290.2845 Tm
(**)Tj
ET
BT
/T1_6 1 Tf
0 Tc 8 0 0 8 54.8153 286.5432 Tm
(B)Tj
-0.013 Tc 0.026 Tw 0.60509 0.00001 Td
[(er)28 (ger published this s)10 (t)8 (udy in t)17 (w)18 (o p)8 (ar)-11 (t)7 (s)12 (, A)59 (v)18 (enell c)17 (ommen)5 (t)7 (s upon )]TJ
ET
BT
/T1_7 1 Tf
8 0 0 8 284.8164 286.5432 Tm
(Nutrition R)Tj
-0.02299 Tc 0 Tw 4.78815 0.00001 Td
[(ese)-3 (a)-10 (r)14 (c)-10 (h)]TJ
ET
BT
/T1_6 1 Tf
0 Tc 8 0 0 8 352.4013 286.5432 Tm
(p)Tj
-0.013 Tc 0.026 Tw 0.53795 0.00001 Td
[(aper)125 (, \322)20 (s)10 (elenium only\323 p)8 (atien)5 (t)7 (s)12 (. He)19 (yland c)17 (ommen)5 (t)7 (s)]TJ
-38.56449 -1.37501 Td
[(upon \322)20 (s)10 (elenium only\323 and \322)20 (s)10 (elenium plus c)17 (opper)125 (, zinc and t)20 (oc)17 (opher)24 (ol\323 gr)25 (oup)8 (s c)17 (ombined using dat)15 (a fr)25 (om bo)4 (th p)8 (aper)20 (s \()]TJ
ET
BT
/T1_7 1 Tf
8 0 0 8 463.6512 275.5432 Tm
[(Nutrition R)21 (e)10 (s)10 (e)7 (ar)24 (ch )]TJ
ET
BT
/T1_6 1 Tf
0 Tw 8 0 0 8 531.2023 275.5432 Tm
(and)Tj
ET
BT
/T1_7 1 Tf
8 0 0 8 48.189 264.5432 Tm
(In)Tj
0 Tc 0.80458 0.00001 Td
(t)Tj
-0.013 Tc 0.026 Tw 0.33905 0.00001 Td
[(ensiv)18 (e C)12 (ar)24 (e Medicine)]TJ
ET
BT
/T1_6 1 Tf
0 Tw 8 0 0 8 130.8203 264.5432 Tm
(\).)Tj
ET
BT
/T1_6 1 Tf
4.56 0 0 4.56 48.189 257.2845 Tm
(***)Tj
ET
BT
/T1_6 1 Tf
0.026 Tw 8 0 0 8 57.0369 253.5433 Tm
[(updat)20 (ed f)5 (igur)24 (e)10 (s fr)25 (om s)10 (t)8 (udy \()25 (no)4 (t me)8 (t)15 (a-)15 (analy)20 (sis)34 (\). S)8 (e = s)10 (elenium.)]TJ
ET
0.95 0.7 0.06 0 K
2 w
/GS1 gs
42.52 228.0711 m
552.756 228.0711 l
S
BT
/GS3 gs
/T1_2 1 Tf
0 Tc 0 Tw 8.5 0 0 8.5 42.5197 234.7402 Tm
(T)Tj
-0.01401 Tc 0.02299 Tw 0.50309 -0.00001 Td
(able 1 )Tj
ET
BT
/T1_6 1 Tf
0 Tc 0 Tw 8.5 0 0 8.5 73.3132 234.7402 Tm
[(S)25 (t)]TJ
-0.013 Tc 0.021 Tw 0.91794 -0.00002 Td
[(udie)10 (s o)14 (f s)10 (elenium in the critic)17 (ally ill. Char)35 (act)19 (eris)10 (tic)5 (s o)15 (f included s)9 (t)8 (udie)10 (s)12 (.)]TJ
ET
BT
0 g
/GS4 gs
/T1_8 1 Tf
0 Tc 0 Tw 5 0 0 5 301.10497 11 Tm
( by guest on September 2, 2015)Tj
0 0 1 rg
/GS4 gs
-7.55899 0 Td
(inc.sagepub.com)Tj
0 g
/GS4 gs
-8.11399 0 Td
(Downloaded from )Tj
ET
endstream
endobj
43 0 obj
<<
/OP true
/OPM 1
/SM 0.00999451
/Type /ExtGState
/op true
>>
endobj
44 0 obj
<<
/OP false
/OPM 1
/SM 0.00999451
/Type /ExtGState
/op false
>>
endobj
45 0 obj
<<
/FL 1
/OP true
/OPM 1
/SM 0.00999451
/Type /ExtGState
/op true
>>
endobj
46 0 obj
<<
/OP false
/OPM 0
/SM 1.0
/op false
>>
endobj
47 0 obj
<<
/BaseFont /GNHJBL+Berkeley-Bold
/Encoding 181 0 R
/FirstChar 32
/FontDescriptor 182 0 R
/LastChar 222
/Subtype /Type1
/Type /Font
/Widths [268 0 0 0 0 0 0 0 0 0
0 0 268 276 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 667 593 704 722 593 574 741
722 352 352 667 574 852 741 741 556 0
630 537 630 0 667 981 648 593 593 0
0 0 0 0 0 463 537 444 556 463
315 481 556 296 0 537 296 815 556 519
556 0 389 426 333 556 481 741 519 500
463 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 463 0 0 0
463 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 556 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
574]
>>
endobj
48 0 obj
<<
/BaseFont /PNKSBH+Interstate-LightItalic
/Encoding 183 0 R
/FirstChar 32
/FontDescriptor 184 0 R
/LastChar 118
/Subtype /Type1
/Type /Font
/Widths [256 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 624 0 0 0 0
0 272 0 0 0 784 684 0 0 0
646 0 0 0 0 0 0 0 0 0
0 0 0 0 0 535 0 491 555 536
0 0 563 251 0 0 0 0 563 562
0 0 405 463 372 563 518]
>>
endobj
49 0 obj
<<
/A 185 0 R
/Border [0 0 0]
/Rect [262.31 9.0 302.105 16.0]
/Subtype /Link
/Type /Annot
>>
endobj
50 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 186 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 187 0 R
/Rect [317.06 478.33 526.37 485.75]
>>
endobj
51 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 188 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 189 0 R
/Rect [317.06 467.71002 548.15 475.14]
>>
endobj
52 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 190 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 191 0 R
/Rect [317.06 457.11002 330.97 464.53003]
>>
endobj
53 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 192 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 193 0 R
/Rect [317.06 414.67 545.67 422.09003]
>>
endobj
54 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 194 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 195 0 R
/Rect [317.06 404.05002 457.4 411.48]
>>
endobj
55 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 196 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 197 0 R
/Rect [318.89 181.23999 532.89 188.68]
>>
endobj
56 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 198 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 199 0 R
/Rect [317.06 170.64001 519.92 178.07]
>>
endobj
57 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 200 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 201 0 R
/Rect [317.06 160.04004 369.05 167.46002]
>>
endobj
58 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 202 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 203 0 R
/Rect [317.47 117.58002 546.63 125.02002]
>>
endobj
59 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 204 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 205 0 R
/Rect [317.06 106.99005 537.44 114.420044]
>>
endobj
60 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 206 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 207 0 R
/Rect [317.06 96.390015 339.52 103.81]
>>
endobj
61 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 208 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 209 0 R
/Rect [317.06 510.15 536.62 517.57]
>>
endobj
62 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 210 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 211 0 R
/Rect [317.06 499.54 549.9 506.96002]
>>
endobj
63 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 212 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 213 0 R
/Rect [317.06 488.93002 476.0 496.36002]
>>
endobj
64 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 214 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 215 0 R
/Rect [318.95 329.79004 528.65 337.21002]
>>
endobj
65 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 216 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 217 0 R
/Rect [317.06 319.18005 532.69 326.60004]
>>
endobj
66 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 218 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 219 0 R
/Rect [317.06 308.56 537.92 315.99]
>>
endobj
67 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 220 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 221 0 R
/Rect [317.06 446.49002 531.4 453.92]
>>
endobj
68 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 222 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 223 0 R
/Rect [316.61 393.43002 531.77997 400.87003]
>>
endobj
69 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 224 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 225 0 R
/Rect [317.06 382.83002 550.03 390.26]
>>
endobj
70 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 226 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 227 0 R
/Rect [317.06 372.22003 388.16 379.65002]
>>
endobj
71 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 228 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 229 0 R
/Rect [317.06 552.58997 552.12 560.01]
>>
endobj
72 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 230 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 231 0 R
/Rect [317.06 541.97003 450.39 549.4]
>>
endobj
73 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 232 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 233 0 R
/Rect [317.27 213.09003 505.63 220.51001]
>>
endobj
74 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 234 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 235 0 R
/Rect [317.06 202.48004 549.33 209.90002]
>>
endobj
75 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 236 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 237 0 R
/Rect [317.06 191.86005 510.06 199.29004]
>>
endobj
76 0 obj
<<
/Length 2
>>
stream
q
endstream
endobj
77 0 obj
<<
/Length 2
>>
stream
q
endstream
endobj
78 0 obj
<<
/Length 2
>>
stream
q
endstream
endobj
79 0 obj
<<
/Length 2
>>
stream
q
endstream
endobj
80 0 obj
<<
/Length 2
>>
stream
q
endstream
endobj
81 0 obj
<<
/Length 2
>>
stream
q
endstream
endobj
82 0 obj
<<
/Length 2
>>
stream
q
endstream
endobj
83 0 obj
<<
/Length 2
>>
stream
q
endstream
endobj
84 0 obj
<<
/Length 2
>>
stream
q
endstream
endobj
85 0 obj
<<
/Length 2
>>
stream
q
endstream
endobj
86 0 obj
<<
/Length 21528
>>
stream
q
0 0.89 595 841 re
W n
1 g
/GS0 gs
0 841.89 0 0 re
f
Q
0 1 0.60001 0.27 k
/GS1 gs
-8.504 785.718 28.346 64.676 re
f
0.27 0.06 0 0 k
21.901 785.1971 573.374 65.197 re
f
0.95 0.7 0.06 0 K
2 w
/GS2 gs
-8.504 785.889 m
595.276 785.889 l
S
BT
0 0 0 1 k
/GS3 gs
/T1_0 1 Tf
8.5 0 0 8.5 401.6363 29.4783 Tm
(V)Tj
0.026 Tw 0.51587 0.00001 Td
(olume 10, Number 1)Tj
8.5376 -0.0706 Td
(,)Tj
0 Tw 0.52672 0.07059 Td
(Januar)Tj
-0.0002 Tc 2.6018 0.00001 Td
(y)Tj
0 Tc 0.74743 0 Td
(2009)Tj
ET
BT
/T1_1 1 Tf
9.3 0 0 9.3 534.3687 28.8783 Tm
(JICS)Tj
ET
BT
/T1_2 1 Tf
9 0 0 9 42.5197 29.0855 Tm
(42)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 0.233 Tw 9.5 0 0 9.5 42.5197 744.4855 Tm
[(attributed to that nutrient, but micr)20 (onutrients function as a)]TJ
0.453 Tw 0 -1.28058 TD
[(network, and pr)20 (oviding a single component in or)19 (der to)]TJ
0.715 Tw 0 -1.28056 TD
[(generate clinically impor)10 (tant outcomes may cr)19 (eate an)]TJ
0.299 Tw 0 -1.28058 TD
(imbalance. Thus, the rationale for those studies combining)Tj
0.367 Tw 0 -1.28057 TD
[(antioxidants is that syner)30 (gistic functions demand a multi-)]TJ
0.021 Tw 0 -1.28058 TD
[(modal appr)20 (oach. )]TJ
ET
BT
0.95 0.7 0.06 0 k
/T1_2 1 Tf
-0.021 Tc 0.02299 Tw 11 0 0 11 42.5197 660.989 Tm
[(W)10 (hat is the op)5 (timal do)9 (s)10 (e o)15 (f s)10 (elenium f)23 (or)]TJ
0 -1.28777 TD
[(supplemen)5 (t)14 (ation on the IC)10 (U?)]TJ
ET
BT
0 0 0 1 k
/T1_3 1 Tf
-0.011 Tc 0.45599 Tw 9.5 0 0 9.5 42.5197 632.0233 Tm
[(Sodium selenite has pr)20 (o-oxidant ef)9 (fects and, in humans,)]TJ
0.129 Tw 0 -1.25951 TD
(symptoms of toxicity occur with whole blood selenium levels)Tj
0.284 Tw 0 -1.25953 TD
(above 1,000)Tj
ET
BT
/T1_4 1 Tf
0 Tc 0 Tw 9.5 0 0 9.5 93.9915 608.0924 Tm
(m)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 0.284 Tw 9.5 0 0 9.5 99.3701 608.0924 Tm
(g/L. Acute selenium intoxication is similar to)Tj
0.22701 Tw -5.98425 -1.25953 Td
(arsenic poisoning and may lead to shock, ARDS and death.)Tj
0.209 Tw 0 -1.25951 TD
[(Chr)20 (onic toxicity occurs with supplementation of 3-7)-250 (mg per)]TJ
0.427 Tw 0 -1.25953 TD
(day over weeks.)Tj
ET
BT
/T1_3 1 Tf
-0.0106 Tc 0 Tw 5.415 0 0 5.415 111.7398 575.8567 Tm
(2)Tj
-0.011 Tc (0,39)Tj
ET
BT
/T1_3 1 Tf
0.427 Tw 9.5 0 0 9.5 130.5187 572.196 Tm
[(The safe upper limit for shor)10 (t ter)-1 (m)]TJ
0.92799 Tw -9.26305 -1.25951 Td
(supplementation is 1,000)Tj
ET
BT
/T1_4 1 Tf
0 Tc 0 Tw 9.5 0 0 9.5 159.8969 560.2307 Tm
(m)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 9.5 0 0 9.5 165.2756 560.2307 Tm
(g/day)Tj
ET
BT
/T1_3 1 Tf
5.415 0 0 5.415 185.8774 563.8912 Tm
(20)Tj
ET
BT
/T1_3 1 Tf
0.92799 Tw 9.5 0 0 9.5 202.5589 560.2307 Tm
(and for long-term)Tj
0.021 Tw -16.84623 -1.25953 Td
(supplementation is 400-550)Tj
ET
BT
/T1_4 1 Tf
0 Tc 0 Tw 9.5 0 0 9.5 153.0229 548.2651 Tm
(m)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 9.5 0 0 9.5 158.4015 548.2651 Tm
[(g/day)135 (.)]TJ
0.408 Tw -11.00455 -1.25952 Td
[(The For)40 (ceville study attempted to use the pr)19 (o-oxidant)]TJ
0.062 Tw -1.19354 -1.25951 Td
[(ef)10 (fects of sodium selenite to clinical advantage by using a lar)29 (ge)]TJ
0.25 Tw 0 -1.25952 TD
(initial dose.)Tj
ET
BT
/T1_3 1 Tf
0 Tw 5.415 0 0 5.415 89.5196 516.0294 Tm
(22)Tj
ET
BT
/T1_3 1 Tf
0.25 Tw 9.5 0 0 9.5 99.7623 512.3688 Tm
[(They r)20 (epor)9 (ted no impr)20 (oved clinical endpoints)]TJ
0.162 Tw -6.02554 -1.25953 Td
[(and no obvious acute toxicity but an incr)20 (ease in multi-or)29 (gan)]TJ
0 Tw 0 -1.25951 TD
(failur)Tj
-0.0105 Tc 2.1392 0 Td
[(e)-276 (in)]TJ
-0.011 Tc 0.02699 Tw 1.7984 0 Td
[(the supplemented gr)9.3 (oup. Selenium excess is linked to)]TJ
0.037 Tw -3.9376 -1.25953 Td
[(oxidative str)20 (ess)]TJ
ET
BT
/T1_3 1 Tf
0 Tw 5.415 0 0 5.415 101.602 480.1331 Tm
(40)Tj
ET
BT
/T1_3 1 Tf
0.037 Tw 9.5 0 0 9.5 109.8195 476.4724 Tm
[(and the pr)20 (oposed bene\336)-1 (cial pr)20 (o-oxidant ef)10 (fect)]TJ
0.021 Tw -7.08419 -1.25953 Td
(may not occur )Tj
ET
BT
/T1_5 1 Tf
-0.00999 Tc 0.02 Tw 9.5 0 0 9.5 100.9919 464.507 Tm
(in vivo)Tj
ET
BT
/T1_3 1 Tf
0 Tc 0 Tw 9.5 0 0 9.5 125.7516 464.507 Tm
(.)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 5.415 0 0 5.415 128.1116 468.1676 Tm
(41)Tj
ET
BT
/T1_3 1 Tf
0.04401 Tw 9.5 0 0 9.5 53.8583 452.5415 Tm
(Most studies have aimed only to normalise plasma selenium)Tj
0.40199 Tw -1.19354 -1.25953 Td
[(levels and optimise plasma GPx function, r)20 (elying on the)]TJ
0.03 Tw 0 -1.25952 TD
[(antioxidant pr)20 (oper)9 (ties of selenium due to its incorporation into)]TJ
0.424 Tw 0 -1.25953 TD
[(selenoenzymes, with doses ranging fr)3.2 (om 300-1,000)]TJ
ET
BT
/T1_4 1 Tf
0 Tc 0 Tw 9.5 0 0 9.5 262.3462 416.6451 Tm
(m)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 9.5 0 0 9.5 267.7249 416.6451 Tm
(g/day)Tj
0.054 Tw -23.70581 -1.25952 Td
[(enterally or par)20 (enterally for 9-28)-250 (days. In or)20 (der to establish the)]TJ
0.185 Tw T*
(optimal dose of antioxidants for the REDOXS trial Heyland\325)Tj
0 Tc 25.49586 0 Td
(s)Tj
-0.011 Tc 0.12 Tw -25.49586 -1.25952 Td
[(gr)20 (oup per)9 (formed a dosing study)145 (, \336)-1 (nding a dose of 800)]TJ
ET
BT
/T1_4 1 Tf
0 Tc 0 Tw 9.5 0 0 9.5 262.3461 380.7488 Tm
(m)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 9.5 0 0 9.5 267.7248 380.7488 Tm
(g/day)Tj
0.104 Tw -23.7058 -1.25953 Td
(selenium to be optimal.)Tj
ET
BT
/T1_3 1 Tf
0 Tw 5.415 0 0 5.415 136.0837 372.444 Tm
(42)Tj
ET
BT
/T1_3 1 Tf
0.104 Tw 9.5 0 0 9.5 144.9372 368.7833 Tm
[(Ther)20 (e is no evidence to suggest that)]TJ
0.05499 Tw -10.78079 -1.25952 Td
(up to 1,000)Tj
ET
BT
/T1_4 1 Tf
0 Tc 0 Tw 9.5 0 0 9.5 90.2462 356.8179 Tm
(m)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 0.05499 Tw 9.5 0 0 9.5 95.6249 356.8179 Tm
[(g/day of par)13.1 (enteral sodium selenite is detrimental)]TJ
0.021 Tw -5.59002 -1.25952 Td
(to health.)Tj
ET
BT
0.95 0.7 0.06 0 k
/T1_2 1 Tf
0 Tc 0 Tw 11 0 0 11 42.5197 322.1831 Tm
(C)Tj
-0.021 Tc 0.62828 0.00001 Td
(onclusions)Tj
ET
BT
0 0 0 1 k
/T1_3 1 Tf
-0.011 Tc 0.18201 Tw 9.5 0 0 9.5 42.5197 307.3829 Tm
[(Selenium is an impor)10 (tant trace mineral, par)9 (ticularly essential)]TJ
0.21001 Tw 0 -1.25951 TD
(for its antioxidant function in critically ill patients. Ther)Tj
-0.0106 Tc 24.33636 0.00001 Td
(e)Tj
-0.011 Tc 0 Tw 0.89201 0 Td
(is)Tj
0.077 Tw -25.22837 -1.25954 Td
[(good evidence that critically ill patients ar)20 (e selenium de\336cient,)]TJ
0.439 Tw T*
[(but patients with conditions of high oxidative str)20 (ess, eg)]TJ
0.08099 Tw 0 -1.25953 TD
[(sepsis/SIRS, ar)20 (e especially at risk. Critically ill patients ar)19 (e also)]TJ
0.218 Tw 0 -1.25952 TD
[(at risk of de\336ciency due to incr)20 (eased biological \337)-1 (uid losses,)]TJ
0 Tw 0 -1.25953 TD
(thr)Tj
0.06 Tw 1.18983 0.00001 Td
[(ough conditions such as bur)-13.2 (ns, trauma and pancr)20 (eatitis and)]TJ
0.021 Tw -1.18983 -1.25953 Td
[(fr)20 (om inter)-10 (ventions such as r)19 (enal r)20 (eplacement therapy)135 (.)]TJ
0.20599 Tw 1.19354 -1.25951 Td
(Supplementation is inexpensive and easy to achieve, with)Tj
0.216 Tw -1.19354 -1.25953 Td
[(shor)10 (t periods of moderate doses quickly nor)-1 (malising plasma)]TJ
0.343 Tw 0 -1.25951 TD
[(selenium levels and plasma glutathione per)20 (oxidase activity)134 (.)]TJ
0.06799 Tw 0 -1.25952 TD
[(NICE r)17.3 (ecommends measuring selenium levels on admission to)]TJ
0.265 Tw T*
(the ICU;)Tj
ET
BT
/T1_3 1 Tf
0 Tw 5.415 0 0 5.415 78.0049 167.4581 Tm
(43)Tj
ET
BT
/T1_3 1 Tf
0.265 Tw 9.5 0 0 9.5 88.3843 163.7975 Tm
(this would allow meaningful supplementation to)Tj
0.127 Tw -4.82785 -1.25952 Td
[(take place and is potentially pr)4.1 (ognostic. Selenium is only one)]TJ
-0.0105 Tc T*
[(of)-271.8 (a)]TJ
-0.00999 Tc 0.02299 Tw 1.77109 0 Td
[(n)1 (u)1 (m)1 (b)1 (e)1 (r)1 ( )1 (o)1 (f)1 ( )1 (m)1 (i)1 (c)1 (r)21 (onutrients for which mechanisms to ensur)19 (e)]TJ
-0.011 Tc 0.209 Tw -1.77109 -1.25952 Td
[(adequate r)20 (eplacement ar)19 (e not in place, especially in patients)]TJ
0.061 Tw 0 -1.25951 TD
[(fed thr)20 (ough TPN. Pur)19 (ely achieving the UK RDA of selenium is)]TJ
0.022 Tw 0 -1.25953 TD
[(likely to be insuf)1.9 (\336)-1 (cient for ICU patients, in whom the literatur)20 (e)]TJ
0.103 Tw 0 -1.25951 TD
[(suggests it should be supplemented par)1.4 (enterally so absorption)]TJ
0.22701 Tw 0 -1.25953 TD
[(can be assur)20 (ed. A dose of 500)]TJ
ET
BT
/T1_4 1 Tf
0 Tc 0 Tw 9.5 0 0 9.5 171.1794 80.0393 Tm
(m)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 0.22701 Tw 9.5 0 0 9.5 176.5581 80.0393 Tm
(g/day seems to be safe and)Tj
-0.00999 Tc 0.021 Tw -14.10931 -1.25953 Td
[(e)1 (f)11 (f)1 (e)1 (c)1 (t)1 (i)1 (v)1 (e)1 ( )1 (a)1 (t)1 ( )1 (r)20 (estoring plasma enzyme activity)135 (.)]TJ
-0.011 Tc 0.049 Tw 1.19354 -1.23846 Td
(Original studies on selenium supplementation in the critical)Tj
0.216 Tw 26.63075 72.4397 Td
[(car)20 (e envir)19 (onment ar)20 (e fr)19 (om heter)20 (ogeneous gr)20 (oups of patients)]TJ
0.05099 Tw 0 -1.23257 TD
[(and include selenium supplemented in various dosing r)20 (egimes.)]TJ
0.839 Tw 0 -1.23258 TD
(On integrating the available data, the meta-analyses)Tj
0.14301 Tw 0 -1.23257 TD
[(demonstrate a potential mor)10 (tality bene\336t fr)19 (o)-1 (m)-1 ( )-1 (s)-1 (u)-1 (p)-1 (p)-1 (l)-1 (e)-1 (m)-1 (e)-1 (n)-1 (t)-1 (i)-1 (n)-1 (g)]TJ
0.302 Tw 0 -1.23258 TD
(selenium in general ICU patients.)Tj
ET
BT
/T1_3 1 Tf
-0.0106 Tc 0 Tw 5.415 0 0 5.415 447.1571 701.3085 Tm
(3)Tj
-0.011 Tc (5,36)Tj
ET
BT
/T1_3 1 Tf
0.302 Tw 9.5 0 0 9.5 464.7487 697.6478 Tm
[(However)70 (, in or)19 (der to)]TJ
0.151 Tw -16.62087 -1.23257 Td
(answer the question of whether selenium supplementation in)Tj
0.382 Tw T*
[(sepsis leads to an impr)20 (ovement in clinically r)19 (elevant end)]TJ
-0.0105 Tc 0 -1.23257 TD
(p)Tj
-0.011 Tc 0.03799 Tw [(oints, an adequately power)20 (ed, randomised, placebo-contr)19 (olled)]TJ
0.021 Tw T*
[(trial of high methodological value is r)20 (equir)19 (ed. )]TJ
ET
BT
/T1_2 1 Tf
-0.01401 Tc 0 Tw 10.5 0 0 10.5 309.2924 631.614 Tm
[(R)26 (e)5 (f)22 (er)15 (enc)12 (e)10 (s)]TJ
ET
BT
/T1_3 1 Tf
-0.011 Tc 0.021 Tw 7.8 0 0 7.8 306.8504 618.1698 Tm
[(1. )-283 (National Institute of Health: Of)10 (\336)-1 (ce of Dietar)-5 (y Supplements. Selenium.)]TJ
1.3083 -1.36018 Td
[(http://dietar)-5 (y-supplements.info.nih.gov/factsheets/selenium.asp Accessed)]TJ
0 -1.36018 TD
(December 2008.)Tj
-1.3083 -1.36019 Td
[(2.)-552 (Exper)10 (t gr)19 (oup on vitamins and minerals. Safe upper levels of vitamins and)]TJ
1.3083 -1.36018 Td
[(minerals. Food Standar)20 (ds Agency London 2003: 232.)]TJ
0 Tw T*
(http://cot.food.gov)Tj
0.021 Tw 7.36161 0.00001 Td
(.uk/pdfs/vitmin2003.pdf Accessed December 2008. )Tj
0 Tw -8.66991 -1.3602 Td
(3. )Tj
ET
BT
/T1_6 1 Tf
0.021 Tw 7.8 0 0 7.8 317.0551 554.5132 Tm
[(Bar)10 (clay MNI, MacPherson A, Dixon J)]TJ
ET
BT
/T1_3 1 Tf
-0.0105 Tc 0 Tw 7.8 0 0 7.8 438.3596 554.5132 Tm
(.)Tj
-0.011 Tc 0.021 Tw 0.51767 0 Td
(Selenium content of a range of UK)Tj
0 Tw -16.06952 -1.36018 Td
(foods. )Tj
ET
BT
/T1_5 1 Tf
-0.0101 Tc 7.8 0 0 7.8 338.3099 543.9038 Tm
(J)Tj
-0.00999 Tc 0.02 Tw 0.56485 0 Td
(Food Compos Anal)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 0 Tw 7.8 0 0 7.8 402.3632 543.9038 Tm
(1995;8:307-18.)Tj
-12.24523 -1.36019 Td
(4. )Tj
ET
BT
/T1_6 1 Tf
0.021 Tw 7.8 0 0 7.8 317.0551 533.2943 Tm
[(Shortt CT)109 (, Duthie GG, Robertson JD )]TJ
ET
BT
/T1_7 1 Tf
7.8 0 0 7.8 439.0256 533.2943 Tm
(et al)Tj
ET
BT
/T1_3 1 Tf
-0.0105 Tc 0 Tw 7.8 0 0 7.8 452.7869 533.2943 Tm
(.)Tj
-0.011 Tc 0.021 Tw 0.51767 0 Td
[(Selenium status of a gr)20 (oup of)]TJ
-17.91917 -1.36018 Td
(Scottish adults. )Tj
ET
BT
/T1_5 1 Tf
-0.00999 Tc 0.02 Tw 7.8 0 0 7.8 367.3866 522.6849 Tm
(Eur J Clin Nutr)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 0 Tw 7.8 0 0 7.8 416.5214 522.6849 Tm
(1997;51:400-04.)Tj
-14.06038 -1.36018 Td
(5. )Tj
ET
BT
/T1_6 1 Tf
0.021 Tw 7.8 0 0 7.8 317.0551 512.0755 Tm
[(Bates CJ, Thane CW)174 (, Pr)10 (entice A, Delves HT)]TJ
ET
BT
/T1_3 1 Tf
-0.0105 Tc 0 Tw 7.8 0 0 7.8 459.4622 512.0755 Tm
(.)Tj
-0.011 Tc 0.021 Tw 0.51768 0 Td
(Selenium status and its)Tj
-18.77499 -1.36019 Td
[(corr)19 (elates in a British National Diet and Nutrition Sur)-10 (vey: people aged 65)]TJ
T*
[(years and over)60 (. )]TJ
ET
BT
/T1_5 1 Tf
-0.0101 Tc 0 Tw 7.8 0 0 7.8 366.5789 490.8567 Tm
(J)Tj
-0.00999 Tc 0.02 Tw 0.56472 0 Td
[(T)139 (race Elem Med Biol)]TJ
ET
BT
/T1_3 1 Tf
-0.011 Tc 0 Tw 7.8 0 0 7.8 435.8929 490.8567 Tm
(2002;16:1-8. )Tj
-16.54391 -1.36018 Td
(6. )Tj
ET
BT
/T1_6 1 Tf
7.8 0 0 7.8 317.0551 480.2473 Tm
(Duf)Tj
0 Tc 1.56057 0 Td
(\336)Tj
-0.011 Tc 0.021 Tw 0.56324 0 Td
[(eld AJ, Thomson CD, Hill KE, W)30 (illiams S)]TJ
ET
BT
/T1_3 1 Tf
-0.0105 Tc 0 Tw 7.8 0 0 7.8 469.5486 480.2473 Tm
(.)Tj
-0.011 Tc 0.021 Tw 0.51767 0 Td
(An estimation of)Tj
-20.06811 -1.36019 Td
[(selenium r)20 (equir)19 (ements for New Zealanders. )]TJ
ET
BT
/T1_5 1 Tf
-0.00999 Tc 0.02 Tw 7.8 0 0 7.8 457.671 469.6378 Tm
(Am J Clin Nutr)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 0 Tw 7.8 0 0 7.8 506.0172 469.6378 Tm
(1999;70:896-)Tj
-24.22591 -1.36018 Td
(903.)Tj
-1.3083 -1.36018 Td
(7. )Tj
ET
BT
/T1_6 1 Tf
0.021 Tw 7.8 0 0 7.8 317.0551 448.4189 Tm
(Rayman MP)Tj
ET
BT
/T1_3 1 Tf
-0.0105 Tc 0 Tw 7.8 0 0 7.8 356.2649 448.4189 Tm
(.)Tj
-0.011 Tc 0.021 Tw 0.51761 0 Td
[(Dietar)-5 (y selenium: time to act. )]TJ
ET
BT
/T1_5 1 Tf
-0.00999 Tc 0 Tw 7.8 0 0 7.8 456.0901 448.4189 Tm
(BMJ)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 0.021 Tw 7.8 0 0 7.8 471.2455 448.4189 Tm
(1997; 314: 387-88.)Tj
0 Tw -21.0763 -1.36019 Td
(8. )Tj
ET
BT
/T1_6 1 Tf
0.021 Tw 7.8 0 0 7.8 317.0551 437.8094 Tm
(Rayman MP)Tj
ET
BT
/T1_3 1 Tf
-0.0105 Tc 0 Tw 7.8 0 0 7.8 356.2649 437.8094 Tm
(.)Tj
-0.011 Tc 0.021 Tw 0.51762 0 Td
[(The impor)10 (tance of selenium to human health. )]TJ
ET
BT
/T1_5 1 Tf
-0.00999 Tc 0 Tw 7.8 0 0 7.8 508.5546 437.8094 Tm
(Lancet)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 7.8 0 0 7.8 317.0551 427.2 Tm
(2000;356:233-41. )Tj
-1.3083 -1.36018 Td
(9. )Tj
ET
BT
/T1_6 1 Tf
0.021 Tw 7.8 0 0 7.8 317.0551 416.5906 Tm
(Hawker FH, Stewart PM, Snitch PJ)Tj
ET
BT
/T1_3 1 Tf
-0.0106 Tc 0 Tw 7.8 0 0 7.8 430.4944 416.5906 Tm
(.)Tj
-0.011 Tc 0.021 Tw 0.51747 0 Td
[(Ef)9 (fects o)1 (f)-1 ( )1 (acute illness on)-1 ( )1 (sel)-1 (enium)]TJ
0 Tw -15.06096 -1.36019 Td
(homeostasis. )Tj
ET
BT
/T1_5 1 Tf
-0.00999 Tc 0.02 Tw 7.8 0 0 7.8 359.6363 405.9811 Tm
[(Crit Car)50.3 (e)]TJ
0 Tw 3.92571 0 Td
(Med)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 7.8 0 0 7.8 405.4051 405.9811 Tm
(1990;18:442-46.)Tj
-12.63522 -1.36018 Td
(10.)Tj
ET
BT
/T1_6 1 Tf
0.021 Tw 7.8 0 0 7.8 317.0551 395.3717 Tm
[(For)10 (ceville X, V)43 (itoux D, Gauzit R )]TJ
ET
BT
/T1_7 1 Tf
7.8 0 0 7.8 424.8793 395.3717 Tm
(et al)Tj
ET
BT
/T1_3 1 Tf
-0.0105 Tc 0 Tw 7.8 0 0 7.8 438.6406 395.3717 Tm
(.)Tj
-0.011 Tc 0.021 Tw 0.51769 0 Td
(Selenium, systemic immune)Tj
-16.10557 -1.36019 Td
[(r)19 (esponse syndr)20 (ome, sepsis and outcome in critically ill patients. )]TJ
ET
BT
/T1_5 1 Tf
-0.00999 Tc 0.02 Tw 7.8 0 0 7.8 521.354 384.7622 Tm
[(Crit Car)50 (e)]TJ
0 Tw -26.19217 -1.36018 Td
(Med)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 7.8 0 0 7.8 332.2029 374.1528 Tm
(1998;26:1536-44. )Tj
-3.25032 -1.36018 Td
(11.)Tj
ET
BT
/T1_6 1 Tf
0.021 Tw 7.8 0 0 7.8 317.0551 363.5435 Tm
[(Sakr Y)119 (, Reinhart K, Bloos F )]TJ
ET
BT
/T1_7 1 Tf
7.8 0 0 7.8 407.9053 363.5435 Tm
(et al)Tj
ET
BT
/T1_3 1 Tf
-0.0107 Tc 0 Tw 7.8 0 0 7.8 421.6665 363.5435 Tm
(.)Tj
-0.011 Tc 0.021 Tw 0.51738 0 Td
[(T)49 (ime course and r)20 (elationship between)]TJ
-13.9291 -1.36019 Td
[(plasma selenium concentrations, systemic in\337ammator)-5 (y r)19 (esponse, sepsis,)]TJ
T*
[(and multi-or)24.1 (gan failur)20 (e. )]TJ
ET
BT
/T1_5 1 Tf
-0.00999 Tc 0.02 Tw 7.8 0 0 7.8 394.539 342.3246 Tm
(Br J Anaesth)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 0 Tw 7.8 0 0 7.8 434.5653 342.3246 Tm
(2007;98:775-84.)Tj
-16.3737 -1.36019 Td
(12.)Tj
ET
BT
/T1_6 1 Tf
0.021 Tw 7.8 0 0 7.8 317.0551 331.7151 Tm
[(Angstwur)-20 (m MW)95 (A, Schottdor)-10 (f J, Schopohl J, G\212rtner R)]TJ
ET
BT
/T1_3 1 Tf
-0.0105 Tc 0 Tw 7.8 0 0 7.8 495.1871 331.7151 Tm
(.)Tj
-0.011 Tc 0.51763 0 Td
(Selenium)Tj
0.021 Tw -23.35506 -1.36019 Td
[(r)19 (eplacement in patients with sever)20 (e systemic in\337ammator)-5 (y r)19 (esponse)]TJ
0 -1.36017 TD
[(s)-1 (y)-1 (n)-1 (d)-1 (r)19 (ome impr)19 (oves clinical outcome. )]TJ
ET
BT
/T1_5 1 Tf
-0.00999 Tc 0.02 Tw 7.8 0 0 7.8 438.0797 310.4963 Tm
[(Crit Car)50 (e Med)]TJ
ET
BT
/T1_3 1 Tf
-0.011 Tc 0 Tw 7.8 0 0 7.8 483.8485 310.4963 Tm
(l999;27:1807-13. )Tj
-22.69206 -1.36018 Td
(13.)Tj
ET
BT
/T1_6 1 Tf
0.021 Tw 7.8 0 0 7.8 317.0551 299.8869 Tm
[(Mishra V)189 (, Baines M, Perr)-20 (y SE )]TJ
ET
BT
/T1_7 1 Tf
7.8 0 0 7.8 414.6532 299.8869 Tm
(et al)Tj
ET
BT
/T1_3 1 Tf
-0.0106 Tc 0 Tw 7.8 0 0 7.8 428.4145 299.8869 Tm
(.)Tj
-0.011 Tc 0.021 Tw 0.51747 0 Td
[(Ef)9 (fect of selenium su)1 (pp)-1 (lementation)]TJ
-14.79431 -1.36019 Td
(on biochemical markers and outcome in critically ill patients. )Tj
ET
BT
/T1_5 1 Tf
-0.00999 Tc 0.02 Tw 7.8 0 0 7.8 514.253 289.2773 Tm
(Clin Nutr)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 0 Tw 7.8 0 0 7.8 317.0551 278.6679 Tm
(2007;26:41-50.)Tj
-1.3083 -1.36019 Td
(14.)Tj
ET
BT
/T1_6 1 Tf
0.021 Tw 7.8 0 0 7.8 317.0551 268.0584 Tm
[(Angstwur)-20 (m MW)95 (A, Engelmann L, Zimmer)-20 (mann T )]TJ
ET
BT
/T1_7 1 Tf
7.8 0 0 7.8 480.7045 268.0584 Tm
(et al)Tj
ET
BT
/T1_3 1 Tf
-0.0105 Tc 0 Tw 7.8 0 0 7.8 494.4658 268.0584 Tm
(.)Tj
-0.011 Tc 0.021 Tw 0.51763 0 Td
(Selenium in)Tj
-23.26258 -1.36018 Td
[(Intensive Car)20 (e \(SIC\) Study: Results of a pr)19 (ospective randomised, placebo-)]TJ
0 -1.36019 TD
[(contr)20 (olled, multiple-centr)19 (e study in patients with sever)20 (e systemic)]TJ
0 Tw T*
[(in\337)-1.5 (ammator)]TJ
-0.0106 Tc 5.012 0.00002 Td
[(y)-269.2 (r)]TJ
-0.011 Tc 0.021 Tw 1.07949 0.00001 Td
[(esponse syndr)13.4 (ome, sepsis and septic shock. )]TJ
ET
BT
/T1_5 1 Tf
-0.00999 Tc 0.02 Tw 7.8 0 0 7.8 504.4117 236.2301 Tm
[(Crit Car)50.3 (e)]TJ
0 Tw 3.92572 0.00001 Td
(Med)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 7.8 0 0 7.8 317.0551 225.6208 Tm
(2007;35:118-26.)Tj
-1.3083 -1.36019 Td
(15.)Tj
ET
BT
/T1_6 1 Tf
0.021 Tw 7.8 0 0 7.8 317.0551 215.0113 Tm
[(Stor)-20 (y DA, Ronco C, Bellomo R)]TJ
ET
BT
/T1_3 1 Tf
-0.0107 Tc 0 Tw 7.8 0 0 7.8 417.4284 215.0113 Tm
(.)Tj
-0.011 Tc 0.021 Tw 0.51738 0 Td
[(T)99 (race element and vitamin)]TJ
-13.38575 -1.36019 Td
[(concentrations and losses in critically ill patients tr)-5.3 (eated with continuous)]TJ
0 -1.36017 TD
(veno-venous haemo\336ltration. )Tj
ET
BT
/T1_5 1 Tf
-0.00999 Tc 0.02 Tw 7.8 0 0 7.8 412.3028 193.7924 Tm
[(Crit Car)50 (e Med)]TJ
ET
BT
/T1_3 1 Tf
-0.011 Tc 0 Tw 7.8 0 0 7.8 458.0716 193.7924 Tm
(1999;27:220-23.)Tj
-19.38733 -1.36018 Td
(16.)Tj
ET
BT
/T1_6 1 Tf
0.021 Tw 7.8 0 0 7.8 317.0551 183.1831 Tm
[(Nakamura A)57.5 (T)109 (, Btaiche IF)200 (, Pasko DA )]TJ
ET
BT
/T1_7 1 Tf
7.8 0 0 7.8 435.7912 183.1831 Tm
(et al)Tj
ET
BT
/T1_3 1 Tf
-0.0108 Tc 0 Tw 7.8 0 0 7.8 449.5525 183.1831 Tm
(.)Tj
ET
BT
/T1_5 1 Tf
-0.00999 Tc 0.02 Tw 7.8 0 0 7.8 453.5893 183.1831 Tm
(In vitr)Tj
0 Tc 2.3718 0.00001 Td
(o)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 0.021 Tw 7.8 0 0 7.8 477.721 183.1831 Tm
(clearance of trace)Tj
-20.59819 -1.3602 Td
[(elements via continuous r)20 (enal r)19 (eplacement therapy)134 (. )]TJ
ET
BT
/T1_5 1 Tf
-0.0101 Tc 0 Tw 7.8 0 0 7.8 481.8971 172.5735 Tm
(J)Tj
-0.00999 Tc 0.02 Tw 0.56488 0 Td
(Renal Nutr)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 0 Tw 7.8 0 0 7.8 317.0551 161.9641 Tm
(2004;14:214-19.)Tj
-1.3083 -1.36019 Td
(17.)Tj
ET
BT
/T1_6 1 Tf
0.021 Tw 7.8 0 0 7.8 317.0551 151.3546 Tm
(Berger MM, Shenkin A, Revelly J-P )Tj
ET
BT
/T1_7 1 Tf
7.8 0 0 7.8 433.0136 151.3546 Tm
(et al)Tj
ET
BT
/T1_3 1 Tf
-0.0106 Tc 0 Tw 7.8 0 0 7.8 446.7748 151.3546 Tm
(.)Tj
-0.011 Tc 0.021 Tw 0.51757 0 Td
[(Copper)69 (, selenium, zinc and)]TJ
-17.1483 -1.36018 Td
(thiamine balances during continuous venovenous haemodia\336ltration in)Tj
0 -1.36018 TD
(critically ill patients. )Tj
ET
BT
/T1_5 1 Tf
-0.00999 Tc 0.02 Tw 7.8 0 0 7.8 383.8016 130.1358 Tm
(Am J Clin Nutr)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 0 Tw 7.8 0 0 7.8 432.1478 130.1358 Tm
(2004;80:410-16.)Tj
-16.06377 -1.36019 Td
(18.)Tj
ET
BT
/T1_6 1 Tf
0.021 Tw 7.8 0 0 7.8 317.0551 119.5263 Tm
[(Metnitz PGH, Bar)-2.9 (tens C, Fischer M )]TJ
ET
BT
/T1_7 1 Tf
7.8 0 0 7.8 435.1844 119.5263 Tm
(et al)Tj
ET
BT
/T1_3 1 Tf
-0.0105 Tc 0 Tw 7.8 0 0 7.8 448.9457 119.5263 Tm
(.)Tj
-0.011 Tc 0.021 Tw 0.51769 0 Td
(Antioxidant status in patients)Tj
-17.42674 -1.36018 Td
[(with acute r)20 (espirator)-5 (y distr)19 (e)-1 (s)-1 (s)-1 ( )-1 (s)-1 (y)-1 (n)-1 (d)-1 (r)19 (ome. )]TJ
ET
BT
/T1_5 1 Tf
-0.00999 Tc 0.02 Tw 7.8 0 0 7.8 449.4618 108.9169 Tm
[(Intensive Car)50 (e Med)]TJ
ET
BT
/T1_3 1 Tf
-0.011 Tc 0 Tw 7.8 0 0 7.8 509.7058 108.9169 Tm
(1999;25:)Tj
-24.6988 -1.36019 Td
(l80-85.)Tj
-1.3083 -1.36019 Td
(19.)Tj
ET
BT
/T1_6 1 Tf
0.021 Tw 7.8 0 0 7.8 317.0551 87.698 Tm
[(V)91 (alencia E, Hardy G)]TJ
ET
BT
/T1_3 1 Tf
-0.0105 Tc 0 Tw 7.8 0 0 7.8 382.9705 87.698 Tm
(.)Tj
-0.011 Tc 0.021 Tw 0.51766 0 Td
(Glutathione, nitric oxide and sepsis. )Tj
ET
BT
/T1_5 1 Tf
-0.00999 Tc 0.02 Tw 7.8 0 0 7.8 504.0147 87.698 Tm
[(Br J Intens Car)50 (e)]TJ
ET
BT
/T1_3 1 Tf
-0.011 Tc 0 Tw 7.8 0 0 7.8 317.0551 77.0886 Tm
(2000;10:167-75.)Tj
-1.3083 -1.36019 Td
[(20.)-43 (Selenase)]TJ
ET
BT
/T1_3 1 Tf
0 Tc 4.446 0 0 4.446 343.5195 69.6829 Tm
(\250)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 0.021 Tw 7.8 0 0 7.8 349.1285 66.4792 Tm
[(biosyn pr)20 (oduct literatur)19 (e http://www)125 (.phar)-1 (mapal.com/)]TJ
0 Tw -4.11197 -1.36019 Td
(phar)Tj
0.021 Tw 1.86501 0.00001 Td
(mapal/pdf/selenase.pdf Accessed December 2008.)Tj
ET
1 w
/GS1 gs
42.52 39.685 m
552.756 39.685 l
S
BT
/GS3 gs
/T1_2 1 Tf
-0.021 Tc 0.02901 Tw 12.5 0 0 12.5 42.5197 793.7901 Tm
[(R)26 (e)24 (vie)21 (w ar)-18 (ticle)10 (s)]TJ
ET
BT
0 g
/GS4 gs
/T1_8 1 Tf
0 Tc 0 Tw 5 0 0 5 301.10497 11 Tm
( by guest on September 2, 2015)Tj
0 0 1 rg
/GS4 gs
-7.55899 0 Td
(inc.sagepub.com)Tj
0 g
/GS4 gs
-8.11399 0 Td
(Downloaded from )Tj
ET
endstream
endobj
87 0 obj
<<
/Length 224
>>
stream
Q
0.33333 0.69412 0.96078 RG
0.8 w
317.06 478.32999 m
526.37 478.32999 l
S
0.33333 0.69412 0.96078 RG
0.8 w
317.06 467.71002 m
548.15002 467.71002 l
S
0.33333 0.69412 0.96078 RG
0.8 w
317.06 457.11002 m
330.97 457.11002 l
S
endstream
endobj
88 0 obj
<<
/Length 154
>>
stream
Q
0.33333 0.69412 0.96078 RG
0.8 w
317.06 414.67001 m
545.66998 414.67001 l
S
0.33333 0.69412 0.96078 RG
0.8 w
317.06 404.05002 m
457.39999 404.05002 l
S
endstream
endobj
89 0 obj
<<
/Length 233
>>
stream
Q
0.33333 0.69412 0.96078 RG
0.8 w
318.89001 181.23999 m
532.89001 181.23999 l
S
0.33333 0.69412 0.96078 RG
0.8 w
317.06 170.64001 m
519.91998 170.64001 l
S
0.33333 0.69412 0.96078 RG
0.8 w
317.06 160.04004 m
369.04999 160.04004 l
S
endstream
endobj
90 0 obj
<<
/Length 222
>>
stream
Q
0.33333 0.69412 0.96078 RG
0.8 w
317.47 117.58002 m
546.63 117.58002 l
S
0.33333 0.69412 0.96078 RG
0.8 w
317.06 106.99005 m
537.44 106.99005 l
S
0.33333 0.69412 0.96078 RG
0.8 w
317.06 96.39001 m
339.51999 96.39001 l
S
endstream
endobj
91 0 obj
<<
/Length 221
>>
stream
Q
0.33333 0.69412 0.96078 RG
0.8 w
317.06 510.14999 m
536.62 510.14999 l
S
0.33333 0.69412 0.96078 RG
0.8 w
317.06 499.54001 m
549.90002 499.54001 l
S
0.33333 0.69412 0.96078 RG
0.8 w
317.06 488.93002 m
476 488.93002 l
S
endstream
endobj
92 0 obj
<<
/Length 224
>>
stream
Q
0.33333 0.69412 0.96078 RG
0.8 w
318.95001 329.79004 m
528.65002 329.79004 l
S
0.33333 0.69412 0.96078 RG
0.8 w
317.06 319.18005 m
532.69 319.18005 l
S
0.33333 0.69412 0.96078 RG
0.8 w
317.06 308.56 m
537.91998 308.56 l
S
endstream
endobj
93 0 obj
<<
/Length 78
>>
stream
Q
0.33333 0.69412 0.96078 RG
0.8 w
317.06 446.49002 m
531.40002 446.49002 l
S
endstream
endobj
94 0 obj
<<
/Length 230
>>
stream
Q
0.33333 0.69412 0.96078 RG
0.8 w
316.60999 393.43002 m
531.77997 393.43002 l
S
0.33333 0.69412 0.96078 RG
0.8 w
317.06 382.83002 m
550.03003 382.83002 l
S
0.33333 0.69412 0.96078 RG
0.8 w
317.06 372.22003 m
388.16 372.22003 l
S
endstream
endobj
95 0 obj
<<
/Length 151
>>
stream
Q
0.33333 0.69412 0.96078 RG
0.8 w
317.06 552.58997 m
552.12 552.58997 l
S
0.33333 0.69412 0.96078 RG
0.8 w
317.06 541.97003 m
450.39001 541.97003 l
S
endstream
endobj
96 0 obj
<<
/Length 227
>>
stream
Q
0.33333 0.69412 0.96078 RG
0.8 w
317.26999 213.09003 m
505.63 213.09003 l
S
0.33333 0.69412 0.96078 RG
0.8 w
317.06 202.48004 m
549.33002 202.48004 l
S
0.33333 0.69412 0.96078 RG
0.8 w
317.06 191.86005 m
510.06 191.86005 l
S
endstream
endobj
97 0 obj
<<
/OP true
/OPM 1
/SM 0.00999451
/Type /ExtGState
/op true
>>
endobj
98 0 obj
<<
/OP false
/OPM 1
/SM 0.00999451
/Type /ExtGState
/op false
>>
endobj
99 0 obj
<<
/FL 1
/OP true
/OPM 1
/SM 0.00999451
/Type /ExtGState
/op true
>>
endobj
100 0 obj
<<
/OP false
/OPM 0
/SM 1.0
/op false
>>
endobj
101 0 obj
<<
/BaseFont /PDSBPJ+Berkeley-BoldItalic
/Encoding 238 0 R
/FirstChar 32
/FontDescriptor 239 0 R
/LastChar 116
/Subtype /Type1
/Type /Font
/Widths [259 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 500 0 0 0 444
0 0 0 0 0 0 278 0 0 0
0 0 0 0 315]
>>
endobj
102 0 obj
<<
/A 240 0 R
/Border [0 0 0]
/Rect [262.31 9.0 302.105 16.0]
/Subtype /Link
/Type /Annot
>>
endobj
103 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 241 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 242 0 R
/Rect [53.91 460.26 284.82 467.68002]
>>
endobj
104 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 243 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 244 0 R
/Rect [52.72 449.75003 159.70001 457.18002]
>>
endobj
105 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 245 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 246 0 R
/Rect [53.0 659.74 281.97998 667.18]
>>
endobj
106 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 247 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 248 0 R
/Rect [52.72 649.26 278.83002 656.68]
>>
endobj
107 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 249 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 250 0 R
/Rect [52.72 638.75 229.08 646.18]
>>
endobj
108 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 251 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 252 0 R
/Rect [53.36 386.74002 274.33002 394.18002]
>>
endobj
109 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 253 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 254 0 R
/Rect [52.72 376.25003 245.75 383.68002]
>>
endobj
110 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 255 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 256 0 R
/Rect [52.72 365.76 104.71001 373.18002]
>>
endobj
111 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 257 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 258 0 R
/Rect [318.95 596.76 550.83 604.18]
>>
endobj
112 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 259 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 260 0 R
/Rect [317.06 586.25 505.25 593.68]
>>
endobj
113 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 261 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 262 0 R
/Rect [52.67 565.26 281.06 572.68005]
>>
endobj
114 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 263 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 264 0 R
/Rect [52.72 554.76 247.13 562.18005]
>>
endobj
115 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 265 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 266 0 R
/Rect [52.72 544.26 271.16 551.68005]
>>
endobj
116 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 267 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 268 0 R
/Rect [52.72 533.75 163.69 541.18005]
>>
endobj
117 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 269 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 270 0 R
/Rect [55.1 743.74 284.06 751.18]
>>
endobj
118 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 271 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 272 0 R
/Rect [52.72 733.25 274.05 740.68]
>>
endobj
119 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 273 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 274 0 R
/Rect [52.72 722.75 135.26001 730.18]
>>
endobj
120 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 275 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 276 0 R
/Rect [317.38 575.76 550.03 583.18005]
>>
endobj
121 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 277 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 278 0 R
/Rect [317.06 565.26 543.88 572.68005]
>>
endobj
122 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 279 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 280 0 R
/Rect [317.06 554.75 432.05 562.18005]
>>
endobj
123 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 281 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 282 0 R
/Rect [318.08 544.26 546.37 551.68005]
>>
endobj
124 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 283 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 284 0 R
/Rect [317.06 533.75 520.93 541.18005]
>>
endobj
125 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 285 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 286 0 R
/Rect [53.02 439.26 275.79 446.68002]
>>
endobj
126 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 287 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 288 0 R
/Rect [52.72 428.76 275.09 436.18002]
>>
endobj
127 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 289 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 290 0 R
/Rect [54.4 407.76 283.54 415.18002]
>>
endobj
128 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 291 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 292 0 R
/Rect [52.72 397.25003 185.63 404.68002]
>>
endobj
129 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 293 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 294 0 R
/Rect [52.28 712.24 258.74 719.68]
>>
endobj
130 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 295 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 296 0 R
/Rect [52.72 701.76 265.37 709.18]
>>
endobj
131 0 obj
<<
/Type /Annot
/Subtype /Link
/BS 297 0 R
/C [1.0 1.0 1.0]
/F 64
/H /P
/A 298 0 R
/Rect [52.72 691.25 259.5 698.68]
>>
endobj
132 0 obj
<<
/Length 2
>>
stream
q
endstream
endobj
133 0 obj
<<
/Length 2
>>
stream
q
endstream
endobj
134 0 obj
<<
/Length 2
>>
stream
q
endstream
endobj
135 0 obj
<<
/Length 2
>>
stream
q
endstream
endobj
136 0 obj
<<
/Length 2
>>
stream
q
endstream
endobj
137 0 obj
<<
/Length 2
>>
stream
q
endstream
endobj
138 0 obj
<<
/Length 2
>>
stream
q
endstream
endobj
139 0 obj
<<
/Length 2
>>
stream
q
endstream
endobj
140 0 obj
<<
/Length 2
>>
stream
q
endstream
endobj
141 0 obj
<<
/Length 2
>>
stream
q
endstream
endobj
142 0 obj
<<
/Length 2
>>
stream
q
endstream
endobj
143 0 obj
<<
/Length 15635
>>
stream
q
0 0.89 595 841 re
W n
1 g
/GS0 gs
0 841.89 0 0 re
f
Q
0 1 0.60001 0.27 k
/GS1 gs
575.433 785.718 28.346 64.676 re
f
0.27 0.06 0 0 k
0 785.1971 573.449 65.197 re
f
0.95 0.7 0.06 0 K
2 w
/GS2 gs
0 785.889 m
603.78 785.889 l
S
BT
0 0 0 1 k
/GS3 gs
/T1_0 1 Tf
9.3 0 0 9.3 42.5509 28.8783 Tm
(JICS)Tj
ET
BT
/T1_1 1 Tf
8.5 0 0 8.5 65.941 29.4783 Tm
(V)Tj
0.026 Tw 0.51587 0.00001 Td
(olume 10, Number 1)Tj
8.5376 -0.0706 Td
(,)Tj
0 Tw 0.52672 0.07059 Td
(Januar)Tj
-0.0002 Tc 2.60181 0.00001 Td
(y)Tj
0 Tc 0.74743 0 Td
(2009)Tj
ET
BT
/T1_2 1 Tf
9 0 0 9 540.6995 29.0855 Tm
(43)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 7.8 0 0 7.8 42.5197 745.6837 Tm
(21.)Tj
ET
BT
/T1_4 1 Tf
0.021 Tw 7.8 0 0 7.8 52.7244 745.6837 Tm
[(Zimmer)-20 (mann T)110 (, Albr)9 (echt S, K\237hne H )]TJ
ET
BT
/T1_5 1 Tf
7.8 0 0 7.8 177.0332 745.6837 Tm
(et al)Tj
ET
BT
/T1_3 1 Tf
-0.0105 Tc 0 Tw 7.8 0 0 7.8 190.7944 745.6837 Tm
(.)Tj
-0.011 Tc 0.021 Tw 0.51768 0 Td
(\(Selenium administration in)Tj
-18.21896 -1.34615 Td
[(p)-1 (a)-1 (t)-1 (i)-1 (e)-1 (n)-1 (t)-1 (s)-1 ( )-1 (w)-1 (i)-1 (t)-1 (h)-1 ( )-1 (s)-1 (e)-1 (p)-1 (s)-1 (i)-1 (s)-1 ( )-1 (s)-1 (y)-1 (n)-1 (d)-1 (r)19 (ome. A pr)19 (ospective randomised study\). )]TJ
ET
BT
/T1_6 1 Tf
-0.00999 Tc 0 Tw 7.8 0 0 7.8 260.9236 735.1837 Tm
(Med)Tj
-26.6922 -1.34615 Td
(Klin)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 0.021 Tw 7.8 0 0 7.8 67.7999 724.6837 Tm
(1997;92\(supp 3\):3-4.)Tj
0 Tw -3.24105 -1.34615 Td
(22.)Tj
ET
BT
/T1_4 1 Tf
0.021 Tw 7.8 0 0 7.8 52.7244 714.1837 Tm
[(For)10 (ceville X, Laviolle B, Annane D )]TJ
ET
BT
/T1_5 1 Tf
7.8 0 0 7.8 167.5101 714.1837 Tm
(et al)Tj
ET
BT
/T1_3 1 Tf
-0.0106 Tc 0 Tw 7.8 0 0 7.8 181.2714 714.1837 Tm
(.)Tj
-0.011 Tc 0.021 Tw 0.51747 0 Td
[(Ef)9 (fects of high doses of)]TJ
-16.99785 -1.34615 Td
[(selenium, as sodium selenite, in septic shock: a placebo-contr)19 (olled,)]TJ
0 -1.34615 TD
[(randomised, double-blind, phase II study)134 (. )]TJ
ET
BT
/T1_6 1 Tf
-0.00999 Tc 0.02 Tw 7.8 0 0 7.8 186.5418 693.1837 Tm
[(Crit Car)50 (e)]TJ
ET
BT
/T1_3 1 Tf
-0.011 Tc 0 Tw 7.8 0 0 7.8 217.2339 693.1837 Tm
(2007;11:R73.)Tj
-22.39926 -1.34615 Td
(23.)Tj
ET
BT
/T1_4 1 Tf
0.021 Tw 7.8 0 0 7.8 52.7244 682.6837 Tm
(Berger MM, Cavadini C, Bart A )Tj
ET
BT
/T1_5 1 Tf
7.8 0 0 7.8 157.1863 682.6837 Tm
(et al)Tj
ET
BT
/T1_3 1 Tf
-0.0105 Tc 0 Tw 7.8 0 0 7.8 170.9476 682.6837 Tm
(.)Tj
-0.011 Tc 0.021 Tw 0.51764 0 Td
(Selenium losses in 10 burned)Tj
0 Tw -15.67446 -1.34615 Td
(patients. )Tj
ET
BT
/T1_6 1 Tf
-0.00999 Tc 0.02 Tw 7.8 0 0 7.8 81.6755 672.1837 Tm
(Clin Nutr)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 0 Tw 7.8 0 0 7.8 113.1989 672.1837 Tm
(1992;11:75-82.)Tj
-9.06143 -1.34615 Td
(24.)Tj
ET
BT
/T1_4 1 Tf
0.021 Tw 7.8 0 0 7.8 52.7244 661.6837 Tm
[(Berger MM, Spertini F)199 (, Shenkin A )]TJ
ET
BT
/T1_5 1 Tf
7.8 0 0 7.8 164.7694 661.6837 Tm
(et al)Tj
ET
BT
/T1_3 1 Tf
-0.0107 Tc 0 Tw 7.8 0 0 7.8 178.5306 661.6837 Tm
(.)Tj
-0.011 Tc 0.021 Tw 0.51739 0 Td
[(T)99 (race element supplementation)]TJ
-16.64638 -1.34615 Td
[(modulates pulmonar)-5 (y infection rates after major burns: a double-blind,)]TJ
T*
[(placebo-contr)20 (olled trial. )]TJ
ET
BT
/T1_6 1 Tf
-0.00999 Tc 0.02 Tw 7.8 0 0 7.8 130.6299 640.6837 Tm
(Am J Clin Nutr)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 0 Tw 7.8 0 0 7.8 178.9761 640.6837 Tm
(l998;68:365-71.)Tj
-17.49441 -1.34615 Td
(25.)Tj
ET
BT
/T1_4 1 Tf
0.021 Tw 7.8 0 0 7.8 52.7244 630.1837 Tm
[(Berger MM, Eggimann P)189 (, Heyland DK )]TJ
ET
BT
/T1_5 1 Tf
7.8 0 0 7.8 177.0425 630.1837 Tm
(et al)Tj
ET
BT
/T1_3 1 Tf
-0.0105 Tc 0 Tw 7.8 0 0 7.8 190.8038 630.1837 Tm
(.)Tj
-0.011 Tc 0.021 Tw 0.51764 0 Td
(Reduction of nosocomial)Tj
-18.22013 -1.34615 Td
(pneumonia after major burns by trace element supplementation:)Tj
T*
[(a)-1 (g)-1 (g)-1 (r)19 (egation of two randomised trials. )]TJ
ET
BT
/T1_6 1 Tf
-0.00999 Tc 0.02 Tw 7.8 0 0 7.8 172.7314 609.1837 Tm
[(Crit Car)50 (e)]TJ
ET
BT
/T1_3 1 Tf
-0.011 Tc 0 Tw 7.8 0 0 7.8 203.4235 609.1837 Tm
(2006;10:R153.)Tj
-20.62869 -1.34615 Td
(26.)Tj
ET
BT
/T1_4 1 Tf
0.021 Tw 7.8 0 0 7.8 52.7244 598.6837 Tm
(Berger MM, Binnert C, Baines M )Tj
ET
BT
/T1_5 1 Tf
7.8 0 0 7.8 161.5834 598.6837 Tm
(et al)Tj
ET
BT
/T1_3 1 Tf
-0.0107 Tc 0 Tw 7.8 0 0 7.8 175.3446 598.6837 Tm
(.)Tj
-0.011 Tc 0.021 Tw 0.51739 0 Td
[(T)99 (race element supplements)]TJ
-16.23792 -1.34615 Td
[(in\337uence pr)19 (otein metabolism and tissue levels after major burns. )]TJ
ET
BT
/T1_6 1 Tf
-0.00999 Tc 0 Tw 7.8 0 0 7.8 260.5906 588.1838 Tm
(Intensive)Tj
0.02 Tw -26.64951 -1.34615 Td
[(Car)50 (e Med)]TJ
ET
BT
/T1_3 1 Tf
-0.011 Tc 0 Tw 7.8 0 0 7.8 84.2143 577.6838 Tm
(2004;30\(supp\):S61.)Tj
-5.34546 -1.34615 Td
(27.)Tj
ET
BT
/T1_4 1 Tf
0.021 Tw 7.8 0 0 7.8 52.7244 567.1838 Tm
[(Porter JM, Ivatur)-20 (y RR, Azimuddin K, Swami R)]TJ
ET
BT
/T1_3 1 Tf
-0.0105 Tc 0 Tw 7.8 0 0 7.8 204.6683 567.1838 Tm
(.)Tj
-0.011 Tc 0.021 Tw 0.51768 0 Td
(Antioxidant therapy in)Tj
-19.99766 -1.34615 Td
[(the pr)20 (evention of or)29 (g)-1 (a)-1 (n)-1 ( )-1 (d)-1 (y)-1 (s)-1 (f)-1 (u)-1 (n)-1 (c)-1 (t)-1 (i)-1 (o)-1 (n)-1 ( )-1 (s)-1 (y)-1 (n)-1 (d)-1 (r)19 (ome and infectious)]TJ
T*
[(complications after trauma: early r)20 (esults of a pr)19 (ospective randomised)]TJ
-0.00999 Tc 0 Tw T*
[(study)134 (.)1 ( )]TJ
ET
BT
/T1_6 1 Tf
-0.0101 Tc 7.8 0 0 7.8 73.0733 535.6838 Tm
(Am)Tj
-0.00999 Tc 1.59183 0 Td
[(Sur)60 (geon)]TJ
ET
BT
/T1_3 1 Tf
-0.011 Tc 7.8 0 0 7.8 111.7067 535.6838 Tm
(1999;65:478-83.)Tj
-8.87013 -1.34615 Td
(28.)Tj
ET
BT
/T1_4 1 Tf
0.021 Tw 7.8 0 0 7.8 52.7244 525.1838 Tm
[(Berger MM, Baines M, Chiol\216r)19 (o RL )]TJ
ET
BT
/T1_5 1 Tf
7.8 0 0 7.8 169.4982 525.1838 Tm
(et al)Tj
ET
BT
/T1_3 1 Tf
-0.0106 Tc 0 Tw 7.8 0 0 7.8 183.2594 525.1838 Tm
(.)Tj
-0.011 Tc 0.021 Tw 0.51754 0 Td
(In\337uence of early trace element)Tj
-17.25279 -1.34615 Td
(and vitamin E supplements on antioxidant status after major trauma: a)Tj
T*
[(contr)20 (olled trial. )]TJ
ET
BT
/T1_6 1 Tf
-0.00999 Tc 0.02 Tw 7.8 0 0 7.8 103.8475 504.1838 Tm
(Nutr Res)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 0 Tw 7.8 0 0 7.8 132.6972 504.1838 Tm
(2001;21:41-54.)Tj
-11.56122 -1.34615 Td
(29.)Tj
ET
BT
/T1_4 1 Tf
0.021 Tw 7.8 0 0 7.8 52.7244 493.6838 Tm
(Berger MM, Reymond MJ, Shenkin A )Tj
ET
BT
/T1_5 1 Tf
7.8 0 0 7.8 176.02 493.6838 Tm
(et al)Tj
ET
BT
/T1_3 1 Tf
-0.0106 Tc 0 Tw 7.8 0 0 7.8 189.7813 493.6838 Tm
(.)Tj
-0.011 Tc 0.021 Tw 0.51754 0 Td
(In\337uence of selenium)Tj
-18.08893 -1.34616 Td
[(supplements on the post-traumatic alterations of the thyr)20 (oid axis: a)]TJ
T*
[(placebo-contr)20 (olled trial. )]TJ
ET
BT
/T1_6 1 Tf
-0.00999 Tc 0.02 Tw 7.8 0 0 7.8 130.6299 472.6837 Tm
[(Intensive Car)50 (e Med)]TJ
ET
BT
/T1_3 1 Tf
-0.011 Tc 0 Tw 7.8 0 0 7.8 190.8739 472.6837 Tm
(2001;27:91-100.)Tj
-19.01977 -1.34615 Td
(30.)Tj
ET
BT
/T1_4 1 Tf
7.8 0 0 7.8 52.7244 462.1837 Tm
(Har)Tj
0.021 Tw [-0.5 (dy G, Har)-2.4 (dy I)]TJ
ET
BT
/T1_3 1 Tf
-0.0105 Tc 0 Tw 7.8 0 0 7.8 109.7886 462.1837 Tm
(.)Tj
-0.011 Tc 0.021 Tw 0.51764 0 Td
[(Selenium: an impor)1.7 (tant component of sepsis therapy?)]TJ
ET
BT
/T1_6 1 Tf
-0.00999 Tc 0.02 Tw 7.8 0 0 7.8 52.7244 451.6837 Tm
[(Br J Intensive Car)50 (e)]TJ
ET
BT
/T1_3 1 Tf
-0.011 Tc 0 Tw 7.8 0 0 7.8 111.681 451.6837 Tm
(2005;15:28-36.)Tj
-8.86683 -1.34615 Td
(31.)Tj
ET
BT
/T1_4 1 Tf
0.021 Tw 7.8 0 0 7.8 52.7244 441.1837 Tm
(Kuklinski B, Buchner M, Schweder R, Nagel R)Tj
ET
BT
/T1_3 1 Tf
-0.0105 Tc 0 Tw 7.8 0 0 7.8 203.9279 441.1837 Tm
(.)Tj
-0.011 Tc 0.021 Tw 0.51767 0 Td
[(\(Acute pancr)20 (eatitis- a)]TJ
0 Tw -19.90274 -1.34615 Td
(fr)Tj
0.021 Tw 0.62531 0 Td
[(ee radical disease. Decr)9.2 (ease in fatality with sodium selenite therapy\). )]TJ
ET
BT
/T1_6 1 Tf
-0.00999 Tc 0 Tw 7.8 0 0 7.8 52.7244 420.1837 Tm
(Z)Tj
0.02 Tw 0.82392 0 Td
(Gesamte Inn Med)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 0 Tw 7.8 0 0 7.8 114.3954 420.1837 Tm
(1991;46:145-49.)Tj
-9.21483 -1.34615 Td
(32.)Tj
ET
BT
/T1_4 1 Tf
0.021 Tw 7.8 0 0 7.8 52.7244 409.6837 Tm
(McCloy R)Tj
ET
BT
/T1_3 1 Tf
-0.0106 Tc 0 Tw 7.8 0 0 7.8 85.0748 409.6837 Tm
(.)Tj
-0.011 Tc 0.021 Tw 0.51755 0 Td
[(Chr)20 (onic pancr)19 (eatitis at Manchester)70 (, UK: focus on antioxidant)]TJ
-0.00999 Tc 0 Tw -4.66504 -1.34615 Td
(therapy)Tj
-0.0108 Tc 2.93921 0 Td
(.)Tj
ET
BT
/T1_6 1 Tf
-0.00999 Tc 7.8 0 0 7.8 79.687 399.1837 Tm
(Digestion)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 0.021 Tw 7.8 0 0 7.8 110.2489 399.1837 Tm
(1998;59\(supp 4\):36-48.)Tj
0 Tw -8.68323 -1.34615 Td
(33.)Tj
ET
BT
/T1_4 1 Tf
0.021 Tw 7.8 0 0 7.8 52.7244 388.6837 Tm
(Lindner D, Lindner J, Baumann G )Tj
ET
BT
/T1_5 1 Tf
7.8 0 0 7.8 165.9996 388.6837 Tm
(et al)Tj
ET
BT
/T1_3 1 Tf
-0.0105 Tc 0 Tw 7.8 0 0 7.8 179.7608 388.6837 Tm
(.)Tj
-0.011 Tc 0.021 Tw 0.51768 0 Td
(\(Investigation of antioxidant)Tj
-16.80439 -1.34615 Td
[(therapy with sodium selenite in acute pancr)20 (eatitis\). )]TJ
ET
BT
/T1_6 1 Tf
-0.00999 Tc 0.02 Tw 7.8 0 0 7.8 217.6204 378.1837 Tm
(Med Klin)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 0 Tw 7.8 0 0 7.8 52.7244 367.6837 Tm
(2004;99:708-12.)Tj
-1.30829 -1.34615 Td
(34.)Tj
ET
BT
/T1_4 1 Tf
7.8 0 0 7.8 52.7244 357.1837 Tm
(Siriwar)Tj
0.021 Tw 3.03523 0 Td
(dena AK, Mason JM, Balachandra S )Tj
ET
BT
/T1_5 1 Tf
7.8 0 0 7.8 194.0619 357.1837 Tm
(et al)Tj
ET
BT
/T1_3 1 Tf
-0.0105 Tc 0 Tw 7.8 0 0 7.8 207.8232 357.1837 Tm
(.)Tj
-0.011 Tc 0.021 Tw 0.51763 0 Td
(Randomised, double)Tj
13.48646 49.80769 Td
[(blind, placebo contr)20 (olled trial of intravenous antioxidant )]TJ
T*
[(\(n-acetylcysteine, selenium, vitamin C\) therapy in sever)20 (e acute)]TJ
0 Tw T*
[(pancr)20 (eatitis. )]TJ
ET
BT
/T1_6 1 Tf
-0.00999 Tc 7.8 0 0 7.8 357.5049 724.6837 Tm
(Gut)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 7.8 0 0 7.8 371.0683 724.6837 Tm
(2007;56:1439-44.)Tj
-8.23306 -1.34615 Td
(35.)Tj
ET
BT
/T1_4 1 Tf
0.021 Tw 7.8 0 0 7.8 317.0551 714.1837 Tm
[(A)45 (venell A, Noble DW)174 (, Barr J, Engelhardt T)]TJ
ET
BT
/T1_3 1 Tf
-0.0105 Tc 0 Tw 7.8 0 0 7.8 456.0179 714.1837 Tm
(.)Tj
-0.011 Tc 0.021 Tw 0.51768 0 Td
(Selenium supplementation)Tj
-18.33342 -1.34615 Td
[(for critically ill adults \(Cochrane Reviews\) In: The Cochrane Librar)-5 (y)144 (,)]TJ
T*
[(Issue 4, 2004. Chichester)69 (, UK: John W)30 (iley & Sons, Ltd.)]TJ
0 Tw -1.3083 -1.34615 Td
(36.)Tj
ET
BT
/T1_4 1 Tf
0.021 Tw 7.8 0 0 7.8 317.0551 682.6837 Tm
[(Critical Car)10 (e Nutrition Gr)19 (oup)]TJ
ET
BT
/T1_3 1 Tf
-0.0105 Tc 0 Tw 7.8 0 0 7.8 414.8975 682.6837 Tm
(.)Tj
-0.011 Tc 0.021 Tw 0.51768 0 Td
(Supplemental antioxidant nutrients:)Tj
-13.06157 -1.34615 Td
[(par)20 (enteral selenium. http://www)124 (.criticalcar)20 (enutrition.com/)]TJ
T*
(docs/cpg/11.2_selenium_07.pdf Accessed December 2008.)Tj
0 Tw -1.3083 -1.34615 Td
(37.)Tj
ET
BT
/T1_4 1 Tf
0.021 Tw 7.8 0 0 7.8 317.0551 651.1837 Tm
(SIGNET trial)Tj
ET
BT
/T1_3 1 Tf
-0.0105 Tc 0 Tw 7.8 0 0 7.8 360.1899 651.1837 Tm
(:)Tj
-0.011 Tc 0.021 Tw 0.51767 0 Td
[(University of Edinbur)30 (gh)]TJ
0 Tw -7.35606 -1.34615 Td
(38.)Tj
ET
BT
/T1_4 1 Tf
0.021 Tw 7.8 0 0 7.8 317.0551 640.6837 Tm
(Heyland DK, Dhaliwal R, Day AG )Tj
ET
BT
/T1_5 1 Tf
7.8 0 0 7.8 429.6694 640.6837 Tm
(et al)Tj
ET
BT
/T1_3 1 Tf
-0.0105 Tc 0 Tw 7.8 0 0 7.8 443.4307 640.6837 Tm
(.)Tj
-0.011 Tc 0.021 Tw 0.51766 0 Td
(REducing Deaths due to)Tj
-16.71966 -1.34615 Td
[(OXidative Str)20 (ess \(The REDOXS)]TJ
ET
BT
/T1_3 1 Tf
0 Tc 0 Tw 4.446 0 0 4.446 417.2959 633.3875 Tm
(\251)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 0.021 Tw 7.8 0 0 7.8 422.9049 630.1837 Tm
(Study\): rationale and study design for a)Tj
-13.57049 -1.34615 Td
(randomised trial of glutamine and antioxidant supplementation in)Tj
T*
(critically-ill patients. )Tj
ET
BT
/T1_6 1 Tf
-0.0101 Tc 0 Tw 7.8 0 0 7.8 384.2171 609.1837 Tm
(P)Tj
-0.00999 Tc 0.02 Tw 0.78687 0 Td
(Nutr Soc)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tc 0 Tw 7.8 0 0 7.8 419.3529 609.1837 Tm
(2006;65:250-63.)Tj
-14.4234 -1.34615 Td
(39.)Tj
ET
BT
/T1_4 1 Tf
0.021 Tw 7.8 0 0 7.8 317.0551 598.6837 Tm
[(Angstwur)-20 (m MW)95 (A, G\212rtner R)]TJ
ET
BT
/T1_3 1 Tf
-0.0105 Tc 0 Tw 7.8 0 0 7.8 412.4414 598.6837 Tm
(.)Tj
-0.011 Tc 0.021 Tw 0.51768 0 Td
(Practicalities of selenium supplementation)Tj
-12.74669 -1.34615 Td
(in critically ill patients. )Tj
ET
BT
/T1_6 1 Tf
-0.00999 Tc 0.02 Tw 7.8 0 0 7.8 392.2421 588.1838 Tm
[(Cur)20 (r Opin Clin Nutr)]TJ
ET
BT
/T1_3 1 Tf
-0.011 Tc 0 Tw 7.8 0 0 7.8 457.2253 588.1838 Tm
(2006;9:233-38. )Tj
-19.27883 -1.34615 Td
(40.)Tj
ET
BT
/T1_4 1 Tf
0.021 Tw 7.8 0 0 7.8 317.0551 577.6838 Tm
(Stewart MS, Spallholz JE, Neldner KH, Pence BC)Tj
ET
BT
/T1_3 1 Tf
-0.0105 Tc 0 Tw 7.8 0 0 7.8 477.2452 577.6838 Tm
(.)Tj
-0.011 Tc 0.021 Tw 0.51766 0 Td
(Selenium compounds)Tj
-21.05485 -1.34615 Td
[(have disparate abilities to impose oxidative str)20 (ess and )-1 (induce apoptosis.)]TJ
ET
BT
/T1_6 1 Tf
-0.00999 Tc 0.02 Tw 7.8 0 0 7.8 317.0551 556.6838 Tm
[(Fr)49 (ee Radical )1 (Bio Med)]TJ
ET
BT
/T1_3 1 Tf
-0.011 Tc 0 Tw 7.8 0 0 7.8 384.0213 556.6838 Tm
(1999;26:42-48.)Tj
-9.89371 -1.34615 Td
(41.)Tj
ET
BT
/T1_4 1 Tf
0.021 Tw 7.8 0 0 7.8 317.0551 546.1838 Tm
(Heyland DK)Tj
ET
BT
/T1_3 1 Tf
-0.0105 Tc 0 Tw 7.8 0 0 7.8 357.04 546.1838 Tm
(.)Tj
-0.011 Tc 0.021 Tw 0.51767 0 Td
(Selenium supplementation in critically ill patients: can too)Tj
-5.64394 -1.34615 Td
(much of a good thing be a bad thing? )Tj
ET
BT
/T1_6 1 Tf
-0.00999 Tc 0.02 Tw 7.8 0 0 7.8 438.2457 535.6838 Tm
[(Crit Car)50 (e)]TJ
ET
BT
/T1_3 1 Tf
-0.011 Tc 0 Tw 7.8 0 0 7.8 468.9378 535.6838 Tm
(2007;11:153-56.)Tj
-20.78044 -1.34615 Td
(42.)Tj
ET
BT
/T1_4 1 Tf
0.021 Tw 7.8 0 0 7.8 317.0551 525.1838 Tm
(Heyland DK, Dhaliwal R, Day AG )Tj
ET
BT
/T1_5 1 Tf
7.8 0 0 7.8 429.6694 525.1838 Tm
(et al)Tj
ET
BT
/T1_3 1 Tf
-0.0105 Tc 0 Tw 7.8 0 0 7.8 443.4307 525.1838 Tm
(.)Tj
-0.011 Tc 0.021 Tw 0.51767 0 Td
(Optimizing the dose of)Tj
-16.71967 -1.34615 Td
(glutamine dipeptides and antioxidants in critically ill patients: a phas\
e I)Tj
-0.00999 Tc T*
[(d)1 (o)1 (s)1 (e)1 (-)1 (\336)1 (nding study)134 (.)1 ( )]TJ
ET
BT
/T1_6 1 Tf
-0.0101 Tc 0 Tw 7.8 0 0 7.8 379.0531 504.1838 Tm
(J)Tj
-0.00999 Tc 0.02 Tw 0.56484 0 Td
[(Par)50 (enter Enteral Nutr)]TJ
ET
BT
/T1_3 1 Tf
-0.011 Tc 0 Tw 7.8 0 0 7.8 451.8525 504.1838 Tm
(2007;31:109-18.)Tj
0.021 Tw -18.59001 -1.34615 Td
[(43.)-43 (National Collaborating Centr)19 (e for Acute Car)20 (e, Februar)-6 (y 2006. Nutrition)]TJ
1.3083 -1.34616 Td
[(suppor)10 (t in adults: Oral nutrition suppor)9 (t, enteral tube feeding and)]TJ
T*
[(par)20 (enteral nutrition.)]TJ
ET
1 w
/GS1 gs
42.52 39.685 m
552.756 39.685 l
S
BT
/GS3 gs
/T1_2 1 Tf
-0.021 Tc 0.02901 Tw 12.5 0 0 12.5 465.8717 793.7901 Tm
[(R)26 (e)24 (vie)21 (w ar)-18 (ticle)10 (s)]TJ
ET
0.27 0.06 0 0 k
/GS1 gs
306.142 357.4611 246.614 92.115 re
f
BT
0 0 0 1 k
/GS3 gs
/T1_0 1 Tf
0 Tc -0.04201 Tw 9.5 0 0 9.5 312.1417 436.8799 Tm
(Stephanie Strachan )Tj
ET
BT
/T1_7 1 Tf
-0.007 Tc -0.039 Tw 8 0 0 8 400.2933 436.8799 Tm
[(SpR Ane)10 (s)9 (the)8 (tic)5 (s and IC)8 (U)20 (, S)12 (t Geor)28 (ge)22 (\325)49 (s)]TJ
0 Tw -11.01895 -1.5 Td
[(Ho)8.9 (spit)]TJ
-0.039 Tw 2.83897 0 Td
(al, L)Tj
0 Tw 1.7815 0 Td
(ondon)Tj
0 Tc -4.62047 -1.50001 Td
[(s)16.6 (t)]TJ
-0.007 Tc 0.79576 0 Td
[(ephs)8.3 (tr)35 (achan@ho)4 (tmail.)22 (c)17 (om)]TJ
ET
BT
/T1_0 1 Tf
0 Tc -0.04201 Tw 9.5 0 0 9.5 312.1417 395.2106 Tm
[(Duncan W)30 (yncoll )]TJ
ET
BT
/T1_7 1 Tf
-0.007 Tc -0.039 Tw 8 0 0 8 388.2837 395.2106 Tm
[(In)5 (t)19 (ensiv)18 (e C)12 (ar)25 (e C)17 (onsult)14 (an)5 (t)9 (, S)12 (t T)12 (homas)20 (\325)]TJ
0 Tw -9.51775 -1.5 Td
(Ho)Tj
-0.039 Tw 1.23108 0 Td
[(spit)15 (al, L)12 (ondon)]TJ
-1.23108 -2.20866 Td
[(T)11 (his ar)-10 (ticle w)35 (as submit)15 (t)19 (ed f)22 (o)-1 (l)-1 (l)-1 (o)17 (wing a dis)10 (s)5 (at)14 (ation f)22 (or the DICM)]TJ
ET
BT
0 g
/GS4 gs
/T1_8 1 Tf
0 Tc 0 Tw 5 0 0 5 301.10497 11 Tm
( by guest on September 2, 2015)Tj
0 0 1 rg
/GS4 gs
-7.55899 0 Td
(inc.sagepub.com)Tj
0 g
/GS4 gs
-8.11399 0 Td
(Downloaded from )Tj
ET
endstream
endobj
144 0 obj
<<
/Length 152
>>
stream
Q
0.33333 0.69412 0.96078 RG
0.8 w
53.91 460.26001 m
284.82001 460.26001 l
S
0.33333 0.69412 0.96078 RG
0.8 w
52.72 449.75003 m
159.70001 449.75003 l
S
endstream
endobj
145 0 obj
<<
/Length 215
>>
stream
Q
0.33333 0.69412 0.96078 RG
0.8 w
53 659.73999 m
281.97998 659.73999 l
S
0.33333 0.69412 0.96078 RG
0.8 w
52.72 649.26001 m
278.83002 649.26001 l
S
0.33333 0.69412 0.96078 RG
0.8 w
52.72 638.75 m
229.08 638.75 l
S
endstream
endobj
146 0 obj
<<
/Length 224
>>
stream
Q
0.33333 0.69412 0.96078 RG
0.8 w
53.36 386.74002 m
274.33002 386.74002 l
S
0.33333 0.69412 0.96078 RG
0.8 w
52.72 376.25003 m
245.75 376.25003 l
S
0.33333 0.69412 0.96078 RG
0.8 w
52.72 365.76001 m
104.71001 365.76001 l
S
endstream
endobj
147 0 obj
<<
/Length 148
>>
stream
Q
0.33333 0.69412 0.96078 RG
0.8 w
318.95001 596.76001 m
550.83002 596.76001 l
S
0.33333 0.69412 0.96078 RG
0.8 w
317.06 586.25 m
505.25 586.25 l
S
endstream
endobj
148 0 obj
<<
/Length 284
>>
stream
Q
0.33333 0.69412 0.96078 RG
0.8 w
52.67 565.26001 m
281.06 565.26001 l
S
0.33333 0.69412 0.96078 RG
0.8 w
52.72 554.76001 m
247.13 554.76001 l
S
0.33333 0.69412 0.96078 RG
0.8 w
52.72 544.26001 m
271.16 544.26001 l
S
0.33333 0.69412 0.96078 RG
0.8 w
52.72 533.75 m
163.69 533.75 l
S
endstream
endobj
149 0 obj
<<
/Length 211
>>
stream
Q
0.33333 0.69412 0.96078 RG
0.8 w
55.1 743.73999 m
284.06 743.73999 l
S
0.33333 0.69412 0.96078 RG
0.8 w
52.72 733.25 m
274.04999 733.25 l
S
0.33333 0.69412 0.96078 RG
0.8 w
52.72 722.75 m
135.26001 722.75 l
S
endstream
endobj
150 0 obj
<<
/Length 221
>>
stream
Q
0.33333 0.69412 0.96078 RG
0.8 w
317.38 575.76001 m
550.03003 575.76001 l
S
0.33333 0.69412 0.96078 RG
0.8 w
317.06 565.26001 m
543.88 565.26001 l
S
0.33333 0.69412 0.96078 RG
0.8 w
317.06 554.75 m
432.04999 554.75 l
S
endstream
endobj
151 0 obj
<<
/Length 148
>>
stream
Q
0.33333 0.69412 0.96078 RG
0.8 w
318.07999 544.26001 m
546.37 544.26001 l
S
0.33333 0.69412 0.96078 RG
0.8 w
317.06 533.75 m
520.92999 533.75 l
S
endstream
endobj
152 0 obj
<<
/Length 149
>>
stream
Q
0.33333 0.69412 0.96078 RG
0.8 w
53.02 439.26001 m
275.79001 439.26001 l
S
0.33333 0.69412 0.96078 RG
0.8 w
52.72 428.76001 m
275.09 428.76001 l
S
endstream
endobj
153 0 obj
<<
/Length 148
>>
stream
Q
0.33333 0.69412 0.96078 RG
0.8 w
54.4 407.76001 m
283.54001 407.76001 l
S
0.33333 0.69412 0.96078 RG
0.8 w
52.72 397.25003 m
185.63 397.25003 l
S
endstream
endobj
154 0 obj
<<
/Length 214
>>
stream
Q
0.33333 0.69412 0.96078 RG
0.8 w
52.28 712.23999 m
258.73999 712.23999 l
S
0.33333 0.69412 0.96078 RG
0.8 w
52.72 701.76001 m
265.37 701.76001 l
S
0.33333 0.69412 0.96078 RG
0.8 w
52.72 691.25 m
259.5 691.25 l
S
endstream
endobj
155 0 obj
<<
/Length 484
>>
stream
BT
/F10 8 Tf
1 0 0 1 50 20 Tm
0 0 0 rg
(The author has requested enhancement of the downloaded file. All in-text references ) Tj
0.33333 0.69412 0.96078 rg
(underlined in blue ) Tj
0 0 0 rg
(are linked to publications on ResearchGate.) Tj
ET
BT
/F10 8 Tf
1 0 0 1 50 20 Tm
0 0 0 rg
(The author has requested enhancement of the downloaded file. All in-text references ) Tj
0.33333 0.69412 0.96078 rg
(underlined in blue ) Tj
0 0 0 rg
(are linked to publications on ResearchGate.) Tj
ET
endstream
endobj
156 0 obj
<<
/OP true
/OPM 1
/SM 0.00999451
/Type /ExtGState
/op true
>>
endobj
157 0 obj
<<
/OP false
/OPM 1
/SM 0.00999451
/Type /ExtGState
/op false
>>
endobj
158 0 obj
<<
/FL 1
/OP true
/OPM 1
/SM 0.00999451
/Type /ExtGState
/op true
>>
endobj
159 0 obj
<<
/OP false
/OPM 0
/SM 1.0
/op false
>>
endobj
160 0 obj
<<
/Type /Font
/Subtype /Type1
/BaseFont /Helvetica
/Encoding /WinAnsiEncoding
>>
endobj
161 0 obj
<<
/S /URI
/URI (http://inc.sagepub.com/)
>>
endobj
162 0 obj
<<
/BaseEncoding /MacRomanEncoding
/Differences [32 /space 40 /parenleft /parenright /asterisk /plus 45 /hyphen /period
/slash /zero /one /two /three /four 56 /eight /nine 63
/question 65 /A 67 /C /D 71 /G /H /I
77 /M /N /O /P 82 /R /S /T /U
87 /W 97 /a /b /c /d /e /f /g
/h /i 108 /l /m /n /o /p /q /r
/s /t /u /v /w /x /y]
/Type /Encoding
>>
endobj
163 0 obj
<<
/Ascent 726
/CapHeight 700
/Descent -16
/Flags 262176
/FontBBox [-62 -193 1385 910]
/FontFile3 299 0 R
/FontName /MIAMIH+Interstate-Bold
/ItalicAngle 0
/StemH 0
/StemV 139
/Type /FontDescriptor
/XHeight 729
>>
endobj
164 0 obj
<<
/BaseEncoding /MacRomanEncoding
/Differences [32 /space 40 /parenleft /parenright /asterisk /plus /comma /hyphen /period
/slash /zero /one /two /three /four /five /six /seven /eight
/nine 61 /equal 63 /question /at /A /B /C /D
70 /F /G /H /I 75 /K /L /M /N
80 /P 82 /R /S /T /U 90 /Z 97
/a /b /c /d /e /f /g /h /i /j
/k /l /m /n /o /p /q /r /s /t
/u /v /w /x /y /z 169 /copyright 210 /quotedblleft
/quotedblright 213 /quoteright]
/Type /Encoding
>>
endobj
165 0 obj
<<
/Ascent 726
/CapHeight 700
/Descent -18
/Flags 32
/FontBBox [-52 -193 1300 914]
/FontFile3 300 0 R
/FontName /MXMCYF+Interstate-Light
/ItalicAngle 0
/StemH 0
/StemV 76
/Type /FontDescriptor
/XHeight 729
>>
endobj
166 0 obj
<<
/BaseEncoding /MacRomanEncoding
/Differences [32 /space 44 /comma 48 /zero /one /two 57 /nine
74 /J 78 /N 86 /V 97 /a /b 101
/e 108 /l /m /n /o 114 /r 117 /u
121 /y]
/Type /Encoding
>>
endobj
167 0 obj
<<
/Ascent 705
/CapHeight 635
/Descent -246
/Flags 34
/FontBBox [-86 -256 1062 841]
/FontFile3 301 0 R
/FontName /JLNEBO+Berkeley-Book
/ItalicAngle 0
/StemH 0
/StemV 58
/Type /FontDescriptor
/XHeight 712
>>
endobj
168 0 obj
<<
/BaseEncoding /MacRomanEncoding
/Differences [32 /space 44 /comma 67 /C /D 73 /I /J
83 /S 87 /W 97 /a 99 /c 101 /e
104 /h /i 108 /l 110 /n /o /p 114
/r 116 /t /u 121 /y]
/Type /Encoding
>>
endobj
169 0 obj
<<
/Ascent 705
/CapHeight 635
/Descent -241
/Flags 34
/FontBBox [-117 -250 1172 844]
/FontFile3 302 0 R
/FontName /TFXMNR+Berkeley-Black
/ItalicAngle 0
/StemH 0
/StemV 40
/Type /FontDescriptor
/XHeight 712
>>
endobj
170 0 obj
<<
/BaseEncoding /MacRomanEncoding
/Differences [32 /space 37 /percent /ampersand 40 /parenleft /parenright 44 /comma
/hyphen /period /slash /zero /one /two /three /four /five /six
/seven /eight /nine /colon /semicolon /less /equal /greater /question 65
/A /B /C /D /E /F /G /H /I /J
/K /L /M /N /O /P 82 /R /S /T
/U /V /W /X 90 /Z 95 /underscore 97 /a
/b /c /d /e /f /g /h /i /j /k
/l /m /n /o /p /q /r /s /t /u
/v /w /x /y /z 165 /bullet 168 /registered /copyright
208 /endash 213 /quoteright 222 /fi /fl]
/Type /Encoding
>>
endobj
171 0 obj
<<
/Ascent 705
/CapHeight 635
/Descent -246
/Flags 34
/FontBBox [-93 -255 1083 842]
/FontFile3 303 0 R
/FontName /BFOTJG+Berkeley-Medium
/ItalicAngle 0
/StemH 0
/StemV 78
/Type /FontDescriptor
/XHeight 712
>>
endobj
172 0 obj
<<
/BaseEncoding /MacRomanEncoding
/Differences [32 /space 107 /kappa 109 /mu]
/Type /Encoding
>>
endobj
173 0 obj
<<
/Ascent 921
/CapHeight 671
/Descent -223
/Flags 4
/FontBBox [-180 -292 1090 1005]
/FontFile3 304 0 R
/FontName /HGHDRU+Symbol
/ItalicAngle 0
/StemH 0
/StemV 41
/Type /FontDescriptor
/XHeight 684
>>
endobj
174 0 obj
<<
/BaseEncoding /MacRomanEncoding
/Differences [58 /colon 75 /K 100 /d /e 111 /o 114
/r /s 119 /w 121 /y]
/Type /Encoding
>>
endobj
175 0 obj
<<
/Ascent 705
/CapHeight 635
/Descent -249
/Flags 262242
/FontBBox [-182 -260 1071 839]
/FontFile3 305 0 R
/FontName /YLPTDE+Berkeley-BlackItalic
/ItalicAngle -8
/StemH 0
/StemV 161
/Type /FontDescriptor
/XHeight 712
>>
endobj
176 0 obj
<<
/BaseEncoding /MacRomanEncoding
/Differences [32 /space 59 /semicolon 65 /A /B /C /D /E
/F /G 73 /I /J /K /L /M /N /O
/P 82 /R /S /T 90 /Z 97 /a 99
/c /d /e 103 /g /h /i 107 /k /l
/m /n /o /p 114 /r /s /t /u /v
120 /x]
/Type /Encoding
>>
endobj
177 0 obj
<<
/Ascent 705
/CapHeight 635
/Descent -248
/Flags 98
/FontBBox [-130 -260 1019 839]
/FontFile3 306 0 R
/FontName /JMXSYX+Berkeley-Italic
/ItalicAngle -8
/StemH 0
/StemV 78
/Type /FontDescriptor
/XHeight 712
>>
endobj
178 0 obj
<<
/S /URI
/URI (http://inc.sagepub.com/)
>>
endobj
179 0 obj
<<
/S /URI
/URI (http://inc.sagepub.com/)
>>
endobj
180 0 obj
<<
/S /URI
/URI (http://inc.sagepub.com/)
>>
endobj
181 0 obj
<<
/BaseEncoding /MacRomanEncoding
/Differences [32 /space 44 /comma /hyphen 65 /A /B /C /D
/E /F /G /H /I /J /K /L /M /N
/O /P 82 /R /S /T 86 /V /W /X
/Y /Z 97 /a /b /c /d /e /f /g
/h /i 107 /k /l /m /n /o /p 114
/r /s /t /u /v /w /x /y /z 138
/adieresis 142 /eacute 159 /udieresis 222 /fi]
/Type /Encoding
>>
endobj
182 0 obj
<<
/Ascent 705
/CapHeight 635
/Descent -244
/Flags 262178
/FontBBox [-102 -250 1129 847]
/FontFile3 307 0 R
/FontName /GNHJBL+Berkeley-Bold
/ItalicAngle 0
/StemH 0
/StemV 116
/Type /FontDescriptor
/XHeight 712
>>
endobj
183 0 obj
<<
/BaseEncoding /MacRomanEncoding
/Differences [32 /space 67 /C 73 /I 77 /M /N 82
/R 97 /a 99 /c /d /e 104 /h /i
110 /n /o 114 /r /s /t /u /v]
/Type /Encoding
>>
endobj
184 0 obj
<<
/Ascent 726
/CapHeight 700
/Descent -18
/Flags 96
/FontBBox [-113 -193 1274 914]
/FontFile3 308 0 R
/FontName /PNKSBH+Interstate-LightItalic
/ItalicAngle -12
/StemH 0
/StemV 77
/Type /FontDescriptor
/XHeight 729
>>
endobj
185 0 obj
<<
/S /URI
/URI (http://inc.sagepub.com/)
>>
endobj
186 0 obj
<<
/S /B
/W 0.0
>>
endobj
187 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/12760468_An_estimation_of_selenium_requirement_for_New_Zealanders?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
188 0 obj
<<
/S /B
/W 0.0
>>
endobj
189 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/12760468_An_estimation_of_selenium_requirement_for_New_Zealanders?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
190 0 obj
<<
/S /B
/W 0.0
>>
endobj
191 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/12760468_An_estimation_of_selenium_requirement_for_New_Zealanders?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
192 0 obj
<<
/S /B
/W 0.0
>>
endobj
193 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/20838143_Hawker_FH_Stewart_PM_Snitch_PJ_Effects_of_acute_illness_on_selenium_homeostasis?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
194 0 obj
<<
/S /B
/W 0.0
>>
endobj
195 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/20838143_Hawker_FH_Stewart_PM_Snitch_PJ_Effects_of_acute_illness_on_selenium_homeostasis?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
196 0 obj
<<
/S /B
/W 0.0
>>
endobj
197 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/298979794_In_vitro_clearance_of_trace_elements_via_continuous_renal_replacement_therapy?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
198 0 obj
<<
/S /B
/W 0.0
>>
endobj
199 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/298979794_In_vitro_clearance_of_trace_elements_via_continuous_renal_replacement_therapy?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
200 0 obj
<<
/S /B
/W 0.0
>>
endobj
201 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/298979794_In_vitro_clearance_of_trace_elements_via_continuous_renal_replacement_therapy?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
202 0 obj
<<
/S /B
/W 0.0
>>
endobj
203 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/13103745_Antioxidant_status_in_patients_with_acute_respiratory_distress_syndrome?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
204 0 obj
<<
/S /B
/W 0.0
>>
endobj
205 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/13103745_Antioxidant_status_in_patients_with_acute_respiratory_distress_syndrome?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
206 0 obj
<<
/S /B
/W 0.0
>>
endobj
207 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/13103745_Antioxidant_status_in_patients_with_acute_respiratory_distress_syndrome?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
208 0 obj
<<
/S /B
/W 0.0
>>
endobj
209 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/11483602_Bates_CJ_Thane_CW_Prentice_A_Delves_HT_Selenium_status_and_its_correlates_in_a_British_National_Diet_and_Nutrition_Survey_people_aged_65_years_and_over_J_Trace_Elem_Med_Biol_16_1-8?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
210 0 obj
<<
/S /B
/W 0.0
>>
endobj
211 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/11483602_Bates_CJ_Thane_CW_Prentice_A_Delves_HT_Selenium_status_and_its_correlates_in_a_British_National_Diet_and_Nutrition_Survey_people_aged_65_years_and_over_J_Trace_Elem_Med_Biol_16_1-8?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
212 0 obj
<<
/S /B
/W 0.0
>>
endobj
213 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/11483602_Bates_CJ_Thane_CW_Prentice_A_Delves_HT_Selenium_status_and_its_correlates_in_a_British_National_Diet_and_Nutrition_Survey_people_aged_65_years_and_over_J_Trace_Elem_Med_Biol_16_1-8?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
214 0 obj
<<
/S /B
/W 0.0
>>
endobj
215 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/12792066_Angstwurm_MWA_Schottdorf_J_Schopohl_J_Gartner_R_Selenium_replacement_in_patients_with_severe_systemic_inflammatory_response_syndrome_improves_clinical_outcome_Crit_Care_Med_27_1807-1813?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
216 0 obj
<<
/S /B
/W 0.0
>>
endobj
217 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/12792066_Angstwurm_MWA_Schottdorf_J_Schopohl_J_Gartner_R_Selenium_replacement_in_patients_with_severe_systemic_inflammatory_response_syndrome_improves_clinical_outcome_Crit_Care_Med_27_1807-1813?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
218 0 obj
<<
/S /B
/W 0.0
>>
endobj
219 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/12792066_Angstwurm_MWA_Schottdorf_J_Schopohl_J_Gartner_R_Selenium_replacement_in_patients_with_severe_systemic_inflammatory_response_syndrome_improves_clinical_outcome_Crit_Care_Med_27_1807-1813?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
220 0 obj
<<
/S /B
/W 0.0
>>
endobj
221 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/14171251_Dietary_selenium_Time_to_act?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
222 0 obj
<<
/S /B
/W 0.0
>>
endobj
223 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/13533576_Selenium_systemic_immune_response_syndrome_sepsis_and_outcome_in_critically_ill_patients?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
224 0 obj
<<
/S /B
/W 0.0
>>
endobj
225 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/13533576_Selenium_systemic_immune_response_syndrome_sepsis_and_outcome_in_critically_ill_patients?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
226 0 obj
<<
/S /B
/W 0.0
>>
endobj
227 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/13533576_Selenium_systemic_immune_response_syndrome_sepsis_and_outcome_in_critically_ill_patients?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
228 0 obj
<<
/S /B
/W 0.0
>>
endobj
229 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/223802119_Selenium_Content_of_a_Range_of_UK_Foods?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
230 0 obj
<<
/S /B
/W 0.0
>>
endobj
231 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/223802119_Selenium_Content_of_a_Range_of_UK_Foods?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
232 0 obj
<<
/S /B
/W 0.0
>>
endobj
233 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/13354202_Trace_element_and_vitamin_concentrations_and_losses_in_critically_ill_patients_treated_with_continuous_venovenous_hemofiltration?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
234 0 obj
<<
/S /B
/W 0.0
>>
endobj
235 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/13354202_Trace_element_and_vitamin_concentrations_and_losses_in_critically_ill_patients_treated_with_continuous_venovenous_hemofiltration?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
236 0 obj
<<
/S /B
/W 0.0
>>
endobj
237 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/13354202_Trace_element_and_vitamin_concentrations_and_losses_in_critically_ill_patients_treated_with_continuous_venovenous_hemofiltration?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
238 0 obj
<<
/BaseEncoding /MacRomanEncoding
/Differences [32 /space 97 /a 101 /e 108 /l 116 /t]
/Type /Encoding
>>
endobj
239 0 obj
<<
/Ascent 705
/CapHeight 635
/Descent -249
/Flags 262242
/FontBBox [-158 -260 1022 844]
/FontFile3 309 0 R
/FontName /PDSBPJ+Berkeley-BoldItalic
/ItalicAngle -8
/StemH 0
/StemV 102
/Type /FontDescriptor
/XHeight 712
>>
endobj
240 0 obj
<<
/S /URI
/URI (http://inc.sagepub.com/)
>>
endobj
241 0 obj
<<
/S /B
/W 0.0
>>
endobj
242 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/288763213_Selenium_An_important_component_of_sepsis_therapy?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
243 0 obj
<<
/S /B
/W 0.0
>>
endobj
244 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/288763213_Selenium_An_important_component_of_sepsis_therapy?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
245 0 obj
<<
/S /B
/W 0.0
>>
endobj
246 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/13584474_Trace_element_supplementation_modulates_pulmonary_infection_rates_after_major_burns_A_double-blind_placebo-controlled_trial?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
247 0 obj
<<
/S /B
/W 0.0
>>
endobj
248 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/13584474_Trace_element_supplementation_modulates_pulmonary_infection_rates_after_major_burns_A_double-blind_placebo-controlled_trial?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
249 0 obj
<<
/S /B
/W 0.0
>>
endobj
250 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/13584474_Trace_element_supplementation_modulates_pulmonary_infection_rates_after_major_burns_A_double-blind_placebo-controlled_trial?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
251 0 obj
<<
/S /B
/W 0.0
>>
endobj
252 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/8129609_Investigation_of_antioxidant_therapy_with_sodium_selenite_in_acute_pancreatitis_A_prospective_randomized_blind_trial?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
253 0 obj
<<
/S /B
/W 0.0
>>
endobj
254 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/8129609_Investigation_of_antioxidant_therapy_with_sodium_selenite_in_acute_pancreatitis_A_prospective_randomized_blind_trial?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
255 0 obj
<<
/S /B
/W 0.0
>>
endobj
256 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/8129609_Investigation_of_antioxidant_therapy_with_sodium_selenite_in_acute_pancreatitis_A_prospective_randomized_blind_trial?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
257 0 obj
<<
/S /B
/W 0.0
>>
endobj
258 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/7173182_Practicalities_of_selenium_supplementation_in_critically_ill_patients?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
259 0 obj
<<
/S /B
/W 0.0
>>
endobj
260 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/7173182_Practicalities_of_selenium_supplementation_in_critically_ill_patients?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
261 0 obj
<<
/S /B
/W 0.0
>>
endobj
262 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/13067803_Antioxidant_therapy_in_the_prevention_of_organ_dysfunction_syndrome_and_infectious_complications_after_trauma_Early_results_of_a_prospective_randomized_study?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
263 0 obj
<<
/S /B
/W 0.0
>>
endobj
264 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/13067803_Antioxidant_therapy_in_the_prevention_of_organ_dysfunction_syndrome_and_infectious_complications_after_trauma_Early_results_of_a_prospective_randomized_study?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
265 0 obj
<<
/S /B
/W 0.0
>>
endobj
266 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/13067803_Antioxidant_therapy_in_the_prevention_of_organ_dysfunction_syndrome_and_infectious_complications_after_trauma_Early_results_of_a_prospective_randomized_study?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
267 0 obj
<<
/S /B
/W 0.0
>>
endobj
268 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/13067803_Antioxidant_therapy_in_the_prevention_of_organ_dysfunction_syndrome_and_infectious_complications_after_trauma_Early_results_of_a_prospective_randomized_study?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
269 0 obj
<<
/S /B
/W 0.0
>>
endobj
270 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/13811754_Selenium_administration_in_patients_with_sepsis_syndrome_A_prospective_randomized_study?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
271 0 obj
<<
/S /B
/W 0.0
>>
endobj
272 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/13811754_Selenium_administration_in_patients_with_sepsis_syndrome_A_prospective_randomized_study?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
273 0 obj
<<
/S /B
/W 0.0
>>
endobj
274 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/13811754_Selenium_administration_in_patients_with_sepsis_syndrome_A_prospective_randomized_study?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
275 0 obj
<<
/S /B
/W 0.0
>>
endobj
276 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/13397754_Selenium_compounds_have_disparate_abilities_to_impose_oxidative_stress_and_induce_apoptosis?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
277 0 obj
<<
/S /B
/W 0.0
>>
endobj
278 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/13397754_Selenium_compounds_have_disparate_abilities_to_impose_oxidative_stress_and_induce_apoptosis?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
279 0 obj
<<
/S /B
/W 0.0
>>
endobj
280 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/13397754_Selenium_compounds_have_disparate_abilities_to_impose_oxidative_stress_and_induce_apoptosis?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
281 0 obj
<<
/S /B
/W 0.0
>>
endobj
282 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/6147720_Selenium_supplementation_in_critically_ill_patients_Can_too_much_of_a_good_thing_be_a_bad_thing?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
283 0 obj
<<
/S /B
/W 0.0
>>
endobj
284 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/6147720_Selenium_supplementation_in_critically_ill_patients_Can_too_much_of_a_good_thing_be_a_bad_thing?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
285 0 obj
<<
/S /B
/W 0.0
>>
endobj
286 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/21506585_Acute_pancreatitis_-_a_'free_radical_disease'_Decrease_of_lethality_by_sodium_selenite_Na2SeO3_therapy?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
287 0 obj
<<
/S /B
/W 0.0
>>
endobj
288 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/21506585_Acute_pancreatitis_-_a_'free_radical_disease'_Decrease_of_lethality_by_sodium_selenite_Na2SeO3_therapy?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
289 0 obj
<<
/S /B
/W 0.0
>>
endobj
290 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/13453431_Chronic_pancreatitis_at_Manchester_UK_Focus_on_antioxidant_therapy?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
291 0 obj
<<
/S /B
/W 0.0
>>
endobj
292 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/13453431_Chronic_pancreatitis_at_Manchester_UK_Focus_on_antioxidant_therapy?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
293 0 obj
<<
/S /B
/W 0.0
>>
endobj
294 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/296108686_Effects_of_high_doses_of_selenium_in_septic_shock_a_placebo-controlled_randomized_double-blind_phase_II_study?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
295 0 obj
<<
/S /B
/W 0.0
>>
endobj
296 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/296108686_Effects_of_high_doses_of_selenium_in_septic_shock_a_placebo-controlled_randomized_double-blind_phase_II_study?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
297 0 obj
<<
/S /B
/W 0.0
>>
endobj
298 0 obj
<<
/S /URI
/URI (https://www.researchgate.net/publication/296108686_Effects_of_high_doses_of_selenium_in_septic_shock_a_placebo-controlled_randomized_double-blind_phase_II_study?el=1_x_8&enrichId=rgreq-d53f01f7e25ffe9ef649f0f99180b9cf-XXX&enrichSource=Y292ZXJQYWdlOzI4NTkyNDk1MztBUzozMjE3NDg4NzA4NjA4MDJAMTQ1MzcyMjMxNjM1Mg==)
>>
endobj
299 0 obj
<<
/Length 4240
/Length1 4240
/Subtype /Type1C
>>
stream
MIAMIH+Interstate-Bold @ MUi"
V _ _nx 1993, Tobias Frere-Jones. Designed by Tobias Frere-Jones. Produced by The Font Bureau, Inc. Interstate-BoldInterstate 5 3 F W J X B S U D M T 8 I O V N P R G E Z Q 4 H C ( Y 1
) 0 * $ 6 . 5 " / % 7 T mp N}Vb_%J d
%
W
;zx
a
E*˟wI%䮸͋)P !oNhmJKHKɱqLL*: &5: +ת)wtk}eYVӆHɧ\\;ww(>~b}[q}~>,Q"w1pg``gg``gwwa]VcTr~WVWVb~Vq]V +bŏrQbb- B
56XyhN+ʋmfqul[-QOh.r|gt^Pv|rw#.yi^Zhvrs殢}wdtw5nixrjyg`F3/Iප3g`isUI`ìl__K'&!55ǼϾwwfmF("v-:-.{÷}oSCI4\lezsp{~UHPS]"fsދ
="8mJ^##EjEH.hg]srQ@ͰqUS`j/DTQ!5.bB+[<mRU'EW_pVtQY*8II!>]fj5:ad^KRg+2KǻgK{wdwP$NjVn89iWnN&&PqWaIw*iwE(OT_vrsF(欧īo-Iw*E(OT_vrs欧īo-I>wE0joRRk(/·h{w*<;(V4_mfgddHTgvrs槧Ħo-槧Ħo-I>3\!- 4WKN"p]g|{YtWoP,Ơ߳TEd]]dd]]d,Y5&'555 BkHIIlܪͫN;3Cmrc]A1X7vqwuy`Ug 㨹{nwsni+Uc)LL23iwCmF9rc]A1X7j7qwuy`Ug 㨹{nOvw(5}b}[q}}5,`EM3CX/Yhvtqb.ty1 3n]VckvZ^ T'v'h,m˽q]I;=bmmw^Vdt8HLZ&1=Z Sb'@X0970/ Dҷ c$R6 L%BXk,3WdJ3CHmrc]A1X7:nq |#LAqwuy`Ug 㨹{n3iwCX/YhvtqF(ty1 3n]VckvZ^ hYNj^+"NdW] ?#K(iq K6H?wwN28r`ylwiwxxr82N8❩wil4[C\1-1%DON
!wFr)P .% 6$NhmJ7H5ɳoN;N>
+1M.$1-[#D/MOww%P P ˀT)i(SS(ii(SS(i$\*\*ʟwdwP PT _;K(iq K
fMfpL"Nʳo[w TF22U `=F _w#Sw;"#/?'C##!q4c5c@s Ti$&SS$(ii(SS*i"^( ^(Mwtw
}P!ycwXqvy&P䋦qYc""˝p2evww3P}QXn=$yw] w0FwZPP*00$4qabwdw%Pd3qtzP㋥yhqPPz`XX``XX`ċ>%(\oPeHF$H5'F@(D#Hf*vdw^g3$$V8&!'W0!J!K1݁(&9fvKRRKKRRPeȼ-:(bA@"ΰߪhgmxoOq?@'#{8
_
TU
endstream
endobj
300 0 obj
<<
/Length 5004
/Length1 5004
/Subtype /Type1C
>>
stream
MXMCYF+Interstate-Light @ WU&
w b ^nx 1994, Tobias Frere-Jones. Designed by Tobias Frere-Jones. Produced by The Font Bureau, Inc.Interstate-LightInterstate E 5 I F * O U T J W $ B S 4 P D Z H E Q V M C N X G
R Y % K , L 1 " )
; 3 # - . ' / i w [ 6 ( ! G Qf7d8g
Pyprl3~ M
A
(L~
A
B)a*Y*Nֺļ&Ak0&aa0&kk0&aa0&kZNEENNEENAdngoyaJ[ʹ}fhaR(F2 1ǹMw ~Db 8wliw{+BIZl_m@aCļ߳XIBw*A /#;b Eڹh[kgyN5VE D%wdwCP=P8wl{+BIZl_m@ļ߳X%twb`@a6JL4k̳swmc~K7U,Q(2pí|kcSC,FU;7k^cs`XimCWZa_TcpӋ#w G4solssmns{4@wwv=1r1;PuU^QWi?
2?>pNɺTC+= .da/?оd'_DGMzr]Nذe=Ml\V#*Y
bֿK_kXhGK`˰xweyrdSYias@ԮQL[/ q³ѺtaPO-3H&Z+U]fJAQ].CNVWQSb&77F)%+FF,F@MC00NF/7SnbUD9VK3վ^ghivX.Txivw<yVy<OCS:4֭".&OkR]R^CKpi708AE|!00!||00|>IK
KII
IgwG\&>*%FŭgE&L{FǝJ>2FPJI40U7pr@Pf^I3+NM;ҽpc]CRW2@]f]mS8Y!ɾh_07iwpm@aqf^I3+NM;ҽK]f]mS8Y!ɾh_07M8"DYhcf@bֵfaoNA!`@4MXnF8wx@RZB7c@+JͼK#ww7m@aC07iwM8"DYhcf@aCaoNA!`@4MXnFZwlyx-H 6`cYlr^AM_m^p@Գ_װ_۟ww?@9yfx-G-yfx9>xfy.LmihnlhhnwayymBXh-CCLbb$.
}E%|}07p+8@Pf^I3+NM;ҽ]f]mS8Y!ɾh_&wwY6+=-7{n{.78+6JnJLMP?O&=]-;+$5)GܠvmpB#v G4solssmns{(@+r,nSwdwIa6_ogS@yq=P]@c %wwc:N7@vkY@aC+wƺw#oPPJSv>Z4]OGǪ+7GaacYƋWHA_Y0[H^41UYGR_WWX].kw"+P> =.XZ ?IX1-w 8p`A=/a],^L}<4IVwshu%sm̋S0'OFEHWeMdr.=u#A}~XX3ͧ;))9<>]r3nXO/F33 JPW.+QƳPP9PVN O9wFkwP5PFF7xʒnL]wwP==P<,K =7j&/%SK/BvY_B_YGY__eK%&jl) =7K,)lSu<WtGqilboeWGw,P:*.ϋ=3Z`#NX_5rw:ww-:+g7iJ
::CvLáKsncEKƠ<P'NiY4=nCٰ`K;cW"FBY32m2&;bWVT¨Ջ`KRnpWk"J~mδٻG}nkjomjjo*vdw@Q((l(:M:lU(H(HUz:z:(gwl%#(Qi[^ELy)J\?&*>1ML!DU-@w =PwvwXLP6;7{brJmrz974PnpVgLWOW@n%w| /PTT|wdwP@[q||?Py]ssIvqsPWJs^sWJsIvqs-P%|s,s%|s2!>+L+TBv\&65E5n5E(w2=4+[B
Q+2=4V&;pNɺTC+= .da/?(U"vqsTP%|sNBļl8R(5ie,,ee,,eijyavbVHRPHGJe`UYvUP2Zawc`ԩv`PriW0D]6._¸ho+)ht^r\Dlźǿ}|y8
˒В
_
TU
endstream
endobj
301 0 obj
<<
/Length 2134
/Length1 2134
/Subtype /Type1C
>>
stream
JLNEBO+Berkeley-Book ? 5
G 3 Copyright (c) 1989 Adobe Systems Incorporated. All Rights Reserved.ITC Berkeley Oldstyle is a trademark of International Typeface Corporation.ITC Berkeley Oldstyle BookBerkeley 7 P M V N F
/ C S + B O Z i a_b ]_dvQpyj^/rYplQ ڜH*{"[.
!H@